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General Introduction
1INTroducTIoN
The treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) 
has significantly improved over the last two decades. This has been achieved via new 
treatment strategies, which included the careful monitoring of treatment effectiveness 
via measurement of residual leukemic cells, i.e. minimal residual disease (MRD). A better 
understanding of the heterogeneity and tissue distribution of leukemic cells, the effect of 
BCP-ALL treatment on the normal B-cell system, and the immunophenotypic differences 
between malignant cells and their normal counterparts are important to further improve 
leukemia treatment. To study these topics, in-depth insight into the B-cell receptor 
(BCR), the immunophenotypic stages of normal B-cell differentiation/maturation, the 
pathobiology of BCP-ALL and the different techniques of MRD detection is required.
B-cells aNd The B-cell recePTor
B-cells are part of the adaptive immune system and are able to recognize specific 
antigens with their BCR. Upon encounter with the specific antigen, and with help of T-cells, 
B-cells become activated and differentiate to plasma cells that secrete immunoglobulins 
(Ig’s) against the antigen. Furthermore, B-cells are able to refine their antigen-recognition 
and to generate immunological memory, resulting in an improved B-cell response upon 
re-encounter with the specific antigen. The BCR, and the related secreted Ig, is a Y-shaped 
molecule consisting of two identical heavy chains and two identical light chains (Figure 1a). 
Both the heavy chains and light chains are composed of a constant domain and a variable 
domain. The heavy chain is encoded by genes on the IGH locus (chromosome 14); its 
constant domain by one of the 9 constant genes (Cµ, Cδ, Cγ3, Cγ1, Cα1, Cγ2, Cγ4, Cε and 
Cα2) and its variable domain by the junction of a Variable (V), Diversity (D) and Joining 
(J) gene. The light chain is encoded by genes on either the IGK locus (chromosome 2), 
resulting in a ĸ-chain, or the IGL locus (chromosome 22), resulting in a λ-chain. The variable 
domain of the light chain is the result of transcription from the V-J gene junction on one 
these loci. The variable domains of the heavy chains and the light chains together form the 
two antigen-binding sites of the Ig. The constant domains of the two heavy chains together 
form the part of the BCR that can attach to other cells or molecules (e.g. complement). 
Depending on which of the 9 constant genes was transcribed, the secreted Ig can have 
different effector functions, including blockage of ligand-receptor interactions, cell lysis 
through activation of complement dependent cytotoxicity (CDC), interaction with Fc 
receptors on effector cells to initiate antibody dependent cellular cytotoxicity (ADCC) and 
opsonization of the pathogen to promote phagocytosis.
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The above described V(D)J junctions are generated through a process called 
V(D)J-recombination. V(D)J-recombination includes the coupling of a specific V, (D) and 
J segment and the random insertion and deletion of nucleotides at the V-D and D-J or 
V-J junction (Figure 1b+c). This process is initiated by double stranded DNA breaks, 
mediated by recombination activating gene 1 and 2 (RAG1 and RAG2) enzymes. All V, 
D and J genes are flanked by recombination signal sequences (RSSs), which consist of 
a heptamer sequence, a spacer region of 12 or 23 base pairs, and a nonamer sequence. 
Rearrangements can only occur between RSSs with a different spacer length (12-23 rule). 
RAG1 and RAG2 enzymes recognize RSSs and introduce single strand breaks between the 
coding segment and the adjacent RSS. This results in hairpin ends at the site of the coding 
segment (coding ends) and blunt ends at the side of the RSS (signal ends). RAG1 and RAG2 
remain associated with the coding and signal ends in a post-cleavage complex, which is 
critical for proper joining of the ends. The two coding ends are kept in close proximity by 
the MRN complex (MRE11, Rad50 and NBN), while ataxia-telangiectasia-mutated protein 
(ATM) induces cell cycle arrest and activation of DNA repair pathways 1,2. Subsequently, 
Ku70, Ku80, DNA-dependent protein kinase (DNA-PKcs) and Artemis are recruited to the 
coding ends, resulting in cleavage of the hairpins by Artemis 3. After opening the hairpins, 
endonucleases and terminal deoxynucleotidyl transferase (TdT) are able to delete and 
Figure 1.
A. Schematic representation of a BCR molecule, showing the constant domains and variable domains encoded 
by the V, D and J genes at the IGH locus.
B. Schematic representation of V(D)J recombination at the IGH locus.
C. Junctional diversity at the IGH locus. Examples of junctional diversity at the IGH locus, showing that nucleotides 
are deleted and non-templated nucleotides (blue) are added.
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1insert non-templated N-nucleotides. Lastly, a complex of DNA ligase V, XRCC4 and XLF 
ligates the two coding ends 4.
In theory, 38 to 46 functional Vh, 25 Dh, and 6 Jh genes can be combined, resulting in 
>5.7 × 103 possible IGH gene rearrangements 5. In turn, the IGH chain can be combined 
with one of the 200 possible IGK and 124 possible IGL gene rearrangements, resulting in 
a combinational diversity of >1.8 × 106. The insertion and deletion of nucleotides at the 
junctions provide an additional junctional diversity of approximately 3 x 107. In total, this 
results in an estimated BCR diversity of >1012 5-7. Besides these theoretical estimations, 
next generation sequencing (NGS) of the IGH, IGK and IGL loci was performed to study 
the naive BCR repertoire in healthy individuals 8. One study showed a lower bound 
estimate of 2.2 x 105 diversity for the heavy chain diversity and 1.6 x 105 for the light chain 
diversity, suggesting a BCR of >1010 9. However, the strict definition of diversity might have 
underestimated the total number of unique sequences in this study 9. As a result of the 
large diversity of BCRs, B-cells with a vast number of antigen-specificities are generated. 
NorMal B-cell dIffereNTIaTIoN/MaTuraTIoN
B-cell precursor differentiation in the bone marrow
B-cell precursors (BCPs) in the bone marrow (BM) differentiate through several 
differentiation stages to become mature B-cells, expressing a functional BCR. Based on 
the immunophenotypic and immunogenotypic changes during BCP differentiation, five 
stages (subsets) are classically defined (Figure 2). First, the pro-B stage, which is the first 
stage that expresses B-cell lineage markers and is characterized by the expression of 
CD22, cytoplasmic CD79a and Cd79b, and CD34 (but not yet CD10). In this stage, Dh-Jh 
rearrangements at the IGH locus occur, although Dh-Jh rearrangement were already found 
in common lymphoid progenitors 10,11. Second, the pre-B-I stage, which is characterized 
by expression of CD19, CD10 and CD34. Also, TdT, the enzyme required for the random 
insertion of nucleotides during V(D)J-recombination, is expressed. In this stage, Vh to 
Dh-Jh rearrangements at the IGH locus are initiated. Only when an in-frame Vh-DhJh 
rearrangement is formed, transition to the next stage occurs. Third, the pre-B-II-Large 
stage, characterized by dim expression of CD20 and loss of CD34 and TdT expression. The 
presence of in-frame Vh-DhJh rearrangements results in the expression of a cytoplasmic 
Igµ heavy chain (cyIgµ). The cyIgµ is coupled to a VpreB surrogate light chain in the 
cytoplasm and expressed as a pre-BCR on the cell surface. Subsequent activation of the 
pre-BCR triggers proliferation of the pre-B-II-Large cells. During this stage, rearrangement 
processes are temporarily abrogated. Fourth, the pre-B-II-Small stage, characterized by 
complete CD34 negativity and loss of CD20 expression. In this stage, the pre-BCR is no 
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longer expressed and Vĸ-Jĸ rearrangements at the IGK locus are initiated. If this results in 
an out-of-frame IGK-rearrangement at both alleles, part of the IGK gene is deleted (which is 
possible by two types of kappa deletion rearrangements: IntronRSS-KDE and Vĸ-KDE) after 
which Vλ-Jλ rearrangements at the IGL locus will follow. Once an in-frame Vĸ-Jĸ or Vλ-Jλ 
rearrangement is formed, transition to the next stage occurs. Fifth, the immature stage, 
characterized by re-expression of CD20. In this stage, the presence of in-frame Vk-Jk or 
Vλ-Jλ rearrangements results in expression of a cytoplasmic Igĸ respectively Igλ light chain. 
The Igµ heavy chain and the Igĸ or Igλ light chain are combined in the cytoplasm and, 
if successfully coupled, expressed as a surface membrane IgM (SmIgM), i.e. a functional 
BCR, on the cell surface. Before migration out of the BM, B-cells with autoreactive BCRs 
are negatively selected via apoptosis or anergy (central tolerance checkpoint), resulting 
in a decrease of autoreactive B-cells from ~75% to ~45% and a decrease of polyreactive 
B-cells from ~55% to less than 10% 12. Receptor editing, i.e. generation of a new light 
chain by recombination of an upstream V gene and downstream J gene, can rescue B-cells 
from negative selection. Later, at the transition from the new BM emigrant to the mature 
naive B cell stage in PB, the percentage of autoreactive B-cells is further reduced to ~20% 
(peripheral tolerance checkpoint) 12.
VH-DJH rearrangement
DH-JH rearrangement
Vκ-Jκ rearrangement
  KDE rearrangement
Vλ-Jλ rearrangement
Pro-B
CD22+
CD79a,b+
CD10-
CD34+
Pre-B-I
CD19+
TdT+
cyIgµ-
CD10++
CD34+
Pre-B-II-
Large
CD19+
TdT-
cyIgµ+
CD10+
CD34dim
CD20+
Pre-B-II-
Small
CD19+
TdT-
cyIgµ+
CD10+
CD34-
CD20-
Immature
CD19+
TdT-
SmIgµ+
CD10+
CD34-
CD20+
Figure 2.
Immunophenotypic stages of BCP differentiation. The most discriminative markers for each stage are indicated. 
Grey bars represent the initiation and continuation of rearrangements at the IGH, IGK and IGL locus.
15
General Introduction
1B-cell maturation in the periphery
Newly generated immature B-cells leave the BM and enter the peripheral blood (PB) in 
the form of transitional B-cells. In the periphery, further maturation of transitional B-cells 
(CD38++IgD+IgM+), via pre-naive B-cells (characterized by a slightly downregulated CD38 
expression), to naïve mature B-cells (CD38dimIgD+IgM+) takes place 13,14. Naive mature 
B-cells may migrate to lymphoid tissues, where they become activated after interaction with 
a specific antigen. After antigen encounter, four different maturation routes can be followed 
(Figure 3). First, naive mature B-cells can directly mature into plasmablasts (CD38++IgD-
IgM+). Second, naive mature B-cells can enter a T-cell dependent germinal center (GC)-
reaction in the lymphoid tissue, during which they undergo somatic hypermutation (SHM) 
to create a BCR with a higher antigen-affinity, and class switch-recombination (CSR) to 
change the isotype of the secreted Ig (depending on the type and location of the antigen). 
PB Lymphoid Tissues
Antigen-unexperienced
Antibody-producing
CD27- memory 
Natural eector
Transitional
CD19+ IgD+
CD27- IgM+
CD38+
CD27- memory
CD19+ IgG+/IgA+
CD27- /IgM+
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CD19+ IgG+/IgA+
CD27+ /IgM+
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IgG+/IgA+/IgM+
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Antigen-experienced
Naive mature
CD19+ IgD+
CD27- IgM+
CD38dim
Natural eector
CD19+
CD27+
IgD+
IgM+
Plasma cellPlasma cell 
in BM
Figure 3.
Schematic overview of the different B-cell subsets in PB and lymphoid tissue. The immunophenotypic markers 
characteristic for each subset are shown. Solid arrows indicate the main differentiation routes, dashed arrows 
indicate migration routes. 
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As a result, plasmablasts (CD38++IgD- and IgG+, IgA+, IgM+ or IgE+) and memory B-cells 
(CD27+IgD- and IgG+, IgA+, IgM+ or IgE+) with a high affinity and an appropriate Ig-isotype 
are generated. Third, naive mature B-cells in the marginal zone of the spleen can, without 
the help of T-cells, develop into natural effector B-cells (CD27+IgD+IgM+) 15. Fourth, naive 
mature B-cells in the mucosal lymphoid tissue can, without the help of T-cells, mature into 
CD27-IgA+ memory B-cells 16. Plasmablasts generated via the first and second maturation 
route migrate to the BM, where they become Ig-secreting plasma cells (CD19+ or CD38++ 
and IgG+, IgA+, IgM+ or IgE+). Memory B-cells circulate through the BM, PB and lymphoid 
compartments. Upon antigen-encounter in the lymphoid tissue, memory B-cells become 
activated and can re-enter the GC-reaction, after which the second maturation route is 
repeated. 
PedIaTrIc B-cell Precursor acuTe lyMPhoBlasT leukeMIa
Epidemiology and clinical manifestation
Each year, approximately 100 children with BCP-ALL are diagnosed in the Netherlands. 
The incidence of pediatric BCP-ALL peaks between the ages of 2 and 5 years 17. BCP-ALL is 
characterized by the clonal expansion of a malignantly transformed BCP and the subsequent 
suppression of the normal hematopoiesis in BM, resulting in anemia, thrombocytopenia 
and neutropenia 18. As a consequence, children with BCP-ALL often present with pallor 
and fatigue, bruising or bleeding and recurrent infections. Furthermore, leukemic cells can 
disseminate to the testis and central nervous system, or infiltrate into lymph nodes, spleen 
and liver, which may result in lymphadenopathy and hepatosplenomegaly 18. 
Pathobiology 
The exact pathogenesis of BCP-ALL is still unclear. However, many genetic factors 
have been associated with the development of BCP-ALL. First, several polymorphic 
variants (IKZF1, CEBPE, ARID5B) and germline mutations (PAX5, ETV6, TP53) cause a genetic 
predisposition to ALL 17,19. These gene variants contribute to the intrinsic vulnerability of 
BCPs to additional events that cause malignant transformation. Also, certain inherited 
genetic syndromes, such as Down syndrome, are associated with an increased risk of 
BCP-ALL 20. In most BCP-ALL patients, the malignant transformation follows the ‘multi-
hit’ model 17,19. In this model, cytogenetic aberrancies, most commonly chromosomal 
translocations (e.g. ETV6-RUNX1, BCR-ABL1), are the initiating events. These translocations 
can already occur in utero and result in a chimeric protein with an aberrant function 21. As 
secondary events, submicroscopic genetic lesions, such as mutations and deletions, are 
acquired in genes which encode regulators of lymphoid development or cell cycle, tumor 
17
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1suppressors or lymphoid signaling molecules (e.g. PAX5, IKZF1, EBF1) 22,23. Together, these 
events ultimately result in arrest of the BCP differentiation and uncontrolled proliferation. 
During disease progression, multiple subclones can evolve from the ancestral BCP-ALL 
clone, as reported by studies showing different copy number alterations, chromosomal 
translocations and IG gene rearrangements within one BCP-ALL population 24-27. According 
to the Darwinian selection model, subclones with additional genetic lesions that provide a 
survival advantage are positively selected. Consequently, a BCP-ALL population can contain 
one or few major clones as well as multiple smaller subclones, evolutionary connected to 
each other in a multi branch-like structure.
BCP-ALL subtypes
BCP-ALL can be classified into subtypes based on immunophenotype and cytogenetics. 
Based on immunophenotype, BCP-ALL cases are traditionally classified as pro-B ALL 
(CD10-cyIgµ-), common ALL (CD10+cyIgµ-) and pre-B ALL (CD10+cyIgµ+). However, 
this classification has proven to be of limited clinical significance. Based on cytogenetic 
aberrancies, pediatric BCP-ALL cases are classified by the presence of an ETV6-RUNX1 
translocation, a BCR-ABL1 translocation, a TCF3-PBX1 translocation, a MLL-rearrangement, 
a translocation involving MYC-deregulation, hyperdiploidy (>50 chromosomes), 
hypodiploidy (<44 chromosomes) or none of these genetic aberrancies (not otherwise 
specified; NOS) (Figure 4) 28,29. Of note, the frequency of MLL-rearrangements is particularly 
high (80%) among infants younger than 1 year 28.
Prognostic factors at diagnosis
The general prognosis for children with BCP-ALL is relatively good; the overall survival 
of children treated according to the Dutch Childhood Oncology Group (DCOG) ALL10 
protocol was 92% 30. However, depending on clinical features, genetic aberrancies and 
treatment response, the risk of relapse differs between patients 19. With regard to clinical 
features, an age of >10 years, an age of <1 year and a white blood cell count of >50,000/uL 
at diagnosis are associated with an adverse prognosis. Several of the cytogenetic BCP-ALL 
subtypes are also associated with prognosis: a TEL-AML1 translocation, hyperdiploidy, and 
some chromosome trisomies have a favorable prognosis, whereas a BCR-ABL1 translocation, 
MLL-rearrangements and hypodiploidy have an adverse prognosis. Furthermore, a genetic 
alteration in IKZF1, which encodes the lymphoid transcription factor Ikaros, is associated 
with poor prognosis 31. Finally, treatment response is a very important predictive factor. The 
presence of >1000 leukemic cells/uL in PB at eight days after start of therapy (prednisone 
response) is associated with poor prognosis. However, the strongest prognostic factor for 
relapse in children with BCP-ALL is the amount of residual leukemic cells, i.e. MRD, during 
the first months after start of treatment 32,33.
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Evaluation of treatment effectiveness as prognostic factor
MRD levels during the first months after start of therapy reflect the intrinsic drug 
sensitivity of the leukemic cells, the pharmacodynamics and pharmacogenomics of the 
host, the type of regimens administered and the treatment adherence 18. Five-fold to ten-
fold higher relapse rates were found in MRD-positive patients compared to MRD-negative 
patients when treated according to the same protocol (Figure 5). Moreover, within the 
MRD-positive patients, a high degree of MRD (>0.1%) was associated with a three-fold 
higher relapse rate when compared with patients with a low degree of MRD (<0.1%) 32. 
MRD is generally monitored in BM samples, taken at different time points during therapy. 
In the Dutch protocols (DCOG), these time points are day 33, day 79, month 5, month 9 
and month 12 after start of therapy. MRD levels at time points day 33 (during induction 
therapy) and day 79 (after induction therapy) determine to which risk group a patient will 
be assigned. Patients are assigned to the Standard Risk (SR) group if both time points are 
MRD negative, to the High Risk (HR) group if both time points are MRD positive with an 
MRD level of at least 10-3, and to the Medium Risk (MR) group if one or both time points 
is/are MRD positive, provided that the MRD level at day 79 is less than 10-3. Based on the 
risk group, patients are treated in different treatment arms; patients with a lower risk of 
Figure 4. 
Distribution of cytogenic subtypes of pediatric BCP-ALL (adapted from Bohjwani et al., Pediatr. Clin. North Am., 
2015) 28.
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1
relapse undergo a less intensive treatment, resulting in less therapy-induced toxicity and 
morbidity 30,34. 
Treatment
Although different treatment protocols exist (developed by different international 
consortia), most are based on the so-called Berlin-Frankfurt-Münster (BFM) backbone 35. 
This backbone typically consists of an induction phase, an intensification/consolidation 
phase and a maintenance phase. The induction phase (4 to 6 weeks) is characterized by 
high doses of a glucocorticoid (prednisone or dexamethasone). This phase usually results 
in morphological remission (<5% leukemic cells in BM). The intensification phase (6 to 12 
months) includes a combination of chemotherapeutic drugs that is designed to consolidate 
remission and prevent development of overt central nervous system leukemia 19. Repeated 
courses of methotrexate are important during this treatment phase. The maintenance 
phase (18 to 30 months) consists of daily oral mercaptopurine or thioguanine and weekly 
oral methotrexate, in some protocols complemented by periodic pulses of glucocorticoid 
and vincristine 19. Treatment of children in the HR group often involves stem cell 
transplantation. In this thesis, all included patients were treated according to the SR or MR 
treatment arm of the DCOG ALL10 or ALL11 protocol (Figure 6).
Figure 5. 
Disease-free survival of MRD-based risk groups in children treated according to DCOG ALL8/ BFM/ AIEOP 
protocols (adapted from Van Dongen et al., Lancet, 1998) 32.
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Chemotherapy-induced suppression of humoral immunity
Although aimed to be directed against the leukemic cells, BCP-ALL therapy also affects 
the immune system, including normal B-cells. Already shortly after start therapy, hardly any 
BCPs and mature B-cells remain in BM respectively PB 36,37. Consequently, patients develop 
hypogammaglobulinemia, which contributes to a high susceptibility to infections 38. During 
intervals in therapy, regeneration of BCPs occurs, resulting in a temporary reappearance of 
early BCPs 39,40. However, B-cell numbers in PB remain extremely low during therapy. After 
end of therapy, mature B-cell numbers and Ig levels quickly recover. However, the mature 
B-cell population shows an aberrant composition, characterized by a relative increase of 
naive mature B-cells, up to one year after end of therapy 37. 
MINIMal resIdual dIsease deTecTIoN 
PCR-based MRD analysis
MRD detection is in Europe primarily performed by PCR-amplification of immunoglobulin 
(IG) or T-cell receptor (TR) gene rearrangements (www.EuroMRD.org) 41. As described in the 
section ‘B-cells and the B-cell receptor’, the junctional regions of rearranged IG genes are 
unique for each B-cell. Since leukemic cells are derived from normal BCPs, leukemic cells 
will in most cases harbor IG gene rearrangements. Moreover, they can harbor certain TR 
gene rearrangements. Rearrangements and/or deletions of the TRB, TRG and TRD genes 
were found in 35%, 59% and 89% of BCP-ALL cases, respectively 42. The high frequency 
(>90%) of cross-lineage TR gene rearrangements in BCP-ALL cells might be explained by 
Figure 6. 
DCOG ALL11 treatment protocol for children with BCP-ALL which are stratified into the SR or MR treatment 
arm.  The number of weeks after diagnosis are indicated. 1A+1B: induction therapy. M: cycle M. *: extension of 
maintenance therapy with one year. The HR treatment arm is omitted, since HR patients were excluded from our 
studies (adapted from the DCOG ALL11 protocol, 2012).
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1ongoing activity of the V(D)J recombination machinery after malignant transformation 
of a BCP 42. Together, the IG and TR gene rearrangements present in a leukemic cell can 
be regarded as unique ‘fingerprints’ of that leukemic cell and thus as targets specific for 
residual leukemic cells 43.
In order to perform PCR-based MRD detection, the MRD targets (i.e. clonal IG/TR gene 
rearrangements) first need to be identified in the diagnosis sample. Therefore, singleplex or 
multiplex V-, D-, and J-primer sets are used to PCR amplify all potential IGH, IGK, IGL, TRG, TRD 
and TRB gene rearrangements 44. Subsequently, heteroduplex analysis of the PCR products 
is performed (Figure 7a), which discriminates clonal IG/TR gene rearrangements (derived 
from leukemic clones) from polyclonal IG/TR gene rearrangements (derived from normal 
B-cells and T-cells). Next, the junctional regions of the clonal IG/TR gene rearrangements 
are sequenced. Based on these sequences, junctional region-specific oligonucleotides, 
so-called allele-specific oligonucleotides (ASOs), are designed 43,45. Finally, ASO RQ-PCR is 
performed on follow up samples, resulting in the quantification of the clonal IG/TR gene 
rearrangement at a specific follow up time point (Figure 7b). This way, MRD levels can be 
detected with a sensitivity of 10-4 to 10-5. 
Advantages of PCR-based MRD detection are the relatively high sensitivity, the 
applicability to almost all patients and the already established standardization and quality 
assessment programs, whereas disadvantages are the laborious design of ASOs and the 
risk of losing MRD targets (due to oligoclonality or clonal evolution) 33.
Flow cytometric MRD analysis
MRD detection can also be performed by using flow cytometry (Figure 8). In 95% of 
the patients, leukemic cells can be recognized based on their aberrant marker expression. 
Leukemic cells can be discriminated from normal BCPs by the expression of BCP-ALL 
specific markers, e.g. CD123, CD66c and CD58, by overexpression or underexpression of 
B-cell differentiation markers, e.g. overexpression of CD10 or underexpression of CD81, 
or by asynchronous expression of B-cell differentiation markers, e.g. expression of TdT 
and high levels of CD20 46-48. Still, it can be difficult to discriminate residual leukemic cells 
from normal BCPs, since many markers are expressed similarly. Specific advantages of flow 
cytometric MRD detection include the potential to also analyze the normal BCP population 
while searching for MRD and the short time between sampling and availability of the MRD 
result 49. However, disadvantages include the difficult discrimination between normal BCP 
and leukemic cells during therapy intervals (when regenerating BCPs might be abundantly 
present), the subjectivity in data analysis (e.g. differences in gating strategies) and data 
interpretation, the need for high cell numbers (to obtain a high sensitivity) and, in some 
cases, the onset of an immunophentoypic shift (e.g. a therapy-induced shift in marker 
expression levels during follow up) 33. These disadvantages result in a moderate sensitivity 
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(>10-4 in the majority of cases) that is lower than that of PCR-based MRD detection. Studies 
which compared 4- to 6-color flow cytometric MRD detection with PCR-based MRD 
detection found, in absence of any cut-off, a concordance of 68% to 82% at early MRD 
time points (<3 months after start of therapy) 50-52. Indeed, most discordant cases were 
found below 10-4. To increase the sensitivity of flow cytometric MRD detection to a level 
comparable to that of PCR-based MRD detection (~10-5), it is necessary to develop ≥8-color 
antibody panels, a procedure for high cell number acquisition, and new tools for objective 
data analysis. 
Figure 7.
A. In heteroduplex analysis, the junctional region heterogeneity of IG/TR gene rearrangements is exploited to 
distinguish between monoclonal and polyclonal lymphocyte expansions. In samples with clonal lymphocytes, 
the PCR products of rearranged IG/TR genes form, after reannealing, homoduplexes, causing relatively sharp 
bands. In contrast, in samples with polyclonal lymphocyte expansions, the PCR products form heteroduplexes, 
resulting in a background smear (Van Dongen et al., Leukemia, 2003) 44.
B. Example of an RQ-PCR MRD analysis using a Vd2-Dd2-Ja11 rearrangement as MRD target. The amplification 
plot (upper panel) shows the dilution experiment of the diagnosis sample and the measurement of the follow 
up sample (all performed in triplicate). The corresponding standard curve (lower panel) is based on the dilution 
experiment and allows calculation of the MRD level in the follow up sample (Van Dongen et al., Blood, 2015).
23
General Introduction
1
NGS-based MRD detection
Since recently, MRD detection is also possible by next generation sequencing of IG/
TR gene rearrangements. After amplification of the IG/TR gene rearrangements by using 
V-, D-, and J-primer sets similar to those used for PCR-based MRD detection, high throughput 
sequencing of the PCR products can be performed by using different platforms. Commonly 
used in NGS-based studies on BCP-ALL MRD is the Illumina platform, which utilizes bridge 
amplification and reversible-terminator chemistry as important techniques 53,54. Using the 
NGS-based approach, all IG/TR gene rearrangements present in the BCP-ALL sample are 
detected. At diagnosis, only the IG/TR gene rearrangements with a frequency of >5% are 
generally regarded as leukemia-derived (as opposed to normal lymphocyte-derived IG/
TR gene rearrangements) 53. During follow up, IG/TR gene rearrangements identified as 
leukemic at diagnosis can be retraced and quantified as MRD level. To correctly quantify 
the MRD level, the read count of each IG/TR gene rearrangement needs to be corrected for 
PCR amplification. This can be achieved by the so-called spike-in method, in which a known 
number of reference IG/TR gene rearrangements was added to each PCR reaction in order 
to determine the correction factor. Depending on the amount of DNA input, NGS-based 
MRD detection can reach a sensitivity between 10-4 and 10-5. Advantages of NGS-based 
MRD detection are the relatively high sensitivity, the use of standard primers (rather than 
ASOs) and the ability to monitor all leukemic IG/TR gene rearrangements (which prevents 
potential loss of MRD targets). However, there are still some major concerns that need to 
be overcome before NGS-based MRD detection can be applied in clinical practice. First, it is 
still arbitrary how to discriminate IG/TR gene rearrangements derived from leukemic cells 
Figure 8.
Dot plots showing an example of flow cytometric MRD measurement at day 79 after start of BCP-ALL treatment. 
Red events indicate MRD (0.07% in total WBC). Green events indicate regenerating normal BCPs. 
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from those derived from normal B-cell and T-cell clones and technical background. Second, 
since multiplex PCR reactions are prone to disproportional amplification, the frequency 
of a clonal IG/TR gene rearrangement might not be fully accurate. Third, standardization, 
quality assessment programs, and validation of NGS-based MRD detection in a multicenter 
and scientifically independent setting are still lacking 33.
aIMs aNd ouTlINe of ThIs ThesIs
In this thesis, we aimed to study both leukemic and newly generated normal B-cells in 
children with BCP-ALL, since a better understanding of the tissue distribution of leukemic 
cells, the effect of BCP-ALL treatment on normal B-cells and the immunophenotypic 
differences between malignant cells and their normal counterparts are important to 
further improve leukemia treatment. First, we focused on the leukemic B-cell population 
at BCP-ALL diagnosis. Recent NGS-based analysis of IG/TR gene rearrangements showed 
that the BCP-ALL population can consist of many more clones than previously thought. 
However, it is still unknown to what extent these clones are distributed throughout 
the body. Therefore, in Chapter 2, we study the number of BCP-ALL clones and their 
distribution throughout the BM and PB compartment, by using NGS-based IG/TR gene 
rearrangement analysis. 
During BCP-ALL therapy, also the normal B-cell system is affected. As a result, both the 
BCP population in BM and mature B-cell population in PB are almost completely destroyed, 
and reconstitution of the B-cell system is needed. However, the complete differentiation/
maturation pattern during B-cell reconstitution and the mechanism behind the relatively 
fast B-cell recovery after end of therapy (increased de novo BCP generation versus enhanced 
proliferation within a B-cell subset) is still unknown. In Chapter 3, we analyze in detail the 
B-cell subsets in both BM and PB during B-cell reconstitution, and study the degree of 
proliferation within different B-cell subsets during and after therapy.
Although the bulk of leukemic cells is effectively killed by chemotherapy, residual 
leukemic cells (i.e. MRD) can remain present. Adequate quantification of MRD is of utmost 
importance for stratification of patients into the different treatment arms. To quantify 
MRD by flow cytometry, BCP-ALL cells need to be discriminated from regenerating BCPs. 
However, studies on the immunophenotypes of regenerating BCPs in particular are very 
limited. Chapter 4 provides a detailed description of the immunophenotypic maturation 
during normal B-cell differentiation and the immunophenotypic maturation during BCP 
regeneration in BM of BCP-ALL patients.
So far, the sensitivity of flow cytometric MRD detection has been inferior to that of 
PCR-based MRD detection. To increase the sensitivity of flow cytometric MRD detection, 
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optimized ≥8-color antibody panel are required. In Chapter 5, we aim to identify new 
markers that can contribute to flow cytometric MRD detection in pediatric BCP-ALL. 
Subsequently, in Chapter 6, we develop a new single-tube antibody panel (8-colors) 
together with a new sample processing procedure, thereby increasing the sensitivity of 
flow cytometric MRD detection to ≤10-5. 
Finally, we integrate all the findings presented in this thesis and discuss their implications 
for clinical practice in Chapter 7. 
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aBsTracT
In B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the initial 
leukemic cells share the same immunoglobulin (IG) and T-cell receptor (TR) 
gene rearrangements. However, due to ongoing rearrangement processes, 
leukemic cells with different IG/TR gene rearrangement patterns can 
develop, resulting in subclone formation. We studied BCP-ALL subclones 
and their distribution in the bone marrow (BM) and peripheral blood (PB) 
compartments.
We used next generation sequencing to study IG/TR gene 
rearrangements (IGH, IGK, TRG, TRD, TRB) in seven paired BM samples and 
five paired BM-PB samples from seven respectively five newly diagnosed 
BCP-ALL patients.
Background-thresholds were defined, which enabled identification 
of leukemic IG/TR gene rearrangements down to very low levels. Paired 
BM-BM analysis showed oligoclonality in all seven patients and up to 34 
leukemic clones per patient. Additional analysis of evolutionary-related 
IGH gene rearrangements revealed up to 171 leukemic clones per patient. 
The percentage of leukemic IG/TR gene rearrangements present in both 
BM samples ranged from 87% to 100% per patient (excluding 46% for 
Vδ-Dδ rearrangements in a patient with TCF3-PBX1). Paired BM-PB analysis 
showed that 98% of all leukemic IG/TR gene rearrangements in BM were 
also found in PB (excluding 78% for Vδ-Dδ rearrangements in an infant 
with MLL-ENL). Remarkably, the vast majority of leukemic IG/TR gene 
rearrangements had a similar frequency in the paired BM-BM and BM-PB 
samples (<5-fold frequency difference). Together, these results indicate 
that BCP-ALL is generally highly oligoclonal. Nevertheless, almost all BCP-
ALL clones, even the minor subclones, are homogeneously distributed 
throughout the BM and PB compartment. 
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INTroducTIoN
During B-cell and T-cell differentiation, genes that encode the B-cell receptor 
(immunoglobulin; IG) and the T-cell receptor (TR) are rearranged, respectively. This process 
of IG and TR gene rearrangement includes the assembly of Variable (V), Diversity (D) and 
Joining (J) gene segments and the random insertion and deletion of nucleotides between 
these gene segments 1,2, resulting in unique V(D)J junctions. In normal B-cells and T-cells, 
productive V(D)J exons encode the antigen-binding domains of the IG and TR molecules. 
The large diversity of V(D)J junctions contributes significantly to the large diversity of IG 
and TR molecules, thereby providing the B- and T-lymphocytes with a wide variety of 
antigen specificities.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) arises from a malignantly 
transformed B-cell precursor (BCP) 3. Therefore, BCP-ALL cells contain IG gene 
rearrangements in the vast majority of cases 4. Additionally, most BCP-ALL cells also harbor 
certain TR gene rearrangements, which are uncommon in normal BCPs 5-7. Since BCP-ALL 
is thought to arise from a single cell, a BCP-ALL population is expected be monoclonal 
with regard to IG/TR gene rearrangements, i.e. to consist of cells which all share the 
same IG/TR gene rearrangements. However, continuing rearrangement processes 
and V-segment replacements that occur in normal BCP cells can also occur during the 
development of BCP-ALL 8-10. As a result, a BCP-ALL population can be oligoclonal, i.e. can 
contain subclones with IG/TR gene rearrangements that deviate from those in the initial 
leukemic cell. 
Previously, several studies analyzed IG/TR gene rearrangements in BCP-ALL diagnosis 
samples by using PCR-based methods in combination with Southern blot (SB), which 
allowed identification of clonal IG/TR gene rearrangements down to the level of 1-5% 11,12. 
In these studies, oligoclonality was detected in 40% of patients when analyzing the IGH and 
TRD loci and in 10-20% of patients when analyzing the IGK and TRB loci 11-13. With regard 
to complete IGH gene rearrangements, a maximum of 9 clonal rearrangements could be 
found per patient 14. More recently, IGH gene rearrangements in BCP-ALL at diagnosis 
were analyzed with highly sensitive next generation sequencing (NGS), which showed 
that many more clonal IGH gene rearrangements (up to 4024) can be present in a single 
patient 15. However, in NGS studies of IG/TR gene rearrangements in BCP-ALL patients, 
it is difficult to discriminate leukemic rearrangements at low-frequency levels from the 
background of normal lymphocyte-derived rearrangements and from technical artifacts. 
Furthermore, NGS-based analysis of gene rearrangements other than complete IGH gene 
rearrangements, has, to the best of our knowledge, so far not been performed in patients 
with BCP-ALL. Therefore, the degree of oligoclonality in BCP-ALL patients, especially at 
low-frequency level, remains unclear.
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BCP-ALL subclones may develop at different locations in the body, after which they may 
disseminate throughout the bone marrow (BM) and peripheral blood (PB) compartment. 
Whereas minimal residual disease (MRD) levels were shown to be comparable between 
paired BM samples during follow up 16, limited data is available on the distribution of BCP-
ALL clones at the time of diagnosis. Our early SB study on IG/TR gene rearrangements in 
paired BM-PB samples at diagnosis, reported that in five out of ten oligoclonal patients, 
subclonal IGH gene rearrangements were found in BM, but not in the corresponding PB 
sample 17. However, the relative frequency of these subclonal IGH gene rearrangements in 
PB might have been too low to be detected with SB. Therefore, it is still unknown to what 
extent BCP-ALL clones are distributed throughout the BM and PB compartments. 
Here, we studied the distribution of leukemic clones in BCP-ALL patients by performing 
NGS of IG/TR gene rearrangements on paired BM-BM samples as well as paired BM-PB 
samples. 
MaTerIals aNd MeThods
Patient and control samples
BM and PB samples from in total 12 children with newly diagnosed BCP-ALL were 
collected from the Erasmus MC - Sophia Children’s Hospital in Rotterdam (Supplementary 
Table 1). These samples included 7 left BM-right BM pairs i.e. BM from the left respectively 
right pelvic bone of the same patient, and 5 BM-PB pairs, all taken at initial diagnosis. 
One BM sample from a healthy child (residual material from a donor for allogenic BM 
transplantation), two BM samples from BCP-ALL patients at one year after end of therapy 
and 5 regenerating BM samples from T-ALL patients at day 79 and month 5 during 
therapy were collected, to be used as control samples. All control samples were MRD 
negative according to allele-specific oligonucleotide PCR assays, which were described 
previously 4,18. All samples were obtained according to the guidelines of the local Medical 
Ethics Committees and in line with the Declaration of Helsinki Protocol.
Next generation sequencing by the Adaptive Biotechnologies method
Genomic DNA was isolated from BM and PB mononuclear cells (MNCs) by the QIAamp 
DNA Mini Kit (Qiagen, Hilden, Germany).
A detailed description of the NGS-based immunosequencing method was published 
elsewhere 19. Briefly, a DNA quantity of 420-480 ng, corresponding to 70,000-80,000 
MNCs, was used for the amplification of complete IGH gene rearrangements (Vh-DJh) and 
a DNA quantity of 120-180 ng, corresponding to 20,000-30,000 MNCs, was used for the 
amplification of incomplete IGH gene rearrangements (Dh-Jh), IGK gene rearrangements 
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(Vĸ-Jĸ, Vĸ-KDE, intronRSS-KDE), TRG gene rearrangements (Vγ-Jγ), TRD gene rearrangements 
(Vδ-Dδ, Dδ-Dδ) and TRB gene rearrangements (Vβ-Jβ). These rearrangements were 
amplified in a first PCR reaction of 25 cycles, using locus-specific primer sets 20. Next, 1/100 
of these PCR products was further amplified in a second PCR reaction of 14 cycles, using 
universal primers complementary to the adaptors which were linked to the locus-specific 
primers with sample-identifiers. The final PCR products were sequenced by using the 
Illumina platform. Low-quality reads were filtered out and sequences with a single read 
were excluded 19. For each sequence, the absolute read count, i.e. the read count corrected 
for PCR amplification by the spike-in method, was calculated (Supplementary Methods). 
Also the frequency for each sequence was determined. Importantly, the frequency 
represents a fraction of the rearranged genes of the involved locus, rather than a fraction 
of all, including germline, IG and TR genes, as is the case in SB and PCR-based IG/TR gene 
rearrangement analysis (Supplementary Methods).
NGS clonal variant comparison pipeline and data analysis
We developed a new analysis tool (PRISCA: PRecISe Clonal Analysis) in Galaxy 21 to 
compare sequences from paired and triplicate samples (Supplementary Methods). The 
graphical output from this tool was used for further data analysis.
Background-thresholds were determined based on the maximum absolute read 
count of normal lymphocyte-derived rearrangements in regenerating BM and normal BM 
samples. Since read counts of normal lymphocyte-derived rearrangements are expected 
to be lower in diagnosis BM than in regenerating BM or normal BM (due to overgrow of the 
leukemic population), these thresholds can be reliably applied to BCP-ALL BM samples at 
diagnosis. In order to use the thresholds in the analysis of BCP-ALL BM samples at diagnosis, 
the thresholds were expressed as a frequency of the total reads of the involved IG/TR gene 
rearrangement. The IG/TR gene rearrangements at diagnosis were subsequently analyzed 
according to the criteria described in the Supplementary Methods.
resulTs
Normal and regenerating BM samples define thresholds for the exclusion of normal 
lymphocyte-derived IG/TR gene rearrangements 
For in-depth analysis of IG/TR gene rearrangements in BCP-ALL patients, it is necessary 
to discriminate the IG/TR gene rearrangements derived from leukemic clones from the 
background that also contains IG/TR gene rearrangements derived from normal B-cell and 
T-cell clones. We therefore aimed to define “read count thresholds” (RCTs) above which we 
can fairly assume normal lymphocyte-derived IG/TR gene rearrangements to be absent. To 
Chapter 2
36
define these RCTs, we determined the maximum absolute read counts (i.e. the read count 
corrected for amplification) of normal lymphocyte-derived IG/TR gene rearrangements in 
eight non-leukemic BM samples, i.e. a normal BM sample from a healthy child, two normal 
BM samples from BCP-ALL patients one year after end of therapy, and five regenerating 
BM samples from T-ALL patients during therapy intervals (reflecting a background with 
potentially high numbers of early BCPs). Importantly, regenerating BM samples did not 
contain residual leukemic IG/TR gene rearrangements (as determined by the absence of 
leukemic IG/TR gene rearrangements which were found by NGS in the corresponding 
diagnosis sample; data not shown). Analysis of complete IGH gene rearrangements 
showed that the maximum read count of complete IGH gene rearrangements in the non-
leukemic BM samples was 26 (Figure 1). The IGH Vh-DJh RCT was therefore set at 30 reads. 
The same strategy was applied to the other types of IG/TR gene rearrangements, resulting 
in an RCT of 30 reads for Dh-Jh rearrangements, 70 reads for Vĸ-Jĸ rearrangements, 40 
reads for Vĸ-KDE rearrangements, 170 reads for intronRSS-KDE rearrangements, 50 
reads for Vγ-Jγ rearrangements, 20 reads for Vδ-Dδ rearrangements, 30 reads for Dδ-Dδ 
rearrangements and 30 reads for Vβ-Jβ rearrangements (Supplementary Figure 1). The 
relatively high maximum read count of intronRSS-KDE rearrangements was probably due 
to the limited junctional variability of intronRSS-KDE rearrangements. Importantly, these 
RCTs are dependent on DNA input and are therefore not universal, but specific for our data. 
Samples run in triplicate show that our thresholds also exclude IG/TR gene rearrangements 
derived from technical artifacts
We aimed to evaluate whether IG/TR gene rearrangements with a read count above 
the RCTs were truly clonal, i.e. were derived from leukemic clones and not from technical 
artifacts (non-clonal rearrangements whose read counts were insufficiently corrected after 
PCR amplification). We therefore performed three independent NGS-runs on the same 
sample, based on the fair assumption that IG/TR gene rearrangements can be regarded 
as clonal if present in all three samples or if present in two of the three samples (since 
small clones can coincidently be absent in a sampling volume). Analysis of complete IGH 
gene rearrangements in a BM sample at diagnosis showed that all complete IGH gene 
rearrangements with a read count above the previously defined RCT, and thus considered 
to be derived from leukemic clones, were present in all three replicates, indicating that these 
were not technical artefacts (Figure 2). Analysis of the other IG/TR gene rearrangement types 
in this diagnosis sample showed the same (Supplementary Figure 2). Thus, by using these 
RCTs, we ensured that the included rearrangements (above the RCT) were very likely to be 
derived from leukemic clones (as opposed to normal lymphocytes or technical artefacts), 
thereby accepting that leukemic rearrangements with a read count below the RCT will be 
ignored. Analysis of IG/TR gene rearrangements in three replicates of a regenerating BM 
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sample from a T-ALL patient showed, as expected, that none of the rearrangements had 
a read count above the RCT. Nevertheless, part of the IG/TR gene rearrangements with a 
read count below the RCT were present in two or three of the replicates, and could thus be 
derived from normal B-cell or T-cell clones (Supplementary Figure 3). 
Figure 1.
Read counts of Vh-DJh rearrangements in BM from a healthy child, a T-ALL patient at a therapy interval 
(regenerating BM) and a BCP-ALL patient at one year after end of therapy (representative examples of the in total 
8 non-leukemic BM samples). Each dot represents a single rearrangement. Vh-DJh with a read count of <1 (caused 
by amplification-correction) were displayed as rearrangements with a read count of 1. The black line indicates the 
established threshold for Vh-DJh rearrangements. 
Regenerating BM showed structurally lower numbers of unique Vh-DJh rearrangements compared to healthy 
control BM and BM one year after end of therapy. This was also true for Vĸ-Jĸ, Vĸ-KDE and intronRSS-KDE 
rearrangements, but not Dh-Jh rearrangements (Supplementary Figure 1). This was expected, since the B-cell 
population in regenerating BM mainly consists of pre-B-I cells 31,32.
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Paired BM samples show homogeneous distribution of BCP-ALL, also for small subclones
Next, we aimed to analyze the number and particularly the tissue distribution of 
clones in BCP-ALL patients. Therefore, we performed NGS of IG/TR gene rearrangements 
in paired BM samples (from the left and the right pelvic bone) from newly diagnosed BCP-
ALL patients (n=7). By applying the previously described thresholds (now expressed as 
frequency) and analysis criteria (Supplementary Methods) to Vh-DJh rearrangements, 
oligoclonality was detected in six out of seven BCP-ALL patients (Figure 3). The number 
of index clones ranged from 1 to 5 (median: 1), whereas the total number of (sub)clones 
ranged from 2 to 34. With regard to distribution of the clones, 84% (74 out of 88) of all 
leukemic Vh-DJh rearrangements were present in both BM samples, ranging from 76% to 
100% per patient (Figure 3; Table 1). Importantly, 61 out of the 74 (82%) paired leukemic 
Vh-DJh rearrangements had a comparable frequency (<5-fold difference) in the two BM 
samples. Among the 13 paired leukemic Vh-DJh with a frequency of >5% (index clones), all 
Vh-DJh rearrangements had a comparable frequency in the two BM samples. The leukemic 
Vh-DJh rearrangements which were present in only one of the two samples, all had a 
very low frequency below 0.2% and often shared a common Dh-Jh stem with a paired 
leukemic Vh-DJh rearrangement (see below). Analysis of the other types of IG/TR gene 
rearrangements also showed that the vast majority of the leukemic rearrangements were 
Figure 2.
Read counts of Vh-DJh rearrangements in BM replicates from a BCP-ALL patient at diagnosis. This BM was 
sequenced in triplicate, resulting in IGH gene rearrangements that were found in one, in two or in all three 
replicates. Each dot represents a single rearrangement. Vh-DJh rearrangements with a read count of <1 (caused 
by amplification-correction), were displayed as rearrangements with a read count of 1. The black line indicates 
the previously defined threshold for Vh-DJh rearrangements (30 reads). 
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paired: 4 out of 5 (80%) Dh-Jh rearrangements, 8 out of 8 (100%) Vĸ-Jĸ rearrangements, 8 
out of 8 (100%) Vĸ-KDE rearrangements, 3 out of 3 (100%) intronRSS-KDE rearrangements, 
55 out of 57 (96%) Vγ-Jγ rearrangements, 30 out of 45 (67%) Vδ-Dδ rearrangements, 
8 out of 9 (89%) Dδ-Dδ rearrangements and 11 out of 11 (100%) Vβ-Jβ rearrangements 
(Supplementary Figure 4). Importantly, 171 out of all 199 (86%) paired leukemic IG/TR 
gene rearrangements showed a comparable frequency in the two BM samples. The overall 
results per patient are summarized in Table 1. 
Analysis of leukemic Dh-Jh stems at very low frequency levels suggests even higher numbers 
of homogeneously distributed subclones 
We subsequently aimed to estimate the number of leukemic IG/TR gene rearrangements 
that were present at very low frequencies and that were, based on the background-
threshold, excluded from previous analyses. Therefore, we visualized all paired complete 
IGH gene rearrangements, irrespective of their frequency (i.e. also with a frequency below 
the threshold). Only paired IGH gene rearrangements (i.e. present in both BM samples) 
were visualized in order to exclude potential technical artifacts. The resulting graph showed 
that, besides the previously detected paired IGH gene rearrangements, many more paired 
IGH gene rearrangements were present below the threshold (Figure 4). However, a paired 
IGH gene rearrangement below the threshold can be either derived from a leukemic clone 
or derived from a normal mature B-cell clone which had been distributed throughout 
Figure 3.
Frequencies of leukemic Vh-DJh rearrangements in paired BM samples (left and right pelvic bone) from BCP-
ALL patients at diagnosis. For each leukemic Vh-DJh rearrangement, the presence in both BM samples (L+R) 
or in only one of the two BM samples (L or R) is indicated. The background-area which also contains Vh-DJh 
rearrangements derived from normal B-cell clones is indicated for each sample (grey). Asterisks indicate that 
these Vh-DJh rearrangement share a common Dh-Jh stem with a paired leukemic Vh-DJh rearrangement. 
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the BM compartment. To discriminate, at sub-threshold level, leukemia-derived IGH gene 
rearrangements from normal B-cell derived IGH gene rearrangements, we searched for 
common Dh-Jh stems. An IGH gene rearrangement below the threshold that shared a 
common Dh-Jh stem with a leukemic IGH gene rearrangement above the threshold was 
considered leukemic too (since both were derived from the same ancestral clone). This 
analysis showed that, on top of the leukemic IGH gene rearrangements found in the 
previous analyses (above the threshold), even more leukemic IGH gene rearrangements 
are present at very low frequency-levels (below the threshold) (summarized in Figure 5). 
The exact number of leukemic IGH gene rearrangement per patient remains unknown, 
since the origin (leukemia or mature B-cell derived) of the IGH gene rearrangements 
with a frequency below the threshold and without a common Dh-Jh stem could not be 
determined. Of note, the IGH gene rearrangements with a common Dh-Jh stem often also 
had a common V-D junction, indicating that V to D-J joining as well as Vh-replacement had 
taken place.
Paired BM-PB samples confirm the homogeneous distribution of BCP-ALL clones via PB 
The above data indicate that BCP-ALL clones are distributed homogeneously over the 
BM compartment, implying that migration via PB is required. Therefore, we investigated 
whether leukemia-derived IG/TR gene rearrangements detected in BM can also be found 
in PB. To do so, we performed NGS of IG/TR gene rearrangements in paired BM–PB samples 
from newly diagnosed BCP-ALL patients (n=5). Leukemic IG/TR gene rearrangements 
found in the BM sample (i.e. with a frequency above the previously established thresholds) 
were searched in the corresponding PB sample and classified as ‘paired’ when also present 
Figure 4.
Frequencies of Vh-DJh rearrangements in paired BM samples (left and right pelvic bone) from BCP-ALL patients 
at diagnosis. All paired Vh-DJh rearrangements are shown, i.e. with a frequency above as well as below the 
threshold. Per sample, the background-area is indicated in grey. 
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in the PB sample. Analysis of complete IGH gene rearrangements showed that 98% (43 out 
of 44) of all leukemic Vh-DJh rearrangements were paired (Figure 6). Of note, 42 out of the 
43 (98%) paired leukemic Vh-DJh rearrangements had a comparable frequency (<5-fold 
difference) in the two corresponding samples. The only leukemic Vh-DJh rearrangement 
present in the BM sample but not in the PB sample, had a frequency of 0.04% and shared 
a common Dh-Jh stem with a paired leukemic Vh-DJh rearrangement. Analysis of the 
other IG and TR gene rearrangement types also showed that the majority of the leukemic 
rearrangements were paired: 30 out of 32 (94%) Dh-Jh rearrangements, 2 out of 2 (100%) 
Vĸ-Jĸ rearrangements, 1 out of 1 (100%) Vĸ-KDE rearrangements, 9 out of 9 (100%) Vγ-Jγ 
rearrangements, 320 out of 403 (79%) Vδ-Dδ rearrangements, 17 out of 17 (100%) Dδ-Dδ 
rearrangements and 4 out of 4 (100%) Vβ-Jβ rearrangements (no clonal intronRSS-KDE 
rearrangements were found) (Supplementary Figure 5). Together, 411 out of all 426 (96%) 
paired leukemic IG/TR gene rearrangements showed a comparable frequency between 
the BM and the corresponding PB sample.
Figure 5.
Schematic representation of the relations between Vh-DJh rearrangements, based on common Dh-Jh stems, in 
BM samples from BCP-ALL patients at diagnosis. The size of the circle represents the frequency of the Vh-DJh 
rearrangement. The blue or red color indicates a leukemic origin (blue; based on frequency, red; based on a 
common Dh-Jh stem), whereas the green color indicates small clones of unknown origin (no leukemic Dh-Jh 
stem).
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dIscussIoN 
To study the number of clones and their distribution in patients with BCP-ALL, we 
performed NGS of IG/TR gene rearrangements in paired BM-BM and BM-PB samples at 
diagnosis. First, we aimed to carefully define background-thresholds (RCTs), which exclude 
normal lymphocyte-derived IG/TR gene rearrangements when using an identical amount 
of DNA per sample. Therefore, we determined the maximum read count of these normal 
lymphocyte-derived IG/TR gene rearrangements in non-leukemic BM, i.e. healthy control 
BM, regenerating BM, and BM one year after end of therapy. Second, by analysing a BCP-
ALL sample at diagnosis in triplicate, we confirmed that all IG/TR gene rearrangements 
with a read count above the preset RCT represented clonal IG/TR gene rearrangements, 
and not technical artifacts. Of note, RCTs could not exclude IG/TR gene rearrangements 
derived from normal lymphocyte expansions directed against leukemic cells, since these 
expansions were probably not present in the studied MRD negative follow up samples 
(and certainly not in the healthy control BM sample). However, since many Vh-DJh 
rearrangements shared a common stem with an index clone and since, besides clonal 
TR gene rearrangements, also clonal IG gene rearrangements were observed (whereas 
Figure 6.
Frequencies of leukemic Vh-DJh rearrangements in paired BM-PB samples from BCP-ALL patients at diagnosis. For 
each leukemic Vh-DJh rearrangement in the BM sample (above the background-threshold), the presence in both 
samples (BM+PB) or in only the BM sample (BM) is indicated. Diamonds represent Vh-DJh rearrangements found 
in BM, triangles represent Vh-DJh rearrangements found in PB. Per sample, the background-area is indicated in 
grey. 
Chapter 2
44
reactive expansions against  leukemic cells would be mainly of T-cell origin), it is likely that 
most IG/TR gene rearrangements with read counts above the RCTs are of leukemic origin.
Analysis of IG/TR gene rearrangements in paired BM-BM diagnosis samples showed that 
all seven patients were oligoclonal. Remarkably high numbers of leukemic Vh-DJh, Vγ-Jγ 
and Vδ-Dδ rearrangements per patient could be detected (e.g. up to 34 leukemic Vh-DJh 
rearrangements). Even higher numbers of leukemic rearrangements per patient were 
detected when common Dh-Jh stem (junction sequence) analysis was used to also include 
Vh-DJh rearrangements below the background-threshold (up to 171 leukemic Vh-DJh 
rearrangements). Previous studies which used SB to analyze IG/TR gene rearrangements 
reported that only 40% of the ALL-patients were oligoclonal, with maximally 9 leukemic 
rearrangements per patient 11,14. The discrepancies between these previous findings and 
our current results can be explained by the difference in sensitivity of the applied methods. 
A more recent study that used NGS to analyze IGH gene rearrangements showed, in line 
with our results, that far more IGH gene rearrangements per patient can be found when 
analysis down to very low frequency-levels is allowed 15. However, in contrast with our 
results, this study also reported on a few patients (4 out of the 51 studied patients) in 
which more than thousand leukemic IGH gene rearrangements were found. Patients with 
such exceptionally high numbers of IGH gene rearrangements were not present in our 
study, which is probably related to the lower number of patients analyzed. Anyway, we 
showed that the number of leukemic IG/TR gene rearrangements per BCP-ALL patient is 
considerably higher than previously observed.
IG/TR gene rearrangements are used as PCR targets for MRD detection 22-26. Insight into 
subclone formation and distribution of these subclones might improve selection of MRD 
targets. Our current findings indicate that MRD targets have so far been selected from only a 
small part of the total number of leukemic IG/TR gene rearrangements present at diagnosis, 
i.e. from those that were sufficiently large to be detected by PCR-based methods (index 
clones with a frequency >5%). Still, more than 90% of the relapsed cases had maintained 
the IG and TR targets selected at diagnosis 25. Apparently, monitoring of only the index 
clones might be sufficient to predict relapse in most BCP-ALL patients. Furthermore, our 
observation that the vast majority of leukemic clones could be detected both in BM and PB 
implies that also PB samples may reliably be used for NGS-based selection of MRD targets.
By analyzing paired BM samples, we showed that the vast majority of the leukemic 
rearrangements were present in both BM samples and that their frequency was generally 
similar in both samples. The few leukemic rearrangements that were present in only one of 
the two samples generally had a low frequency (<2%). Probably, also these low-frequent 
clones were present in the whole BM compartment, but were absent in one of the two 
samples based on statistical chance. By analyzing paired BM-PB samples (from other 
patients), we showed that almost all leukemic rearrangements that were present in BM, 
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were also present in PB, generally at a similar frequency. As an exception to the above 
results, relatively many leukemic Vδ-Dδ rearrangements in patient 15803 (child with a 
TCF3-PBX1 translocation) and in patient 15507 (infant with an MLL-ENL translocation) were 
present in only one of the paired samples (54% and 22%, respectively). Since infants with 
a MLL-R translocation are known to be a distinct form of ALL (e.g. more oligoclonal) 27,28, 
the specific genetic aberrancies might be associated with the deviating results on Vδ-Dδ 
rearrangements 29. 
NGS-based IG/TR gene rearrangement analysis in paired BM-BM and BM-PB samples 
from newly diagnosed BCP-ALL patients has, to our knowledge, not been performed 
previously. Our early SB study on IG gene rearrangements in paired BM-PB samples of 
newly diagnosed BCP-ALL patients showed that relatively many leukemic IGH gene 
rearrangements were detected in the BM sample, but not or in a lower frequency in the 
corresponding PB sample 17, which seems to contradict our current results. However, this 
discrepancy is probably due to technical differences between SB and NGS (as described in 
the Materials and Methods section). 
Together, our paired BM-BM and paired BM-PB NGS analyses showed that almost 
all leukemic rearrangements are present in comparable frequencies in the BM and PB 
compartment. We did not study leukemic IG/TR gene rearrangements in tissues other than 
BM or PB. However, it might be speculated that extramedullary dissemination is different 
from distribution within the BM and PB compartment, since only clones with specific 
characteristics (e.g. homing receptors) are able to migrate to extramedullary sites 30. 
In conclusion, by using NGS data in combination with carefully defined thresholds, we 
were able to study leukemic IG/TR gene rearrangements down to a low level (0.01%-0.1%), 
without the interference of background-rearrangements. By studying paired BM-BM and 
paired BM-PB samples, we showed that the relative quantity of IG/TR gene rearrangements 
within the total (rearranged) BCP-ALL population is generally similar throughout the BM 
compartment and between BM and PB. Apparently, after their development at different BM 
sites in the body, almost all clones within a BCP-ALL population, even the small subclones, 
disseminate homogeneously via PB throughout the BM compartment. 
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suPPleMeNTary MeThods
Calculation of absolute read count and frequency
To determine the absolute read count of a sequence, i.e. the read count of a sequence 
corrected for PCR amplification, a known number of reference sequences was added to 
each PCR reaction. This resulted in a factor of difference between the number of reference 
sequences that was added and the read count after sequencing. Per gene rearrangement 
type, this factor was used to correct the read count of each patient sequence.
To determine the frequency of a sequence, the individual read count of that sequence 
was divided by the total read count for that gene rearrangement type in a sample. However, 
to calculate the frequency of a sequence from the IGK locus or TRD locus, the individual 
read count of the sequence was divided by the sum of the Vk-Jk, Vk-KDE and INTRSS-KDE 
total read counts respectively the sum of the Vd-Dd and Dd-Dd total read counts. 
Frequencies of IG/TR gene rearrangements in NGS versus SB or PCR 
Using PCR and SB, the frequency of leukemic rearrangements is determined within 
all IG and TR genes of the tested MNC’s, including germline (non-rearranged) IG and TR 
genes. In contrast, NGS determines the frequency of a leukemic rearrangement within the 
rearranged genes of a specific locus, without measurement of the germline genes. The 
number of non-leukemic MNCs is often higher in PB than in BM. Consequently, using PCR 
or SB, the frequency of a leukemic rearrangement is often lower in PB than in BM, whereas 
using NGS, the frequency is generally similar between PB and BM.
PRISCA tool in Galaxy
As input file, a list of all unique sequences with their associated sample ID, patient ID, 
gene rearrangement type, frequency and absolute read count was used. During a step-
wise bioinformatic process, sequences that were identical between the paired/triplicate 
samples were linked. Importantly, sequences were defined as identical if all nucleotides 
were similar. Only a difference in length of the sequence was accepted (e.g. a sequence 
which aligns 100% to another sequence, but is two nucleotides shorter, is considered 
identical). The graphical output from this tool displays the frequency of each sequence 
and its presence in only one or in more samples. PRISCA was developed in R (version 3.1.2) 
and on Galaxy (version v15.10). The PRISCA tool is freely available for use at https://bioinf-
galaxian.erasmusmc.nl/galaxy without the need to login and it can be installed on an 
existing Galaxy server through the Galaxy toolshed 1. 
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Analysis criteria
The IG/TR gene rearrangements at diagnosis were analyzed according to the following 
criteria: First, rearrangements were not further analyzed in case of a total read count of less 
than 1,000 (since no IG or TR gene rearrangements with a frequency above the background-
threshold were present in these cases). Second, rearrangements were classified as ‘paired’ 
when present in both corresponding (BM-BM or BM-PB) samples. Third, a rearrangement 
was regarded as leukemia-derived, if the frequency of the rearrangement or the 
frequency of at least one of the paired rearrangements was higher than the threshold. 
Fourth, a leukemia-derived rearrangement was considered to be derived from an index 
clone if the frequency was >5% and from a subclone if the frequency was <5%. Fifth, a 
patient was considered oligoclonal if: 1. More than two leukemic rearrangements of the 
same rearrangement type were found, or 2. Two leukemic rearrangements of the same 
rearrangement type were found and their frequency differed with more than a factor 5 (to 
take variation due to PCR amplification into account).
suPPleMeNTary TaBle 
Supplementary Table 1. Patient/sample characteristics.
type of 
comparison ID number gender
age at 
diagnosis
immunophentypic 
classification
cytogenetic 
aberrancy
tumor load 
BM 
Left BM - 
Right BM 15760 m 12 common-ALL iAMP 96%
15773 f 9 common-ALL ETV6-RUNX1 90%
15803 m 1 pre-B-ALL TCF3-PBX1 71%
16079 m 8 common-ALL ETV6-RUNX1 hyperdiploid 70%
16261 f 3 common-ALL ETV6-RUNX1 85%
16278 f 3 common-ALL - 69%
16300 f 4 common-ALL ETV6-RUNX1 88%
BM - PB 10147 f 18 common-ALL - 65%
14008 f 7 common-ALL hyperdiploid 97%
14803 f 4 pre-B-ALL hyperdiploid 56%
15507 f 0 pro-B-ALL MLL-ENL 100%
9781 f 5 common-ALL hyperdiploid 87%
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suPPleMeNTary fIGures
Supplementary Figure 1.
Read counts of Dh-Jh, Vĸ-Jĸ, Vĸ-KDE, intronRSS-KDE, Vγ-Jγ, Vδ-Dδ, Dδ-Dδ and Vβ-Jβ rearrangements in BM from a 
healthy child, BM from a representative T-ALL patient at a therapy interval (regenerating BM; n=5) and BM from a 
representative BCP-ALL patient at one year after end of therapy (n=2). Each dot represents a single rearrangement. 
Rearrangements with a read count of <1 (caused by amplification-correction) were displayed as rearrangements 
with a read count of 1. The black line indicates the threshold for the involved type of rearrangement.
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Supplementary Figure 2.
Read counts of Dh-Jh, Vĸ-Jĸ, Vĸ-KDE, intronRSS-KDE, Vγ-Jγ, Vδ-Dδ, Dδ-Dδ and Vβ-Jβ rearrangements in BM from 
a BCP-ALL patient at diagnosis. Each dot represents a single rearrangement. This BM was sequenced in triplicate, 
resulting in rearrangements that were found in one, in two or in all three of the replicates. Rearrangements with 
a read count of <1 (caused by amplification-correction) were displayed as rearrangements with a read count of 1. 
The black line indicates the previously defined threshold for the involved type of rearrangement. 
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Supplementary Figure 3.
Read counts of Vh-DJh, Dh-Jh, Vĸ-Jĸ, Vĸ-KDE, intronRSS-KDE, Vγ-Jγ, Vδ-Dδ, Dδ-Dδ and Vβ-Jβ rearrangements in 
regenerating BM from an T-ALL patient at a therapy interval. This BM was sequenced in triplicate, resulting in 
rearrangements that were found in one, in two or in all three of the replicates. Rearrangements with a read count 
of <1 (caused by amplification-correction), were displayed as rearrangements with a read count of 1. The black 
line indicates the previously defined threshold for the involved type of rearrangement. 
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Supplementary Figure 4.
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Supplementary Figure 4 (continued).
C
D
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Supplementary Figure 4 (continued).
E
F
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Supplementary Figure 4 (continued).
Frequencies of leukemic Dh-Jh, Vĸ-Jĸ, Vĸ-KDE, intronRSS-KDE, Vγ-Jγ, Vδ-Dδ, Dδ-Dδ and Vβ-Jβ rearrangements 
in paired BM samples (left and right pelvic bone) from BCP-ALL patients at diagnosis. For each leukemic 
rearrangement, the presence in both BM samples (paired) or in only one of the two BM samples is indicated. The 
background-area which also contains IG/TR gene rearrangements derived from normal B-cell and T-cell clones is 
indicated for each sample (grey). 
G
H
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C
D
Supplementary Figure 5 (continued).
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Supplementary Figure 5 (continued).
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G
Supplementary Figure 5 (continued)
Frequencies of leukemic Dh-Jh, Vĸ-Jĸ, Vĸ-KDE, Vγ-Jγ, Vδ-Dδ, Dδ-Dδ and Vβ-Jβ rearrangements in paired BM-PB 
samples from BCP-ALL patients at diagnosis. For each leukemic rearrangement in the BM sample (i.e. with a 
frequency above the BM threshold), the presence in both samples (paired) or in only the BM sample is indicated. 
Diamonds represent rearrangements found in BM, triangles represent rearrangements found in PB. The BM 
background-area which also contains IG/TR gene rearrangements derived from normal B-cell and T-cell clones 
is indicated for each sample (grey). IntronRSS-KDE rearrangements with a frequency above the threshold were 
absent in all patients. 
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aBsTracT
A better understanding of the reconstitution of the B-cell compartment 
during and after treatment for B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL) will help to assess the immunological status and needs 
of posttreatment BCP-ALL patients. Therefore, we aimed to study the 
composition and proliferation of both the B-cell precursor (BCP) population 
in bone marrow (BM) and mature B-cell population in peripheral blood (PB) 
during and after BCP-ALL therapy. Eight-color flow cytometry was used to 
identify BCP and mature B-cell subsets. Cell-cycle analysis using DRAQ5 
and proliferation history analysis using the KREC-assay were performed to 
study B-cell proliferation. We found a normal BCP differentiation pattern 
and a delayed formation of classical CD38dim naive mature B-cells, natural 
effector B-cells and memory B-cells in patients after chemotherapy. This 
B-cell differentiation/maturation pattern was strikingly similar to that 
during initial B-cell development in healthy infants. Tissue-resident plasma 
cells appeared to be partly protected from chemotherapy. Also, we found 
that the fast recovery of naive mature B-cell numbers after chemotherapy 
was the result of increased de novo BCP generation, rather than enhanced 
proliferation within a BCP subset or within the naive mature B-cell subset. 
These results indicate that posttreatment BCP-ALL patients will eventually 
reestablish a B-cell compartment with a composition and a B-cell receptor 
repertoire similar to that in healthy children. However, the infant-like B-cell 
differentiation/maturation during reconstitution also implies a temporarily 
absent memory B-cell compartment shortly after end of therapy. Our data 
suggest that revaccination might be beneficial in posttreatment BCP-ALL 
patients.
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INTroducTIoN 
Normal B-cell differentiation in the bone marrow (BM) is a tightly controlled process in 
which B-cell precursors (BCPs) differentiate through the pro-B, pre-B-I, pre-B-II-Large and 
pre-B-II-Small stage, to finally become immature BCPs, which express a functional B-cell 
receptor (BCR) 1-3. These are released in the peripheral blood (PB) as transitional B-cells 
which can further mature in the lymphoid tissues and spleen to become naive mature, 
natural effector and memory B-cells (Figure 1) 4. 
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Figure 1.
Schematic overview of the different B-cell subsets in BM, PB and lymphoid tissue. The immunologic markers 
characteristic for each subset are shown. Solid arrows indicate the main differentiation routes, dashed arrows 
indicate migration routes. For reasons of clarity, an arrow indicating direct differentiation of the naive mature 
B-cell subset into the plasmablast subset and arrows indicating migration of memory B-cells and plasma cells 
between the compartments are omitted. The specific colors for the different B-cell subsets are consistently 
applied throughout the different figures in the results section. The grey parts are not investigated in this study. 
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The normal B-cell compartment can be severely affected in patients receiving 
chemotherapy regimens, resulting in a compromised humoral immunity and 
consequently a high vulnerability to infections 5, 6. Profound B-lymphocytopenia as a 
result of chemotherapy was previously reported in patients with solid tumors treated with 
docetaxel, patients with breast cancer treated with anthracycline-based regimens and 
patients with acute leukemia treated with multidrug chemotherapy 7-13.
In patients treated for B-cell precursor acute lymphoblastic Leukemia (BCP-ALL), 
regeneration of BCPs in BM and recovery of all mature B-cell subsets in PB is needed in 
order to restore humoral immunity after chemotherapy. Previous studies on BM of ALL 
patients found that chemotherapy dramatically decreased BCP numbers, but that BCP 
regeneration occurred in between treatment phases and after end of ALL therapy 12,13. In 
between treatment phases, the regenerating BCP population consisted mainly of pre-B-I 
BCPs, while after end of therapy, also BCPs in later differentiation stages reappeared 12,13. 
Furthermore, the total percentage of BCPs was higher in regenerating BM of ALL patients 
than in BM of healthy controls 14,15. Previous studies on PB of ALL patients found normal to 
high levels of transitional and naive mature B-cells in PB shortly after end of therapy, while 
hardly any natural effector and memory B-cells were observed during the first year after 
end of therapy 9,10. 
Since these studies reported on the composition of the B-cell populations in either 
BM or PB of ALL patients, it is unclear whether the total (BM and PB) B-cell differentiation/
maturation pattern after chemotherapy is similar to that in healthy individuals. Importantly, 
an abnormal differentiation/maturation pattern could hinder the reestablishment of a 
well-functioning B-cell compartment in the long-term. Also, since proliferation of normal 
B-cells in ALL patients has so far not been studied, it is unknown whether the degree of 
B-cell proliferation in patients after chemotherapy is similar to that in healthy individuals. 
Enhanced proliferation of BCPs and/or naive mature B-cells in order to quickly restore 
B-cell numbers could possibly result in a B-cell compartment with a less diverse naive BCR 
repertoire. 
Here, we aimed to get more insight into the reconstitution of the B-cell compartment 
after profound B-lymphocytopenia induced by BCP-ALL chemotherapy. We therefore 
studied, by performing more detailed analyses than previously done, the composition and 
the proliferation of B-cell populations in both the BM and the PB compartment at different 
time points during and after BCP-ALL therapy. 
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MeThods 
Patient and healthy control samples
In total, 198 PB samples and 132 BM samples from 81 pediatric BCP-ALL patients 
(aged 1 to 18 years old) were collected (Supplementary Table 1). All patients were 
treated according to the Standard Risk (SR) or Medium Risk (MR) treatment arm of the 
Dutch Childhood Oncology Group (DCOG) ALL10 or ALL11 protocol, which contain the 
following key drugs: prednisone, dexamethasone, vincristine, daunorubicin, asparaginase, 
cyclophosphamide, cytarabine, mercaptopurine and doxorubicin 16. Patients with Down 
syndrome, patients assigned to the Ikaros positive-treatment arm and patients assigned 
to the High Risk (HR) treatment arm of the DCOG-ALL11 protocol were excluded, since 
treatment of these patients differs significantly from the large group of remaining BCP-
ALL patients. BM samples from six healthy children (aged 1 to 12 years old) that were BM 
stem cell donor for their siblings with parental informed consent and with approval of 
the Medical Ethical Committee of the Leiden University Medical Center (protocol P08.001) 
were used as healthy control BM. PB samples from (young) adults were used as healthy 
control PB, since PB samples from healthy children were not available. All samples were 
collected with informed-consent and/or according to the guidelines of the Medical Ethical 
Committee of Erasmus MC. 
Immunophenotyping  
Eight-color flow cytometry was performed on BM and PB samples after bulk-lysing 
with ammonium chloride and subsequent staining with the antibody panels as described 
in Supplementary Table 2. The samples were measured on a LSRFortessa or FACSCanto II 
flow cytometer (BD Biosciences, Erembodegem, Belgium) using FACS-Diva software (BD 
Biosciences). Data were analyzed with Inificyt Software (Cytognos, Salamanca, Spain). The 
immunophenotypic definitions of the different B-cell subsets are shown in Figure 1. 
Cell-cycle analysis
Post-Ficoll mononuclear cells (MNCs) from BM samples were stained with antibodies 
directed against cell-surface markers, labeled with DNA-intercalating agent DRAQ5 (3 uL, 
BioStatus, Shepshed, UK), and intracellularly stained after fixation and permeabilization 
with Fix&Perm reagents (An der Grub, Vienna, Austria). Antibody panels are described in 
Supplementary Table 2. Samples were measured (low speed, linear scale in APC channel) 
on a LSRFortessa (BD Biosciences), using FacsDIVA software (BD Biosciences). Using 
Inifinicyt Software (Cytognos), the percentage of cells with high DRAQ5 expression (cells 
in S/G2/M-phase) was determined within each BCP subset. 
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Molecular analysis of replication history
Post-Ficoll MNCs from BM and PB samples were stained with the antibody panels 
described in Supplementary Table 2. Pre-B-II-Small and immature BCP fractions (BM) 
and naive mature B-cell fractions (PB) were sorted using the FACSAriaIII Cell Sorter (BD 
Biosciences) and FACSDiva software (BD Biosciences). The gating strategies for sorting 
of the naive mature B-cell subset and different CD38-related stages within the naive 
mature B-cell subset are described in Supplementary Figure 1. DNA was isolated from the 
sorted cell fractions with the Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich, St. 
Louis, Missouri, USA) according to instructions of the manufacturer. The kappa-deleting 
recombination excision circle (KREC)-assay was performed on the sorted cell fractions as 
described previously 17.
Statistical analysis
The Mann-Whitney U test in Prism 5.0 software (GraphPad, La Jolla, California, USA) was 
used. A P-value of less than 0.05 was considered statistically significant. 
resulTs 
Composition of the BCP population in BM during and after therapy 
At day 15 and at day 33, induction therapy caused a complete loss of BCPs and a very 
low total WBC count in BM (Figure 2a). At day 79 and month 5, the preceding therapy 
intervals induced BCP regeneration. However, the intervals were too short to achieve a 
complete BCP differentiation, resulting in relatively high percentages of early pre-B-I BCPs 
and a relatively low percentage of total BCPs (less than one third of that in healthy children) 
(Figure 2a+b). From month 5 onwards, continuous maintenance therapy resulted in very 
low percentages of BCPs at month 9 and month 12. One year after end of therapy, the 
percentage of total BCPs in BM and the relative distribution of the BCP subsets within the 
BCP population had normalized (time points after end of therapy are indicated with # in 
the figures). 
Composition of the B-cell population in PB during and after therapy 
Since B-cell numbers in PB of children vary with age, B-cell numbers in PB of patients 
were expressed as percentage of the age-matched reference value. At day 15 and day 33, 
transitional B-cells had already completely disappeared and absolute numbers of naive 
mature B-cells, natural effector B-cells, memory B-cells and plasmablasts had dropped far 
below the normal reference values (Figure 3). From day 79 until end of therapy, hardly any 
mature B-cells, except for plasmablasts, were present (in both SR patients and MR patients, 
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Figure 2.
A. Percentage of pre-B-I, pre-B-II and immature BCPs in total BM WBC, in patients at different time point during 
therapy (n>15 per time point), in patients at one year after end of therapy (n=7) and in healthy children (n=6). The 
grey curve correlates to the right y-axis and shows the average WBC count per time point. Treatment phases are 
indicated below the x-axis. Bars represent mean values with SEMs.
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although numbers were slightly higher in SR patients; data not shown). Remarkably, 
plasmablasts returned to normal or high numbers in half of the patients at day 79 and 
month 5. At 6 weeks after end of therapy, transitional B-cells reappeared, exceeding 
normal reference values, while the other mature B-cell subsets remained at very low levels. 
At three months after end of therapy, also naive mature B-cell numbers exceeded the 
normal reference values. Until one year posttreatment, transitional and naive mature B-cell 
numbers remained above normal reference values, whereas numbers of natural effector 
B-cells and memory B-cells increased, but remained below normal reference values. 
Link between B-cell subsets in BM and PB during and after therapy
We next aimed to link the results on BCP subsets in BM to the results on mature B-cell 
subsets in PB. At day 15 and day 33, BCPs were absent in BM, but low numbers of naive 
mature B-cells were still present in PB (Figure 4a). At day 79 and at month 5, only very 
few immature BCPs were formed during regeneration in BM, resulting in only very few 
transitional and naive mature B-cells in PB. During the remaining months of therapy, BCPs 
in BM and transitional and naive mature B-cells in PB were virtually absent. At one year 
after end of therapy, a BCP population comparable to that in healthy children had been 
reestablished in BM, resulting in high numbers of transitional and naive mature B-cells in 
PB. 
day 79 month 5 1 year after end
of therapy
healthy child
B
Figure 2 (continued).
B. Dot plots showing representative examples of the CD19+ B-cell population (plasma cells excluded) in BM of 
a patient at day 79, a patient at month 5, a patient at one year after end of therapy and a healthy child. Contours 
indicate 1.5 SD. The percentage of pre-B-I BCPs within the total CD19+ B-cell population in BM is shown.
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Changes in plasma cell numbers in BM and plasmablast numbers in PB occurred more 
or less synchronously (Figure 4b). Particularly the increase in plasmablasts at day 79 and 
month 5 in PB was paralleled by an increase of plasma cells in BM. The immunoglobulin-
isotype subset distribution of the plasmablast population varied slightly at different time 
points, but both IgM+ plasmablasts and class-switched IgA+ and IgG+ plasmablasts 
remained present during and after therapy (Figure 4c).
No enhanced proliferation during BCP regeneration in BM
To evaluate whether proliferation is enhanced during BCP regeneration, we 
determined the degree of proliferation per BCP subset by measuring the percentage of 
cells in the S/G2/M-phase. As expected, pre-B-II-Large BCPs showed the highest degree 
of proliferation (Figure 5). Remarkably, also pro-B and pre-B-I BCPs showed a significant 
degree of proliferation. Pre-B-II-Small and immature BCPs showed hardly any proliferation 
(<5%; data not shown). Importantly, pre-B-I and pre-B-II-Large BCPs in regenerating BM 
(day 79 and month 5) proliferated to the same extent as pre-B-I and pre-B-II-Large BCPs in 
Figure 3.
Absolute numbers of mature B-cells expressed as a percentage of the aged-matched reference value (medians 
of healthy children), at different time points during therapy (n>15 per time point) and after end of therapy (n>10 
per time point). Boxes show medians with 2nd and 3rd quartiles. Whiskers show the most extreme values within 
1.5 times the interquartile ranges. Values more than 1.5 times the interquartile ranges are plotted individually. 
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healthy control BM. Small differences in pro-B BCP proliferation between regenerating BM 
and healthy control BM could be attributed to the limited number of healthy controls with 
sufficient pro-B BCPs (n=3). KREC-analysis confirmed that pre-B-II-Small and immature 
BCPs in non-regenerating BM did not proliferate (data not shown). KREC-analysis of 
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Figure 4.
A. Absolute numbers of BCPs per microliter in BM and absolute number of transitional and naive mature B-cells 
per microliter in PB at different time points during therapy (BM and PB: n>15 per time point) and at one year after 
end of therapy (BM n=7; PB n=11). Bars represent mean valus with SEMs. Transitional and naive mature B-cell 
numbers in PB of healthy children are based on literature 18.
B. Absolute numbers of plasmablasts in PB and CD19+ plasma cells in BM, at different time points during therapy 
(BM and PB: n>15 per time point) and at one year after end of therapy (BM n=7; PB n=11). Bars represent mean 
values with SEMs.
C. Percentage of the immunoglobulin-isotype subsets within total plasmablasts in PB. n>5 per time point. 
Immunoglobulin-isotype percentages in PB of healthy controls are based on literature 24. 
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pre-B-II-Small and immature BCPs in regenerating BM could not be performed due to very 
low numbers of these cells at day 79 and month 5.
No enhanced proliferation in the naive mature B-cell subset during and after therapy 
To evaluate the replication history of the naive mature B-cells at different time points 
during and after therapy, KREC-analysis was performed. This analysis showed that the 
naive mature B-cell subset in all day-15 and day-33 PB samples, and some month-5 PB 
samples, seemed to have undergone a higher number of cells divisions than the naive 
mature B-cell subset in healthy control PB samples (Figure 6a). After end of therapy, the 
number of cell divisions of the naive mature B-cell subset was not significantly different 
from that in healthy controls. However, more detailed analysis showed that the variations 
in the observed number of cell divisions appeared to be related to the variable composition 
of the naive B-cell subset at the different time points. The larger the proportion of CD38low 
naive mature B-cells, the higher the number of cell divisions (Figure 6b+c). This correlation 
between CD38 expression and replication within the naive mature B-cell subset was 
confirmed by separately analyzing CD38high, CD38dim and CD38low naive mature B-cells 
from healthy control PB (Figure 6d). Thus, the naive mature B-cells in patients during and 
after therapy showed a similar number of cell divisions as the corresponding naive mature 
B-cells (i.e. with the same CD38 expression) in healthy controls. 
Figure 5.
Percentage of S/G2/M-cells within the pro-B BCP subset (CD34+CD19-CD36/CD123-CD22+), pre-B-I BCP subset 
(CD19+CD10+IgM-cyIgM-) and pre-B-II-Large BCP subset (CD19+CD10+IgM-cyIgM+cyCD179a+) in BM at day 79 
(n=9), BM at month 5 (n=10) and BM from healthy controls (n=7; 3 children, 4 adults). Bars represent mean values 
with SEMs. *p<0.05. 
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Figure 6.
A. Number of cell divisions after IGK IntronRSS-KDE rearrangement in the naive mature B-cell subset, at different 
time points during and after therapy. Each dot represents a patient. Medians are shown. **p<0.01. Naive B-cell 
numbers at 6 weeks after end of therapy were too low for KREC-analysis. Healthy controls are young adults, but 
previous studies showed that the median number of naive mature B-cell replications in adults was similar to that 
in children 39,40. 
B. Dot plots showing representative examples of the CD19+ B-cell population in PB of a patient at day 33, a 
patient at 6 weeks after end of therapy, a patient at 3 months after end of therapy, a patient at 9 months after end 
of therapy and a healthy control. As a reference, the CD38 expression of naive mature B-cells in healthy controls 
is indicated with a black square.
C. Correlation between CD38 expression and the number of cell divisions in the naive mature B-cell subset, at 
different time points during and after therapy. Green circles represent mean numbers of cell divisions (with SD), 
corresponding to right y-axis. Grey bars represent mean levels of CD38 expression, corresponding to left y-axis. 
D. Comparison of the number of cell divisions between CD38high, CD38dim, CD38low and total naive B-cells 
in PB from healthy controls. Each symbol corresponds to one of the three healthy controls. Medians are shown. 
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The subset distribution of the mature B-cell population in PB after end of therapy is similar to 
that in PB of infants
Since our results indicated that virtually the entire B-cell compartment had to be 
rebuilt after end of BCP-ALL treatment, we compared the subset distribution of the mature 
B-cell population in PB of patients at 0-6 months or 6-12 months posttreatment with 
that of healthy infants that were 0-6 months and 6-12 months of age, respectively (infant 
reference values from literature 18). We did not further subdivide the naive mature B-cell 
subset into the different CD38-based maturation stages, since infant reference values for 
these subpopulations do not exist. This comparison showed that the subset distribution 
of the mature B-cell population in patients after end of therapy, aged 4 years and older, 
paralleled that in healthy infants (Figure 7). 
Figure 7.
Distribution of the B-cell subsets within the total mature B-cell population in PB of patients after end of therapy 
compared to that in PB of healthy infants. Since the age of the included ALL patients is >4 years, healthy children 
>4 years old are used as a reference. The subset distribution in infants and children > 4 years are based on normal 
reference values in literature 18. 
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dIscussIoN 
BCP-ALL treatment has a dramatic impact on the normal B-cell compartment. We 
aimed to understand reconstitution of the B-cell compartment after BCP-ALL therapy. We 
therefore performed a detailed study on the composition of the B-cell population and the 
degree of proliferation in the specific B-cell subsets at different time points during and 
after ALL therapy. Of importance, we studies B-cells in both BM and PB, which to our best 
knowledge has not been done before. 
Our results on the dynamics of B-cell subsets in BM and PB during and after ALL-therapy 
showed that chemotherapy dramatically affected the BCP population in BM and the 
mature B-cell population in PB, which was in agreement with previous studies 9-13. The two 
therapy intervals (with a duration of one week and two weeks, respectively) were too short 
to achieve complete BCP differentiation in BM and therefore too short to replenish PB with 
new mature B-cells. These results were in line with previous results on BCP recovery in ALL 
patients treated according to the DCOG ALL8 protocol 12,13. In posttreatment PB, we showed 
a relatively fast recovery of transitional and naive mature B-cell numbers (within 6 weeks 
and 3 months, respectively), but a delayed recovery of natural effector and memory B-cell 
numbers. In previous studies, a similar pattern of mature B-cell recovery after chemotherapy 
was found in patients treated for ALL (according to older protocols), in patients treated for 
other types of cancer (e.g. breast cancer) and, remarkably, in patients who had received 
a stem cell transplantation (SCT) after chemotherapeutic conditioning 8-10,19-22. These 
data indicate that once B-cell recovery is induced (at a variable time point depending on 
the type of preceding chemotherapy or SCT), reconstitution of the B-cell compartment 
follows a consistent pattern. Our data indicate that between two and six weeks of BCP 
regeneration are needed to generate new transitional B-cells. Subsequently, less than six 
weeks are necessary to restore normal levels of naive mature B-cells. However, more than 
one year is required to reestablish normal levels of antigen-experienced B-cells, such as 
memory B-cells. 
In some patients, an increase of plasmablasts in PB was observed during therapy 
intervals, which correlated with an increase of plasma cells in BM. A large part of these 
plasmablasts were class-switched and predominantly of the IgA-isotype. Since memory 
B-cell numbers in PB remained very low, also during therapy intervals, plasmablasts 
reappearing at day 79 and month 5 had to be derived from long-lived plasma cells in 
the tissue. Studies on antibody levels in ALL patients showed that vaccination-induced 
immunoglobulins were, although decreased, still present after therapy 23. Other studies 
showed that, in steady-state conditions, long-lived plasma cells in BM and tissue recirculate 
in PB 24,25. Together, these data suggest that some long-lived plasma cells residing in the 
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tissue, in particular IgA-plasma cells in the mucosal surfaces, are protected from cytotoxic 
therapy and are able to recirculate as plasmablasts in PB during and after BCP-ALL therapy.
Since regenerating BM samples from children directly after end of therapy were 
not available, we used regenerating BM samples taken at therapy intervals (day 79 
and month 5) to study the role of BCP proliferation in the reconstitution of the B-cell 
compartment after BCP-ALL therapy. We found that BCPs in BM of patients at day 79 and 
month 5 proliferated at a similar rate as BCPs in BM of healthy individuals. Proliferation 
of BCPs during B-cell recovery after ALL chemotherapy was not studied before. However, 
other proliferation studies found, in line with our results, that early lymphoid precursors in 
cytopenia-induced reactive BM samples and early BCPs in regenerating/infant BM samples 
(mixed group) proliferated at a similar rate as their equivalents in healthy adult BM 26,27. 
These data indicate that the increased percentage of pre-B-I BCPs in regenerating BM 
after chemotherapy (although less pronounced in our data than in previous studies) is not 
caused by enhanced proliferation but rather by a larger influx of non-committed stem cells 
into the B-cell lineage. This way, BCP regeneration after chemotherapy is likely to result 
in the reestablishment of a diverse naive BCR repertoire (i.e. not narrowed by enhanced 
proliferation). 
Our results on B-cell replication in PB showed that the naive mature B-cell subset was 
composed of naive B-cells with different levels of maturation. Maturation within the naive 
mature B-cell subset was characterized by a decrease in CD38 expression and an increase 
in number of passed replication cycles. The naive mature B-cell subset present shortly 
after start of therapy (at day 15 and day 33) consisted of residual CD38low naive mature 
B-cells with a relatively high number of replications. In contrast, the naive mature B-cell 
subset present directly after end of chemotherapy predominantly consisted of newly 
generated CD38high naive mature B-cells with a low number of replications. Variations in 
replication number of the total naive mature B-cell subset were therefore caused by the 
variable composition of the naive mature B-cell subset at the different time points and 
not by a changed degree of B-cell proliferation. Thus, the proliferation history of the naive 
mature B-cells in PB of patients during and after therapy was similar to that in PB of healthy 
individuals. To our knowledge, no previous studies exist on mature B-cell proliferation or 
on BCR repertoire formation after ALL therapy. A study on immune reconstitution after SCT 
showed that the proliferation history of naive mature B-cells after autologous SCT was also 
similar to that in healthy individuals 28. In another SCT-study, a restricted BCR repertoire 
was found during the first year after SCT, but this was most likely the result of low numbers 
of sequenced IGH gene-rearrangements early posttransplant 29. These data indicate that 
recovery of the naive mature B-cell numbers after BCP-ALL therapy is the result of de 
novo B-cell generation, rather than enhanced proliferation within the naive B-cell subset, 
resulting in the reestablishment of a diverse naive BCR repertoire after therapy.
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Comparing our data on reconstitution of the mature B-cell population after BCP-ALL 
therapy with literature data on development of the mature B-cell population in infants, 
we found remarkable similarities. Firstly, we found that, also in infants, natural effector 
and memory B-cell numbers remained low until at least one year after birth. Moreover, 
the subset distribution of the mature B-cell population in patients at a certain time 
point after end of therapy was almost identical to that in infants at the same time point 
after birth. This comparison between posttreatment patients and infants has not been 
performed previously, but SCT-studies showed that the B-cell subset distribution during 
reconstitution after SCT was also similar to that during the first year of life 19-21. Secondly, we 
found, as already discussed, that almost all newly generated naive mature B-cells during 
the first half year after end of chemotherapy were CD38high (indicating a low degree of 
maturation), while the first CD38dim naive mature B-cells only appeared after six to nine 
months posttreatment. Previous studies showed that also in cord blood (and in PB of 
patients in the first half year after SCT), almost all naive mature B-cells were CD38high 20,30,31. 
CD38high B-cells represent pre-naive B-cells, which are in an intermediate stage between 
the CD38bright transitional B-cells and the classical CD38dim naive mature B-cells 30,31. It 
is unlikely that the transition from pre-naive to classical naive mature B-cell stage takes 
more than six months (longer than the life-span of a naive mature B-cell). Thus, it seems 
that pre-naive B-cells in PB of patients during the first half year after end of therapy are, 
similar to those in PB of infants, temporarily less able to mature to the CD38dim naive 
mature B-cell stage. Possibly, this is due to a lack of contact with germinal centers, which 
were found to be decreased in both neonates and patients after chemotherapeutic 
conditioning regimens 19,32,33. Together, these data indicate that the recovery of the B-cell 
subsets in patients after BCP-ALL therapy is similar to the initial development of the B-cell 
subsets in infants. Since the DCOG ALL10 and ALL11 protocols consist of a backbone that 
is derived from the Berlin-Frankfurt-Münster (BFM) protocol, our results can presumably be 
generalized to all BCP-ALL patients treated according to a BFM-based protocol.
Thus, although we showed that residual plasma cells might still be present in the 
tissue after end of BCP-ALL therapy, previous studies showed that these plasma cells do 
not produce protective levels of immunoglobulins anymore in a significant part of the 
patients 23,34. Also, we showed that the B-cell population shortly after BCP-ALL therapy 
was, similar to that in healthy infants, lacking natural effector B-cells and memory 
B-cells. In healthy infants, this inexperienced B-cell population is supported by the 
national vaccination programs starting from the second month after birth 35-38. Therefore, 
revaccination might also be beneficial in BCP-ALL patients shorty after end of therapy. 
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suPPleMeNTary TaBles aNd fIGure
Supplementary Table 1. Characteristics of the 81 BCP-ALL patients collected from the
Sophia Children’s hospital in Rotterdam.
Characteristic n %
Age at diagnosis
   <1 year 0 0
   1-10 years 67 83
   >10 years 14 17
Sex
   male 50 62
   female 31 38
WBC in PB at diagnosis
   <50.000/uL 74 91
   >50.000/uL 7 9
Immunophenotype
   pro-B ALL 0 0
   common ALL 61 75
   pre-B ALL 20 25
Cytogenetics*
   TCF3-PBX1 0 0
   MLL-rearranged 0 0
   hyperdiploidy 31 38
   TEL-AML1 26 32
   normal 18 22
   unknown 6 7
* Patients with IKZF1 mutation, BCR-ABL fusion gene and patients with Down syndrome were
excluded from this study since their treatment protocol is significantly different
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Supplementary Table 2A. Antibody panels used for flow cytometry. 
PB/ 
BV421
PO/ 
BV510
BV605 FITC PE PerCP-
Cy5.5
PE-
Cy7
APC APC-H7/ 
APC-C750
Labeling for:
CD27 IgM - IgG IgD CD45 CD19 IgA CD38 Immunophenotyping PB
CD20 CD45 - CD81 - CD34 CD19 CD10 CD38 Immunophenotyping BM
CD20 IgM CD19 CD34 CD10 - - DRAQ5 - Cell-cycle analysis tube 1
CD10 IgM CD19 cyIgM cy- 
CD179a
- - DRAQ5 - Cell-cycle analysis tube 2
- CD34 CD19 CD36+ 
CD123
CD22 - - DRAQ5 - Cell-cycle analysis tube 3
CD27 - - - IgD - CD19 (CD5) CD38 Sort naive mature B-cells
- CD45 - CD34 CD20 IgM CD19 CD10 - Sort BCP subsets BM
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Supplementary Table 2B. Detailed antibody characteristics.
Marker Fluorochrome Clone Supplier Volume per test
CD5 APC UCHT2 Biolegend 25 uL (20x diluted)
CD10 APC HI10a BD Biosciences 5uL
CD10 BV421 HI10a Biolegend 1 uL
CD10 PE ALB1 Beckman Coulter 20 uL
CD123 FITC AC145 Miltenyi Biotech 10 uL
CD179a PE 4G7 Beckman Coulter 25 uL (50x diluted)
CD19 PE-Cy7 J3-119 Beckman Coulter 5 uL
CD19 BV605 SJ25C1 BD Biosciences 5 uL
CD20 PB 2H7 Biolegend 1 uL
CD20 PE L27 BD Biosciences 2.5 uL
CD22 PE S-HCL-1 BD Biosciences 10 uL
CD27 BV421 M-T271 BD Biosciences 1 uL
CD34 PerCP-Cy5.5 8G12 BD Biosciences 7uL
CD34 BV510 581 Biolegend 5 uL
CD34 FITC 8G12 BD Biosciences 10 uL
CD36 FITC CLB-IVC7 Sanquin 5 uL
CD38 APC-H7 HB7 BD Biosciences 3 uL
CD38 APC-C750 LS198-4-3 Beckman Coulter 1uL
CD45 PerCP-Cy5.5 2D1 BD Biosciences 5 uL 
CD45 PO HI30 Invitrogen 5uL
CD81 FITC JS81 BD Biosciences 5 uL
IgA APC IS11-8E10 Miltenyi Biotech 5 uL (50x diluted)
IgD PE Polyclonal SBA 2.5 uL (5x diluted)
IgG FITC G18-145 BD Biosciences 2.5 uL
IgM FITC Polyclonal SBA 25 uL (50x diluted)
IgM BV510 MHM-88 Biolegend 1.5 uL
IgM PerCP-Cy5.5 MHM-88 Bioloegend 2.5 uL
DNA dye
DRAQ5 similar to APC - Biostatus 3 uL
 
Supplementary Figure 1.
A. Stepwise gating strategy used for sorting of the naive mature B-cell subset.
B. Stepwise gating strategy used for sorting of CD38high, CD38dim and CD38low naive mature B-cells in healthy 
control PB. To improve separation of CD38high from CD38dim naive mature B-cells, CD5-APC was added to the 
antibody panel which was previously used to sort the total naive mature B-cell subset. 
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aBsTracT
Flow cytometric detection of minimal residual disease (MRD) in 
children with B-cell precursor acute lymphoblastic leukemia (BCP-
ALL) requires discrimination between residual leukemic cells and 
B-cell precursors (BCPs) which regenerate during therapy intervals. 
Therefore, detailed knowledge on the immunophenotypes of normal 
and regenerating BCPs is crucial. In this study, EuroFlow-based 8-color 
flow cytometry and new analysis tools were used to first characterize the 
immunophenotypic maturation of normal BCPs in bone marrow (BM) from 
healthy children. This resulted in a continuous multiparametric pathway 
consisting of 7 maturation stages, including transition phases that formed 
the missing links between the conventional B-cell differentiation stages. 
This pathway was subsequently used as a reference to characterize the 
immunophenotypic maturation of regenerating BCPs in BM from children 
treated for BCP-ALL. Within regenerating BCPs, we identified pre-B-I 
cells that expressed low or dim CD34 levels, in contrast to the classical 
CD34high pre-B-I cell immunophenotype. These CD34-/dim pre-B-I cells 
were relatively abundant in regenerating BM (11-85% within the pre-B-I 
subset), while hardly present in healthy control BM (9-13% within the pre-
B-I subset; p=0.0027). Furthermore, analysis of BCP-ALL diagnosis samples 
showed that part of the BCP-ALL cases (23%) immunophenotypically 
overlapped with CD34-/dim pre-B-I cells. Our results indicate that newly 
identified CD34-/dim pre-B-I cells in regenerating BM can be mistaken 
for residual BCP-ALL cells, which could potentially result in false-positive 
MRD outcomes. Therefore, regenerating BM, in which CD34-/dim pre-B-I 
cells are relatively abundant, should be used as reference frame in flow 
cytometric MRD measurements. 
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INTroducTIoN 
B-cell precursors (BCPs) in bone marrow (BM) differentiate to mature B-cells, which 
are released into peripheral blood (PB). Based on classical immunophenotyping, 
BCP differentiation can be subdivided into a pro-B (CD22+CD19-CD34+), pre-B-I 
(CD19+CD10highCD34+), pre-B-II-Large (CD19+CD10+CD34-CD20high), pre-B-II-
Small (CD19+CD10+CD34-CD20low) and immature (CD19+CD10+Igĸ/λ+) stage 1-3. The 
percentages of BCPs in BM of healthy individuals are variable and decline with age 4,5.
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a clonal expansion of a 
malignantly transformed BCP cell. Therapy in BCP-ALL patients targets the malignant cells, 
but also affects the remaining normal BCP population. However, normal BCPs are able to 
regenerate during therapy intervals and after end of therapy. During BCP regeneration, the 
BCP population is relatively increased 6-8. 
To determine treatment response and subsequent prognosis in children treated for 
BCP-ALL, minimal residual disease (MRD) measurements are performed 9-11. Flow cytometry 
is one of the methods used for MRD detection, in which residual leukemic cells are 
recognized based on their aberrant immunophenotype 12-17. Since the immunophenotype 
of leukemic cells resembles that of BCPs, it is particularly difficult to detect residual leukemic 
cells during therapy intervals, i.e. when regenerating BCPs are abundantly present 18-20. 
Leukemic cells can be discriminated from regenerating BCPs by the expression of BCP-ALL 
specific markers, by overexpression or underexpression of B-cell differentiation markers or 
by asynchronous expression of B-cell differentiation markers 8,21-26. 
In this study, we first aimed to map the immunophenotypic maturation of normal BCPs 
in BM from healthy children. Previous studies on normal B-cell differentiation, using 4-color 
to 6-color immunostainings, provided a consensus model, in which four to five discrete 
BCP stages could be discerned 1-4,26-28. However, BCPs which expressed a combination of 
differentiation markers that did not fit into any of these stages were observed in BM from 
healthy individuals 29,30. These BCPs might represent transition phases between the well-
defined BCP stages.
Secondly, we aimed to characterize the immunophenotypic maturation of regenerating 
BCPs in children treated for BCP-ALL, since this will result in a better discrimination between 
leukemic cells and regenerating BCPs and consequently may improve flow cytometric 
MRD detection. Most of the previous studies on regenerating BCPs during and after ALL 
therapy focused on the relative ratios between the known BCP stages 4,6,7,29,31. Studies that 
specifically evaluated the immunophenotypic maturation of regenerating BCPs used 
3-color or 4-color flow cytometry, which is not sufficient for a detailed analysis 4,29,31.
In this study, we used a single 8-color immunostaining and EuroFlow-based multivariate 
analysis strategies 32 to visualize the immunophenotypic maturation of normal BCPs in 
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healthy children as a continuous multiparametric pathway, which was subsequently 
used to characterize the immunophenotypic maturation of regenerating BCPs in children 
treated for BCP-ALL.
MeThods 
BM samples from healthy children and BCP-ALL patients
BM was obtained from three healthy children (all male; aged 2, 5 and 13 years old) 
that were BM stem cell donor for their siblings with parental informed consent and 
with approval of the medical ethical committee of the Leiden University Medical Center 
(protocol P08.001). Twenty-eight diagnosis BM samples and 32 follow up BM samples 
were collected from pediatric BCP-ALL patients treated according to the Dutch Childhood 
Oncology Group (DCOG) ALL11 protocol and assigned to the standard risk (SR) treatment 
group or medium risk (MR) treatment group. The follow up BM samples were acquired 
during the interval after induction therapy (at 3 months after start of therapy, n=10), 
during the interval after therapy phase M (at 5 months after start of therapy, n=19) and at 
one year after end of therapy (n=3) (Supplementary Figure 1) 6,7 . All follow up BM samples 
were MRD negative, as determined by real-time quantitative PCR analysis of rearranged 
immunoglobulin and T-cell receptor genes 33,34. Samples were obtained according to the 
guidelines of the local Medical Ethics Committees and in line with the Declaration of 
Helsinki Protocol.
EuroFlow-based immunophenotyping
BM samples were bulk-lysed with ammonium chloride. Subsequently, at least 3 x 106 
leukocytes per tube were stained with the following antibodies: CD20-PB (2H7; Biolegend, 
San Diego, California, USA), CD45-PO (HI30; Invitrogen, Carlsbad, California, USA), Terminal 
deoxynucleotidyl Transferase (TdT)-FITC (HT-6; DAKO, Glostrup, Denmark), SmIgĸ-PE 
(polyclonal; Cytognos, Salamanca, Spain), SmIgλ-PE (polyclonal; Cytognos), CyIgμ-PerCP 
Cy5.5 (MHM-88; Biolegend), CD19-PE Cy7 (J3-119; Beckman Coulter, Brea, California, 
USA), CD34-APC (8G12; BD Biosciences, Erembodegem, Belgium), CD10-APC C750 (HI10a; 
Cytognos). Cell surface markers were stained first, followed by staining of intracellular 
markers using Fix&Perm reagents (An der Grub, Wien, Austria) 32. At least 1 x 106 events 
were acquired on a FACSCanto-II flow cytometer (BD Biosciences) using FACSDiva software 
(BD Biosciences). Flow cytometric data were analyzed with Infinicyt Software (Cytognos), 
using different approaches which are described in detail within the Results section 32,35. 
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High-speed cell sorting
One normal BM sample and two regenerating BM samples were stained with the same 
antibodies as described above and by applying the Foxp3/Transcription-Factor-Staining 
Buffer Set for intracellular staining (resulting in a higher DNA yield than after applying 
Fix&Perm reagents). One additional BM sample with a very low WBC count was stained for 
only surface markers, in order to further optimize DNA yield (intracellular markers were not 
required due to absence of BCPs beyond the pre-B-I stage). After sorting of the selected 
BCP fractions (FACSAria-III, BD Biosciences), DNA was extracted using the Mammalian 
Genomic DNA Miniprep Kit (Sigma-Aldrich, St. Louis, Missouri, USA). 
GeneScan analysis of IGH gene rearrangements 
IGH gene rearrangements in the sorted BCP fractions were amplified with BIOMED2-
primers and subsequently analyzed with GeneScan as described previously 2,36. The 
presence of high frequencies of in-frame rearrangements could be deduced from triplet 
spacing of the GeneScan peaks 2,36. 
Statistical methods
The Mann-Whitney U test in Prism 5.0 software was used (GraphPad, La Jolla, California, 
USA). 
resulTs 
Detailed analysis of the normal BCP differentiation 
We first aimed to evaluate the immunophenotypic maturation of normal CD19+ BCPs. 
Therefore, B-cell populations from three BM samples of healthy children were merged 
in an Automatic Population Separator (APS) and analyzed with the Infinicyt maturation 
tool (Supplementary Methods). This resulted in a multiparametric maturation pathway 
consisting of an arbitrary number of 20 immunophenotypic stages (Figure 1a). The 
expression levels of the individual differentiation markers in each stage were visualized in 
a maturation diagram (Figure 1c). Stages in which the individual differentiation markers 
showed similar expression levels were then combined, resulting in a total of 7 distinct 
immunophenotypic stages (Figure 1b). These 7 maturation stages formed a continuous 
multiparametric pathway, in which each stage gradually evolved into the next: Stage 1 
BCPs expressed high levels of the early progenitor markers CD34 and CD10, low levels 
of the mature B-cell markers CD45 and CD20, and high levels of TdT, an enzyme which is 
only detectable at high levels during IGH gene rearrangements. Stage 1 BCPs did not yet 
express cyIgμ and Igκ/λ, markers which can only be present after formation of a functional 
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IGH gene rearrangement or functional IGK/IGL gene rearrangement, respectively. This first 
immunophenotypic stage matches the classical pre-B-I stage. In stage 2, progressively 
more BCPs became cyIgμ-positive, and BCPs expressed higher levels of CD20 and slightly 
lower levels of CD10, while still remaining TdT-positive and CD34-positive. This stage seems 
to represent the transition from the pre-B-I to the pre-B-II-Large stage. In stage 3, all BCPs 
showed cyIgμ positivity, dim levels of CD45 and high levels of CD20, while the expression 
of CD34 and TdT had decreased, although not yet to the lowest level. In combination with 
a larger cell size (high FSC), this immunophenotype is typical for the pre-B-II-Large stage. 
From stage 3 onwards, BCPs remained cyIgμ-positive as a result of a successful IGH gene 
rearrangement. In stage 4, BCPs had become fully TdT-negative and CD34-negative, while 
remaining CD20dim, suggesting a transition stage between the pre-B-II-Large and the pre-
B-II-Small stage. From stage 4 onwards, BCPs remained CD34-negative and TdT-negative. 
In stage 5, CD20 expression had dropped to low levels, resulting in an immunophenotype 
which matches the conventional pre-B-II-Small stage. In stage 6, BCPs expressed Igκ/λ as a 
result of a successful IGK/IGL gene rearrangement. This Igκ/λ expression occurred together 
with increased expression of CD45 and re-expression of CD20, which is characteristic for 
the immature stage. Finally, in stage 7, B-cells had lost their CD10 expression, while levels of 
Igκ/λ , CD45 and CD20 remained high, which is in accordance with the immunophenotype 
of mature B-cells. The immunophenotype of each of the 7 maturation stages was confirmed 
within conventional two-dimensional dot plots (Supplementary Figure 2). 
The immunophenotypic maturation of regenerating BCPs differs from that of normal BCPs
We next aimed to evaluate to what extent the immunophenotypic maturation of 
regenerating BCPs is similar to that of normal BCPs. Therefore, regenerating BM from BCP-
ALL patients at 3 months (n=10) and 5 months (n=19) after start of therapy and at one 
year after end of therapy (n=3) were analyzed. Principal component analysis was used to 
immunophenotypically compare regenerating BCPs (present at 3 and 5 months after start 
Figure 1.
A. Automatic, multiparametric analysis of a CD19+ B-cell population (merge from 3 healthy children) in an APS-
plot, resulting in a B-cell maturation pathway. The B-cell maturation pathway was automatically separated into 20 
stages, ranging from the least mature (1) to the most mature (20) immunophenotype. 
B. By combining stages with comparable immunophenotypes, the arbitrary 20 stages were reduced to 7 distinct 
maturation stages. 
C. FSC, SSC and expression levels of eight differentiation markers during the B-cell maturation pathway shown 
in (A) and (B). The seven distinct B-cell maturation stages are shown below the plot. Additionally, the grey line, 
corresponding to the right y-axis, shows the percentage of cells within the total B-cell population for each 
maturation stage.
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of treatment) with normal BCPs based on FSC, SSC and all eight differentiation markers 
together. After exclusion of Igκ/λ-positive immature BCPs and mature B-cells (stage 6 and 7; 
hardly present in regenerating BM), the regenerating BCPs of each patient were visualized 
in an APS-plot with a fixed normal BCP maturation pathway (Figure 2). As expected, BM 
samples taken at 3 and 5 months after start of therapy showed a shift in distribution 
towards the pre-B-I subset (also shown in conventional dot plots in Supplementary 
Figure 3). Surprisingly, 80% of the regenerating BM samples taken at 3 months after start 
of therapy (n=10) and 89% of the regenerating BM samples taken at 5 months after start 
of therapy (n=19) showed an immunophenotypic maturation that deviated from the 
normal BCP maturation pathway (Figure 2a and b). In these samples, more than 5% (up to 
73%) of the regenerating BCPs was located outside the 2SD boundaries of the normal BCP 
maturation pathway. All regenerating BCPs outside the 2SD boundaries were, according to 
the conventional dot plots, cyIgμ-negative and TdT-positive. Of note, these cells could not 
represent pro-B cells, since CD19-negative cells were excluded from this analysis. These 
results indicated that the cells with an aberrant immunophenotype were probably part of 
the pre-B-I subset. In contrast, BM samples taken at one year after end of therapy showed a 
fully normal immunophenotypic maturation, virtually completely overlapping the normal 
BCP maturation pathway (Figure 2c).
Figure 2. 
APS-plots with representative examples of the patients’ BCP population (purple) at 3 months after start of therapy 
(A), at 5 months after start of therapy (B) and at 1 year after end of therapy (C) plotted against the fixed 2SD 
contours of the normal BCP maturation pathway (shades of green). Stage 6 and 7 (Igκ/λ-positive immature BCPs 
and mature B-cells, respectively), which are virtually absent in regenerating BM, were excluded. Arrows indicate 
regenerating BCPs with an immunophenotype that deviates from the normal BCP maturation pathway.
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The regenerating pre-B-I subset contains a high percentage of CD34-/dim cells
To evaluate which surface markers caused the regenerating pre-B-I cells to deviate 
from the normal pre-B-I cells, regenerating pre-B-I cells and normal pre-B-I cells were 
gated based on cyIgμ-TdT+ and were compared in an unsupervised and balanced APS 
(Figure 3a). This analysis showed that, out of all individual markers, CD34 differed the 
most between normal and regenerating pre-B-I cells (Figure 3b). Evaluation of CD34 
expression in conventional dot plots showed that the difference in CD34 expression was 
the result of a significantly higher percentage of CD34-/dim cells within the pre-B-I subset 
in regenerating BM at month 3 (median 34%; range 12-85%) and month 5 (median 25%; 
range 11-82%) than in normal BM (median 10%; range 9-13%) (Figure 4a+c). In normal BM, 
the CD34-/dim pre-B-I cells accounted for less than 2% of the total BCP population, which 
explains why these cells were not regarded as a separate immunophenotypic stage in 
the above described normal BCP maturation pathway. The percentage of CD34-/dim cells 
within the regenerating pre-B-I subset varied widely between patients, but was unrelated 
to the cellularity of the BM sample, the total percentage of B-cells in the BM sample and 
the exact length of the preceding therapy interval, which was very consistent (data not 
shown). Additionally, also regenerating BM from a patient with central nervous system 
Non-Hodgkin lymphoma two weeks after end of a high-dose methotrexate chemotherapy 
cycle, showed a high percentage of CD34-/dim cells within the pre-B-I subset (Figure 4b).
Figure 3.
A. An unsupervised APS-plots showing a representative example of the separation between normal pre-B-I cells 
(green; cyIgμ-TdT+) and regenerating pre-B-I cells (purple; cyIgμ-TdT+). Medians and 2SD contours are indicated. 
B. APS-plot information showing the contribution of each differentiation marker to the separation between 
normal and regenerating pre-B-I cells shown in panel A. 
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Figure 4.
A. Dot plots showing the CD34 and cyIgμ expression of CD19+ B-cells in a representative BM sample from a 
healthy child and a pediatric BCP-ALL patient at 3 months after start of therapy. The percentages of CD34-/dim 
cells and CD34+ cells within the TdT+ pre-B-I subset (indicated by the rectangle) are shown.
B. Dot plot showing the CD34 and cyIgμ expression of CD19+ B-cells in BM from an adult treated for a central 
nervous system lymphoma, two weeks after HD-MTX chemotherapy. The percentages of CD34-/dim cells and 
CD34+ cells within the TdT+ pre-B-I subset (indicated by the rectangle) are shown.
C. Scatter plots showing the percentage of CD34-/dim cells within the pre-B-I subset in BM from 3 healthy 
children, 10 pediatric BCP-ALL patients at 3 months after start of therapy (Regeneration Month 3), 19 pediatric 
BCP-ALL patients at 5 months after start of therapy (Regeneration Month 5) and 3 pediatric BCP-ALL patients at 1 
year after end of therapy. Horizontal lines represent the median values. 
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Cell-cycle analysis showed absence of sub-G1 peaks in CD34-/dim pre-B-I cells from 
regenerating BM samples (both at month 3 (n=5) and month 5 (n=5)), indicating that these 
cells were non-apoptotic (data not shown). GeneScan analysis of IGH gene rearrangements 
showed an irregular size distribution pattern (without clear triplet spacing) in CD34-/dim 
cyIgμ-TdT+ BCPs sorted from regenerating BM samples (n=3), indicating that selection for 
in-frame IGH gene rearrangements had not yet occurred in these cells (Figure 5). A similar 
Figure 5. 
GeneScan diagrams showing the size distribution of complete IGH gene rearrangements (green) of CD34-/dim 
pre-B-I cells and CD34+ pre-B-I cells in BM from a pediatric BCP-ALL patient at 5 months after start of therapy 
and, to compare, of mature B cells in a tonsil from a healthy control. Internal size standard peaks are shown in red. 
Similar results were found in another month-5 BM sample and supported by an additional month-5 BM sample 
in which only the CD34-/dim cyIgμ-TdT+ fraction contained sufficient cells. The number of BM samples in this 
experiment was limited, since almost all regenerating BM samples showed a low cellularity and a low percentage 
of BCPs within total WBC, which hindered the sorting of sufficient CD34+ cyIgμ-TdT+ and CD34-/dim cyIgμ-TdT+ 
cells.
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irregular size distribution pattern of IGH gene rearrangements was found in CD34+ cyIgμ-
TdT+ BCPs sorted from regenerating BM samples (n=2) and a normal BM sample (n=1) 
(data not shown). These data confirmed that CD34-/dim cyIgμ-TdT+ BCPs were, as already 
assumed based on immunophenotypic analyses, part of to the pre-B-I subset.
BCP-ALL cells can also express a CD34-/dim cyIgμ-TdT+ immunophenotype
Finally, we wanted to investigate whether BCP-ALL cells can immunophenotypically 
overlap with regenerating CD34-/dim pre-B-I cells. Therefore, BCP-ALL populations 
(n=26) and the CD34-/dim pre-B-I cell population (merge of n=29) were separated in an 
APS which only took the expression of cyIgμ, TdT and CD34 into account. This analysis 
showed that, based on these three markers, 6 out of 26 BCP-ALL cases (23%) had a median 
that overlapped with the CD34-/dim pre-B-I cells, i.e. expressed a CD34-/dim cyIgμ-TdT+ 
immunophenotype (Figure 6). 
dIscussIoN 
In order to improve discrimination between residual leukemic cells and the background 
of BCPs in BM of patients treated for BCP-ALL, we studied the immunophenotypic 
maturation of normal and regenerating BCPs. 
Therefore, we designed an 8-color antibody panel that allowed us to optimally 
characterize the full immunophenotypic B cell differentiation in a single tube analysis. For 
Figure 6. 
APS-plot showing the 2SD contours of a CD34-/dim pre-B-I cell population (purple; merge of CD34-/dim pre-B-I 
cells of 29 patients) and the medians of 26 pediatric BCP-ALL cases. The BCP-ALL cases with a median which 
overlaps the regenerating CD34-/dim pre-B-I cell population are indicated in blue.
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this antibody panel, we selected antibodies against markers that were most contributing 
to the key processes in BCP development, that is, first, the production of a functional 
cyIgμ chain (which needs TdT), and secondly the production of the light chains (Igκ/λ) 1. 
To further discriminate the different subsets, we used cell membrane markers previously 
shown to allow recognition of specific subsets 2,3: CD19 (B-cells beyond the pro-B cell stage), 
CD34 (pre-B-I cells), CD10 (immature B-cells), CD20 (mature B-cells) and CD45 (increased 
expression during differentiation). Our analysis of the immunophenotypic maturation of 
normal BCPs revealed a stage (‘stage 2’) in which BCPs were TdT-positive and therefore 
classically defined as pre-B-I, but in which a small fraction of the BCPs already contained 
cyIgμ. Furthermore, the BCPs in this stage were CD20dim. These findings are in contrast 
with the conventional model on human B-cell differentiation, in which all TdT+ BCPs are 
cyIgμ-negative and CD20-negative 1-4,26-28. However, other studies also observed BCPs with 
combined expression of TdT, cyIgμ and, if studied, CD20 29,30. Probably, this stage represents 
a transition phase between the pre-B-I and pre-B-II-Large stage. Secondly, our analysis 
showed a stage (‘stage 4’) in which BCPs had passed the pre-B-II-Large immunophenotype, 
but in which BCPs were still Igκ/λ-negative. Furthermore, the BCPs in this stage gradually 
lost their CD20 expression. This stage probably represents a transition phase between the 
pre-B-II-Large and pre-B-II-Small stage. Together, only by using a single 8-color tube in 
combination with multiparametric analyses, we were able to identify the above described 
B-cell differentiation subsets. 
Analysis of regenerating BM from children treated for BCP-ALL showed that the subset 
distribution of the regenerating BCP population (present during therapy intervals at 
3 and 5 months after start of therapy) had shifted towards the early maturation stages. 
This finding was in accordance with previous studies 6,7. More surprisingly, by analyzing 
regenerating BM, we identified pre-B-I cells with low or dim CD34 expression. The pre-
B-I origin was supported by the presence of complete IGH gene rearrangements which 
were not yet selected for in-frame rearrangements. None of the three previous studies on 
the immunophenotype of BCPs in regenerating BM reported on TdT+ BCPs (pre-B-I cells) 
with a low CD34 expression. However, in two of these studies, regenerating BCPs were 
not directly compared with normal BCPs from healthy individuals 4,31. Moreover, only 3- or 
4-color flow cytometry was used 4,29,31. These aspects might explain why the CD34-/dim pre-
B-I cells in regenerating BM have been overlooked in these studies. Apparently, multicolor 
flow cytometry (at least >4 colors) is necessary to achieve a detailed immunophenotypic 
characterization of BCPs. 
Although CD34-/dim pre-B-I cells were initially not identified within the normal BCP 
maturation pathway, we were later able to find low numbers of these cells in BM from 
healthy controls. By comparing pre-B-I cells in regenerating BM from BCP-ALL patients 
at 3 months and 5 months after start of therapy with those in BM from healthy controls, 
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we showed that the percentage of CD34-/dim cells within the pre-B-I subset was much 
higher in regenerating BM than in BM from healthy controls. A relatively high percentage 
of CD34-/dim cells within the pre-B-I subset was also found in regenerating BM from an 
adult treated for lymphoma. These data indicate that an increased percentage of CD34-/
dim pre-B-I cells is a characteristic of BCP regeneration and is independent of the type of 
preceding therapy. 
The mechanism behind the increase of CD34-/dim pre-B-I cells during BCP regeneration 
remains unclear. The presence of CD34-/dim pre-B-I cells in healthy control BM indicates 
that the reduced expression of CD34 on pre-B-I cells is not caused by chemotherapeutic 
drugs. Also, we found that the frequency of hematotoxic side effects was similar between 
patients with a very high percentage of CD34-/dim pre-B-I cells and all other patients. This 
suggests that the reduced expression of CD34 is also not caused by toxic damage of the 
BM niche, which contains ligands for CD34 molecules. Hypothetically, CD34-/dim pre-B-I 
cells might represent pre-B-I cells that are negatively selected based on two unproductive 
IGH gene rearrangements, but are not yet apoptotic. During normal hematopoiesis, these 
cells may only form a minor subset of the total BCP population. During regeneration, a 
high number of BCPs differentiates simultaneously. By sampling at the time this ‘wave’ 
reaches the pre-B-I stage, the CD34-/dim pre-B-I cells may represent a relatively large part 
of the total BCP population, mainly consisting of pre-B-I cells. 
Finally, our results showed that a significant part of the BCP-ALL cases (23%) expressed 
a CD34-/dim cyIgμ-TdT+ immunophenotype. Previous studies already described BCP-ALL 
cases which were negative for CD34, while negative for cyIgμ or positive for TdT 21,37. Since 
CD34-/dim pre-B-I cells show a marker-expression pattern that is asynchronous according 
to the current B-cell differentiation model, these BCPs can be mistaken for leukemic cells 
with a CD34-cyIgμ-TdT+ immunophenotype. Consequently, the presence of CD34-/dim 
pre-B-I cells in regenerating BM at MRD follow up time points could potentially result in 
a false-positive MRD outcome. Therefore, BCPs from regenerating BM, in which CD34-/
dim pre-B-I cells are relatively abundant, should be used as the normal reference in flow 
cytometric MRD detection (rather than BCPs from healthy control BM, in which CD34-/
dim pre-B-I cells are scarce). Also, since the expression of differentiation markers on BCP-
ALL cells overlaps with regenerating BCPs, MRD detection can be more reliable when 
also based on the expression of BCP-ALL specific markers. Therefore, within the EuroFlow 
Consortium, new 8-color antibody panels are currently being developed to optimize 
discrimination between BCP-ALL and the background of regenerating BCPs. 
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suPPleMeNTary fIGures
Supplementary Figure 1. 
Simplified scheme of the BCP-ALL treatment for SR and MR patients according to the DCOG ALL11 protocol. 
Arrows indicate the sampling time points for the BM samples in this study. Prot 1A+B: protocol 1A+B, consisting 
of induction therapy. Prot M: protocol M.
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Supplementary Figure 2. 
Dot plots showing the expression levels of individual markers for each of the maturation stages (1 t/m 7) 
previously identified in a multidimensional APS-plot. The 2SD contours of the total CD19+ B-cell maturation 
pathway are shown.
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suPPleMeNTary MeThods
Analysis of the immunophenotypic B-cell maturation using Infinicyt Software-tools
CD19- pro-B-cells were excluded. The CD19+ populations of three BM samples 
from healthy children were digitally merged to create one representative normal B-cell 
population. The merged normal B-cell population was visualized in an APS-plot. The 
maturation tool in Inifinicyt Software was applied on the merged normal B-cell population, 
subdividing it into consecutive maturation stages based on forward scatter, side scatter 
and all eight differentiation markers. This resulted in a single multiparametric B-cell 
maturation pathway.
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aBsTracT 
Background Proper distinction between leukemic blasts and normal 
B-cell precursors (BCP) is critical for optimized treatment of BCP acute 
lymphoblastic leukemia (ALL), which justifies the need of identification of 
new markers, differentially expressed on normal BCP and leukemic blasts. 
Methods We performed a multicenter analysis of CD73, CD86 and 
CD304 expression levels on leukemic blasts in 282 pediatric BCP-ALL 
patients and on normal BCP. To determine the antigen expression levels, 
we used a quantitative scale, based on normalized median fluorescence 
intensity measure. 
Results CD73 was expressed at higher level than on pooled normal BCP 
in 71/108 BCP-ALL patients (66%), whereas CD304 and CD86 in 94/202 
(47%) and 35/100 (35%) patients, respectively. The expression of CD304 
was detected at similar percentages in common- and pre-B-ALL subgroups, 
at significantly higher frequencies than in the pro-B-ALL subgroup. A 
significant association (p=0.001) was found between CD304 expression 
and the presence of the ETV6-RUNX1 fusion gene. Interestingly, both CD73 
and CD304 showed a negative association with MLL gene rearrangements 
(p=0.02 and 0.002, respectively). The expression levels of CD73 and CD86 
at day 15 after starting therapy vs. diagnosis were constant or higher in 
26/33 (79%) and 22/47 (47%) of cases, respectively. In turn, CD304 showed 
decreased expression levels during follow-up in 94% of cases, but was still 
positive in 61% of cases.
Conclusions This multicenter EuroFlow study shows that CD73, CD86 
and CD304 are overexpressed in a substantial number of BCP-ALL patients 
and that these markers are relatively stable during treatment, which may 
contribute to improved MRD analysis. 
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INTroducTIoN
Acute leukemias (AL) are a heterogeneous group of hematological malignancies, 
characterized by the neoplastic expansion of immature precursor cells (blasts) of lymphoid 
or myeloid lineage origin. The most frequent type of AL in children is acute lymphoblastic 
leukemia (ALL) which results from the malignant transformation of B or T lymphoid precursor 
cells. Among the two subtypes, B-cell-precursor (BCP) ALL is more prevalent, representing 
around 85% of all pediatric ALL patients 1-3. BCP represent a cell compartment in the bone 
marrow which is morphologically recognized as hematogones. In normal bone marrow, 
BCP form a continuous maturation pathway consisting of three major maturational stages, 
all of which show CD19 expression: pre-B-I cells, pre-B-II cells and immature/transitional 
B-cells, respectively. Leukemic blasts in BCP-ALL share many phenotypic features with 
normal BCP. Despite this, the expression levels of BCP-associated antigens commonly 
assessed in BCP-ALL (e.g. CD10, CD20, CD34, TdT, CD22, CD38, CD45) are frequently altered 
in variable degree, as detected by the multiparametric flow cytometry (FC) technique 4. In 
the past decades, it has been shown that immunophenotypic differences between normal 
BCP and leukemic blasts, i.e., the leukemia-associated immunophenotypes (LAIPs), can 
be found in virtually all (up to 98%) BCP-ALL patients 5. Despite this high frequency, 
these differences may be either very subtle or modulated by treatment-induced up- or 
downregulation of unstable markers such as CD10, CD20, CD34 throughout therapy 6,7,8. 
Furthermore, following different types of chemotherapy, normal BCP might represent a 
significant and variable proportion of all bone marrow cells, which could cause additional 
difficulties in distinguishing BCP from minimal residual disease (MRD) that might be present 
in the bone marrow of BCP-ALL patients during therapy 4,9,10. Proper FC-based distinction 
between leukemic blasts and normal BCP is critical for reliable treatment decisions in BCP-
ALL, which justifies the need for identifying new stable markers which are differentially 
expressed on leukemic blasts vs. normal BCP in a significant fraction of BCP-ALL patients.
Based on the analysis of the leukemia cell surface proteome 11 and genome-wide gene 
expression screening of leukemic cells vs. normal BCP 12, novel markers for more efficient 
MRD monitoring in ALL have been recently identified. Here, we selected three of such 
candidate markers (CD73, CD86 and CD304), in order to assess their power to discriminate 
leukemic blasts from normal BCP, their stability during early follow-up time points 
(day +15 of induction therapy) and thereby, their potential utility for MRD monitoring. 
For this purpose, we performed a multicenter, standardized FC validation study and 
compared the expression of these three markers on leukemic blasts from a large series 
of pediatric BCP-ALL patients (including different immunologic and genetic subtypes) 
with that on normal BCP from non-leukemic bone marrow samples. In order to evaluate 
the utility of individual markers, we used the normalized median fluorescence intensity 
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(nMFI) scale 4, rather than the classical percentage-positivity-based reporting method. This 
approach is particularly helpful for the quantification of differences in antigen expression 
between leukemic blasts and normal BCP, thus facilitating their distinction in subsequent 
follow-up MRD studies. Given that for almost two decades MRD is regarded as one of 
the most powerful independent prognostic factors in BCP-ALL and is currently used for 
risk group stratification 13, studies on new phenotypic features of leukemic cells might 
contribute to improving MRD detection and fine-tuning the treatment intensity in these 
patients.
MaTerIals aNd MeThods
Patients and controls
The overall study group comprised 282 children (male/female ratio of 1.06 and median 
age of 4 years) with newly-diagnosed BCP-ALL from 6 different pediatric hemato-oncology 
centers belonging to the EuroFlow Consortium: Medical University of Silesia in Katowice 
(Zabrze, Poland), Erasmus Medical Center (Rotterdam, The Netherlands), Dutch Childhood 
Oncology Group (The Hague, The Netherlands), Federal University of Rio de Janeiro 
(Rio de Janeiro, Brazil), Charles University (Prague, The Czech Republic) and University 
of Milan-Bicoca (Monza, Italy). The entire study, including data analysis strategies and 
interpretation of the results, was collectively designed by all involved EuroFlow centers 
during regular meetings. All involved centers measured samples and provided FCS 3.0 
data files of BCP-ALL patient samples which were analyzed centrally at Medical University 
of Silesia in Katowice (Zabrze, Poland). Expression patterns of the examined antigens were 
investigated within different EGIL BCP-ALL subtypes, i.e., pro-B-, common- and pre-B –ALL, 
and genetic subgroups of BCP-ALL, i.e., presence vs. absence of MLL gene rearrangements 
and other relevant chromosomal translocations such as t(12;21), t(9;22), t(1;19) with their 
respective fusion gene products (ETV6-RUNX1, BCR-ABL1, TCF3-PBX1, respectively) as 
well as hyperdiploidy and hypodiploidy. Not all studied antigens were assessed in every 
patient (Table 1) and genetic data were also not available for all cases, which explains the 
differences in the total number of cases per specific genetic subgroup (Table 2). A control 
group of 19 bone marrow samples from children with benign hematologic conditions 
such as thrombocytopenia and neutropenia, subjected to bone marrow aspiration for 
diagnostic purposes at all involved centers was studied in parallel. The current study was 
approved by the local ethics committees and informed consent was given by each child or 
their parent/guardian, following the Declaration of Helsinki.
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Sample preparation and quality control
Bone marrow samples were subjected to the EuroFlow standardized lyse/wash sample 
preparation protocols 14 and stained with an 8-color, 2-tube panel of fluorochrome-
conjugated mouse anti-human antibodies, containing a backbone of 6 common markers: 
CD34/PerCP-Cy5.5, clone 8G12 (BD Biosciences, San Jose, CA, USA), CD19/PE-Cy7, clone 
J3-119 (Beckman Coulter, Brea, CA, USA), CD10/APC, clone HI10a (BD Biosciences), CD38/
APC-Ax750, clone LS198-4-3 (Beckman Coulter), CD20/Pacific Blue, clone 2H7 (Biolegend, 
San Diego, CA, USA), CD45/Pacific Orange, clone HI30 (Life Technologies, Carlsbad, CA, 
USA). Additionally, tube 1 contained CD86/FITC, clone FUN-1 (BD Pharmingen) and 
CD304/PE, clone 12C2 (Biolegend) antibodies, while tube 2 contained the CD73/PE, clone 
AD2 (BD Pharmingen, San Jose, CA, USA) antibody. Erythrocyte lysis was performed after 
staining the samples using FACS Lyse solution (BD Biosciences). Stained samples were 
measured with FACSCanto II or LSR II flow cytometers (BD Biosciences) available at each 
participating center, which had been set-up and calibrated following the standardized 
EuroFlow guidelines and protocols 15. During the study, each cytometer was subjected to 
daily quality assessment using fluorescent beads (Sphero Rainbow Calibration Particles; 
Spherotech, Lake Forest, IL, USA) of the same lot and the EuroFlow guidelines for monitoring 
instrument performance in order to ensure the reproducibility of the obtained stainings 15. 
All contributing centers were subjected to the regular external quality assessment trials 
including assessment of standardized instrument settings, reagent panels, and sample 
preparation protocols, which ensured a high degree of data comparability.  For data 
analysis the Infinicyt software was used (Cytognos SL, Salamanca, Spain).
Determination of reference populations and antigen expression levels in nMFI units
The levels of expression of CD73, CD86 and CD304 on leukemic blasts, the 3 major 
stages of maturation of normal BCP (pre-B-I, pre-B-II and immature B-cells) and mature 
B/T/NK lymphocytes, were assessed on a nMFI scale, based on a previously described 
concept 4. To create a complete frame of reference of expression, antigen-specific negative 
and positive reference cell populations (internal controls) were determined. Therefore, 
positive reference cell populations for CD73, CD86 and CD304 antigens consisted of: 
the subset of CD73-positive mature B lymphocytes, plasma cells (PC) and plasmacytoid 
dendritic cells (pDC), respectively. In contrast, mature B/T/NK lymphocytes and the CD73-
negative subset of B/T/NK lymphocytes were used as negative reference cell populations 
for CD86, CD304 and CD73 antigens, respectively (Figure 1 and Supplementary Table 1). 
Briefly, the median of the MFI obtained for each marker on the negative reference 
populations was assigned an nMFI score of 0, whereas the median of the MFI obtained for 
the corresponding positive reference populations was assigned an arbitrary nMFI score of 
10. To normalize the scale, the median of the MFI of the negative reference populations 
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was subtracted from the median of the MFI of the corresponding positive reference 
populations per marker. Subsequently, the obtained MFI ranges were divided into 10 equal 
linear scale intervals, corresponding to a single step on the nMFI scale. Such normalization 
of MFI measure enabled us to build individual scales of expression for each antigen on 
leukemic blasts and normal BCP, enabling also the detection of antigen overexpression 
(i.e., expression higher than on the positive reference population). The nMFI scores of 0–1 
were assigned as negative (absence of expression), the nMFI scores of 2–3 were equivalent 
to heterogeneous-negative-to-dim expression, and the nMFI scores of 4–6 and 7–10 were 
classified as dim and strong expression, respectively. Finally, nMFI values exceeding 10 
reflected antigen overexpression compared to the corresponding positive reference cell 
population (Figure 2).  In parallel, classical, 3-step expression notation was used, in which 
cases with heterogeneous-negative-to-dim and dim expression were altogether classified 
as “dim”, whereas cases with strong expression and overexpression were classified 
as“bright” (Table 1). 
Stability of CD73, CD86, CD304 and other antigens at early follow-up time points
Expression of CD73, CD86, CD304 and other frequently used MRD markers (i.e., CD34, 
CD10, CD20) were evaluated for stability of their expression levels at day +15 of induction 
therapy (MRD15). Since the expression of the backbone markers was not normalized, 
comparisons were based on absolute MFI values (Figure 5, Supplementary Figure 1). The 
absolute MFI of all examined antigens was assessed at diagnosis (Dx) and at day +15 in 
MRD-positive cases. Subsequently, median MFI and ratio of paired MRD15/Dx cases was 
calculated. Only cases that were positive (MFI>150) at diagnosis for CD73 (n=33), CD86 
(n=47), CD304 (n=31), CD34 (n=50), CD10 (n=50) and CD20 (n=23) were included in this 
part of the study (Figure 5, Table 3 and Supplementary Figure 1). 
Statistical methods
The non-normal distribution of nMFI values obtained for all markers analyzed was 
confirmed by the Shapiro-Wilk’s test. To determine the statistical significance of differences 
in the expression levels of the examined antigens within different immunologic and genetic 
subgroups of BCP-ALL cases in ordinal nMFI units, the Mann-Whitney U test was applied. 
Additionally, Bonferroni’s p-value corrections were applied for multiple comparisons 
performed for the same data matrices. For the expression levels given in classical, 3-step 
notation, Pearson chi-square test was used. Statistical significance was set at p≤0.05. All 
statistical analyses were performed centrally at Medical University of Silesia in Katowice 
(Zabrze, Poland), using the Statistica 8.0 software (Statsoft, Tulsa, OK, USA).
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resulTs 
Expression of CD73, CD86 and CD304 on positive and negative reference cell populations
PC expressed the highest levels of CD86 among all cell populations identified in normal 
bone marrow (median nMFI of 10 (range: 6–25)), being higher than those of normal pDC 
(median nMFI of 2 (range: 1–3)). Mature lymphocytes (B and T/NK) showed very low CD86 
expression levels (median nMFI of 1 (range: 0–1)), and therefore used as the negative 
reference cell types for CD86. As expected, the highest levels of CD304 expression (median 
nMFI of 10 (range: 4–22)) were found for pDC, which is a lineage-specific marker, also 
known as BDCA4. None of bone marrow mature lymphocytes showed CD304 expression 
(median nMFI of 0), although some expression of this marker was observed on PC (median 
nMFI of 2 (range: 1–3)). Expression of CD73 was observed in a distinct subset of mature 
B as well as T/NK lymphocytes (mean percentage of CD73-positive cells of 74% (range 
41%–88%) and 26% (range 10%–39%), respectively), with a significantly higher CD73 
expression levels on the former cell population (median nMFI of 10 (range: 4–19) vs. 3 
(range: 3–5), respectively). Based on these results, the subset of CD73-positive mature 
B-cells was selected as the positive reference population for this marker (Figures 1–2 and 
Supplementary Table 1).
Expression of CD73, CD86 and CD304 on normal BCP
Based on the above defined criteria for positivity (nMFI≥2, or at least dim expression 
in classical notation), normal BCP either did not express or expressed very low levels of 
CD73, CD86 and CD304 antigens (Figure 1). In detail, CD86 and CD304 were expressed at 
low levels (median nMFI of 1 (range: 0–2) for both markers) only by pre-B-I cells (CD34+) 
and only in a fraction of all control bone marrow samples analyzed. Pre-B-II and immature 
B-cells did not express CD86 and CD304 (median nMFI of 0 (range: 0–2) and 0.5 (range: 0–1), 
respectively). In contrast, CD73 was very weakly expressed only on pre-B-II and immature 
B-cells (median nMFI of 1 (range: 0–1)), which therefore was consistently classified as 
negative (Figures 1–3, and Supplementary Table 1).
Expression of CD73, CD86 and CD304 on leukemic blasts
CD73 was the most frequently expressed antigen on BCP-ALL blasts, being positive 
(nMFI≥2, or showing at least dim expression in classical notation) in 71/108 (66%) patients. 
These positive cases showed a CD73 expression that was higher than that of all pooled BCP 
types (Figure 3 and Supplementary Table 1). However, in most cases, CD73 was expressed 
at rather low levels; heterogeneous (partial) negative-to-dim and dim CD73 expression 
(nMFI range: 2–6, or dim in classical notation) was observed in 43/108 (40%) patients, 
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Figure 1.
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whereas strong positivity and overexpression of CD73 (nMFI≥7, or bright expression in 
classical notation) was identified in 28/108 (26%) patients (Figures 1–3 and Table 1). 
CD304 and CD86 were, compared to CD73, expressed in a slightly lower percentage of 
BCP-ALL cases: 119/202 (59%) and 58/100 (58%) patients, respectively. Due to the fact that 
CD304 and CD86 exhibited low expression levels on pre-B-I and pre-B-II cells in a fraction 
of all control bone marrow samples (nMFI range: 0–2), expression of these markers on 
leukemic blasts was considered to be higher than normal when the nMFI values were ≥ 3. 
Thus, in 94/202 (47%) and 35/100 (35%) patients, CD304 respectively CD86 were expressed 
at higher levels than on normal pooled BCP (Figure 3). However, CD304 more frequently 
showed strong positivity and overexpression (nMFI≥7, or bright expression) than CD86, 
i.e., in 56/202 (28%) vs. 17/100 (17%) patients, respectively (Figures 1–3 and Table 1). 
Figure 1 (continued).
Normalized, nMFI-based expression levels of CD73, CD86 and CD304 on normal bone marrow cells and leukemic 
blasts.
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Figure 2.
Illustrating bivariate dot plots (A.) and single parameter histograms (B.) of the different patterns of expression 
(nMFI scores) of CD73, CD86 and CD304, observed on leukemic BCP-ALL blasts. The red dots in panels A and B 
represent BCP-ALL blasts with different nMFI compared to different reference cell types; for clarity, the histograms 
in panel B only show the highest nMFI values of BCP-ALL blasts. 
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Figure 3.
Expression of CD73, CD86 and CD304 on normal BCP (white dots) vs. leukemic blasts (black dots) in nMFI units 
The shaded area corresponds to the nMFI spread detected among normal bone marrow BCP.
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Table 1. Overall expression profile of CD73, CD86 and CD304 on leukemic BCP-ALL blasts in nMFI-based 
scale and in classical, 3-step notation (between square parentheses).
Marker expression notation CD73
(n=108)
CD86
(n=100)
CD304
(n=202)
negative (nMFI: 0–1) [negative] 37  (34%) 42  (42%) 83  (41%)
overall positive (nMFI ≥2) 71  (66%) 58  (58%) 119  (59%)
heterogeneous-negative-to-dim 
expression (nMFI: 2–3) [dim]
27  (25%) 28  (28%) 41  (20%)
dim expression (nMFI: 4–6) [dim] 16  (15%) 13  (13%) 22  (11%)
strong/bright expression (nMFI: 
7–10) [bright]
12  (11%) 9  (9%) 22  (11%)
overexpression (nMFI ≥11) [bright] 16  (15%) 8  (8%) 34  (17%)
Results expressed as number of cases (percentage)
Expression of CD73, CD86 and CD304 in different immunologic subgroups of BCP-ALL defined 
by the EGIL classification
Data on the immunologic subtype of BCP-ALL was available for 274 (97%) patients, 
out of which 18 (7%) had pro-B-ALL, 184 (67%) had common-ALL and 72 (26%) had pre-B-
ALL. Overall, similar median nMFI values, median nMFI values of positive cases, expression 
rates (nMFI≥2, or at least dim in classical notation) and overexpression rates (nMFI≥11) 
were observed for CD73 and CD304 between common- and pre-B-ALL cases. Of these two 
markers, only CD304 showed significantly higher expression within common- and pre-
B-ALL compared to that observed within pro-B-ALL (nMFI of CD304-positive cases of 5 
and 7 vs. 2, respectively, p=0.0007 and p=0.0017, respectively; Figure 4, Supplementary 
Table 2, Supplementary Table 3). Regarding CD86, a similar percentage of positive cases 
was observed among all three immunologic subgroups of BCP-ALL, the highest median 
nMFI of CD86-positive cases being observed among pro-B-ALL cases (nMFI of 7 vs. 3 and 
4 for common-ALL and pre-B-ALL, respectively), however without reaching statistical 
significance (Figure 4, Supplementary Table 2 and Supplementary Table 3). 
Expression of CD73, CD86 and CD304 in different genetic subgroups of BCP-ALL
The frequency of expression (i.e., nMFI≥2, or at least dim in classical notation) of CD73, 
CD86 and CD304 was compared among previously defined genetic subgroups of BCP-ALL 
(Table 2). Overall, a significant association (p=0.001) was found between CD304 expression 
measured in nMFI scale and the presence of the ETV6-RUNX1 fusion gene: CD304 was 
positive in 21/25 (84%) ETV6-RUNX1-positive cases with a median nMFI of 7 (range: 2–26) 
vs. positive in 62/117 (53%) ETV6-RUNX1-negative cases, with a median nMFI of 5 (range: 
2–60; Table 2, Supplementary Table 4). Among MLL-rearranged BCP-ALL patients, a slightly 
different expression of CD86 was observed: 5/7 (71%) MLL-rearranged patients were 
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CD86-positive with a median nMFI of 7 (range: 5–44), vs. 46/77 (60%) of the MLL-negative 
patients (median nMFI of 3 (range: 2–24)), although these differences did not reach 
statistical significance (p=0.09). Interestingly, both CD73 and CD304 showed a negative 
association with MLL gene rearrangements (p=0.02 and p=0.002, respectively): CD73 was 
positive in 50/74 (68%) MLL-negative patients (nMFI of 5.5 (range: 2–49)), while only in 2/6 
(33%) of the MLL-rearranged patients (nMFI of 2.5 (range: 2–3)); similarly, expression of 
CD304 was observed in 93/152 (61%) MLL-negative patients (nMFI of 7 (range: 2–60)), but 
only in 2/9 (22%) MLL-rearranged patients (nMFI of 3 (range: 2–4)). No statistically significant 
associations were observed between the pattern of antigen expression of hyperdiploid 
BCP-ALL cases vs. the remaining genetic subgroups of BCP-ALL (i.e., BCR-ABL1-positive, 
TCF3-PBX1-positive, hypodiploidy), which were individually too small (1–3 cases (1.5–3.6%) 
per specified antigen subgroup) to draw reliable conclusions on potential associations 
with specific expression patterns for any of the three antigens investigated. However, both 
CD86 and CD304 were positive in all 3 BCR-ABL1-positive cases, with a median nMFI of 3 
Figure 4.
Expression levels (nMFI values) of CD73, CD86 and CD304 in different immunologic subgroups of BCP-ALL as 
defined by the EGIL classification. * p<0.05.
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(range: 2–10, or dim expression) and 10 (range: 4–14, or bright expression), respectively 
(Table 2, Supplementary Table 4). 
No statistically significant association was found between antigen overexpression 
(exceeding the expression observed on the relevant positive reference cell type, i.e., 
nMFI≥11) and any specific genetic subgroup of BCP-ALL (data not shown).
Stability of CD73, CD86, CD304 and other antigens at early follow-up MRD time points
Evaluation of CD86, CD73 and CD20 expression levels at MRD15 vs. diagnosis, showed 
constant or higher median MFI for CD86 in 22/47 (47%), for CD73 in 26/33 (79%) and for 
CD20 in 19/23 (83%) patients. The median MFI MRD15/Dx ratio for CD86 equaled 1.4, while 
Table 2. Expression of CD73, CD86 and CD304 in different genetic subgroups of BCP-ALL.
CD73-pos
(%)
CD73-pos 
median nMFI
(range)
CD86-pos
(%)
CD86-pos 
median nMFI
(range)
CD304-pos
(%)
CD304-pos 
median nMFI
(range)
MLL-rearranged
neg 50/74
(68%)
5.5
(2–49)
46/77
(60%)
3
(2–24)
93/152
(61%) *
7 *
(2–60)
pos 2/6
(33%)
2.5
(2–3)
5/7
(71%)
7
(5–44)
2/9
(22%) *
3 *
(2–4)
ETV6-RUNX1
neg 37/58
(64%)
6
(2–49)
40/62
(65%)
5
(2–44)
62/117
(53%) *
5 *
(2–60)
pos 12/18
(67%)
3.5
(2–15)
5/8
(63%)
2
(2–9)
21/25
(84%) *
7 *
(2–26)
BCR-ABL1
neg 52/80
(65%)
5
(2–49)
48/81
(60%)
4
(2–44)
92/157
(59%)
6
(2–60)
pos 0
(0%)
– 3/3
(100%)
3
(2–10)
3/3
(100%)
10
(4–14)
TCF3-PBX1
neg 44/64
(69%)
4.5
(2–49)
33/52
(64%)
3
(2–44)
70/116
(60%)
7
(2–60)
pos 0/2
(0%)
– 0
(0%)
– 0/2
(0%)
–
hypodiploidy
neg 27/44
(61%)
5
(2–34)
25/47
(53%)
3
(2–20)
57/93
(61%)
8
(2–33)
pos 17/25
(68%)
4
(2–49)
14/18
(78%)
3
(2–44)
24/44
(55%)
4
(2–60)
hypodiploidy
neg 41/67
(61%)
5
(2–49)
37/64
(58%)
3
(2–44)
79/131
(60%)
7
(2–60)
pos 1/1
(100%)
9
(9)
1/1
(100%)
2
(2)
0/2
(0%)
–
pos – positive, neg – negative; * p<0.05 between positive vs. negative cases for individual genetic aberrations 
(Mann-Whitney U-test). Results expressed as number of cases /total cases (percentage) unless otherwise specified.
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for CD73 and CD20 reached 5.5 and 4.3, respectively, which points out that CD86 was only 
slightly upregulated in comparison to CD73 and CD20. Despite this, complete loss of CD86 
expression at day +15 was observed in only 2/47 (4%) cases. In contrast, the expression of 
the remaining markers (i.e., CD304, CD34, CD10) decreased in the majority of cases after 
therapy (median MFI MRD15/Dx ratio of 0.4, 0.5 and 0.3, respectively; Table 3). Of note, 
CD304 expression decreased in 29/31 (94%) cases, and was completely lost in 10/31 (32%) 
cases. Despite the decrease in CD304 expression levels, this marker still remained positive 
in 19/31 (61%) cases (Table 3 and Figure 5). Interestingly, when cases which were negative 
Table 3. Stability of expression of selected antigens at day +15 of induction treatment (MRD15).
CD73
(n=33)
CD86
(n=47)
CD304
(n=31)
CD34
(n=50)
CD10
(n=50)
CD20
(n=23)
stable or increased 
expression
26 (79%) 22 (47%) 2 (6%) 5 (10%) 0 (0%) 19 (83%)
decreased expression 7 (21%) 25 (53%) 29 (94%) 45 (90%) 50 (100%) 4 (17%)
loss of expression 1 (3%) 2 (4%) 10 (32%) 2 (4%) 0 (0%) 1 (4%)
median MFI ratio 
(MRD15/Diagnosis)
5.5 1.4 0.4 0.5 0.3 4.3
MFI – median fluorescence intensity. Results expressed as number of cases (percentage) unless otherwise 
specified. Only cases at least slightly positive at initial diagnosis (MFI>150) were shown.
Figure 5.
Levels of expression of different markers at diagnosis (Dx) and at day +15 of induction treatment (MRD15) for 
cases that showed positivity at initial diagnosis (MFI>150). Boxes cover the interquartile range (25%–75%) and 
whiskers the non-outlier range. The numbers above the boxes correspond to mean MFI values of the particular 
antigens at Dx and MRD15.
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at diagnosis for a particular antigen were also considered, the percentage of cases with an 
increased MRD15/Dx ratio for CD86 and CD304 raised up to 53% and 24%, respectively, 
suggesting that expression of these markers can be upregulated in a significant proportion 
of cases, even when it was absent at diagnosis (Supplementary Figure 1).
dIscussIoN
MRD evaluated during early phases of treatment is currently the most significant 
predictive factor for relapse and thereby forms the basis for patient risk stratification in 
most ALL treatment protocols contemporarily used worldwide, particularly in childhood 
ALL 16-20. Therefore, it is critical to optimize currently used MRD detection techniques, 
particularly FC-based MRD approaches. In this regard, identification of new candidate 
markers for improved distinction between normal BCP and leukemic blasts still remains 
a challenge in order to increase the applicability, as well as both specificity and sensitivity 
of the assay. An ideal candidate marker should exhibit differential expression on normal 
BCP and leukemic blasts and remain stable during treatment in order to overcome the 
immunophenotypic switches frequently observed for the most commonly used MRD 
markers 7,9,12,21. Further optimization of the FC assay can be achieved by increasing the 
number of markers combined in a tube and by improved data analysis software enabling 
assessment of multiple (up to 12 or even more) antigens simultaneously 22,23. 
Analysis of leukemia cell surface proteome and genome-wide gene expression 
screening of leukemic cells against normal BCP have proven to be powerful techniques 
to search for potential candidate MRD markers in ALL 11,12. Thus, these studies have 
highlighted the potential utility of many new markers, of which CD73, CD86 and CD304 
have here been investigated in detail, as potentially useful targets for MRD monitoring in 
childhood BCP-ALL. For this purpose we used a prospective, multicenter and standardized 
FC approach based on the EuroFlow techniques and tools 14,15. Since the same EuroFlow 
instrument settings, sample preparation and data acquisition protocols 15 were followed at 
each participating center, we were able to apply highly standardized approaches for data 
analysis, including normalization of MFI values on a pooled group of patients and controls, 
with the use of innovative Infinicyt software tools 15,22,23. 
Overall, our results are consistent with previously reported data on the differential 
expression patterns of CD73, CD86 and CD304 in normal BCP vs. leukemic blasts from 
BCP-ALL patients. The pattern of expression of CD304 on normal BCP from our cohort 
of control bone marrow was concordant to that reported by Meyerson et al. 25 and Solly 
et al. 26; in this regard, our results confirmed variably weak/partial CD304 expression on 
pre-B-I cells, which progressively decreased with BCP maturation, becoming negative 
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on mature B-cells (Figure 1, Supplementary Table 1). The frequency of cases with strong 
expression and overexpression (nMFI≥7, or bright expression)) of CD304 on leukemic 
blasts in our childhood BCP-ALL patients was 28%, in line with the results reported by 
Coustan-Smith et al. 12 and Meyerson et al. 25 In contrast, Solly et al. 26 reported that CD304 
was overexpressed in 24/50 (48%) patients, and expressed on >80% of CD45lowCD19+ 
leukemia cells in 18/50 (36%) of BCP-ALL patients 26. This frequency is slightly higher than 
that observed in the current study. These differences might be due to the fact that the 
patient group in the study by Solly et al. was composed of both pediatric and adult BCP-
ALL patients, while both our and the other two former studies were all based on childhood 
ALL patients.
Regarding CD73, two-thirds of our cases showed expression of this marker. This 
frequency of CD73-positive cases is slightly higher than that previously reported by 
others (54.5% 12 and 41.8% 27), even when the expression of CD73 was assessed in specific 
immunological subgroups of BCP-ALL as defined by the EGIL classification (e.g. 33%, 
67% and 69% CD73-positive pro-B-, common- and pre-B-ALL patients were found in 
our series vs. 35%, 45.5% and 50% patients in the series of Wang et al. 27, respectively). 
Of note, this latter series also included adult BCP-ALL patients. In this regard, it should 
be highlighted that common-ALL and pre-B-ALL cases showed similar rates and levels 
of CD73 expression, in line with previous findings by Wieten et al. 28. Interestingly, Wang 
et al. 27 observed increasing expression of CD73 along with the maturation of normal BCP, 
reaching the highest CD73 expression levels on part of the mature B-cells. Although such 
increased expression of CD73 along BCP maturation was not clearly visible in our study, we 
confirmed the bimodal expression pattern for CD73 on mature B-lymphocytes, in addition 
to bone marrow T/NK lymphocytes (Figure 1, Figure 2, Supplementary Table 1). 
Data on CD86 expression is more limited. Coustan-Smith et al. 12 have previously 
reported expression of this marker in around half of all childhood BCP-ALL patients, as 
confirmed in our study. 
As stated above, differences between studies with regard to the frequency of positivity 
for individual markers, might be related to the age composition of the patient group 
included in different study reports. In addition, the differences might also be associated 
with different criteria used to define positivity, or the sensitivity of the specific antibody 
reagents used 12,25–27. Although we used  a commensurate positivity criterion of nMFI≥2 or 
at least dim in the classical notation (i.e., higher than that observed on normal BCP), this 
might not be directly comparable to a given MFI cutoff for positivity, or another definition 
of high vs. low expression based on the ratio between the MFI of a positive cell population 
and the negative (e.g., isotype) control signals used in other studies. 
The pattern of expression of the three markers investigated in the current study showed 
limited associations with the genetic subgroups of BCP-ALL: 1) the relationship between 
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CD304 expression and ETV6-RUNX1 gene rearrangements, which has also been reported by 
Solly et al. 26 (but not confirmed by Coustan-Smith et al. 12) and, 2) the inverse relationship 
between MLL gene rearrangements and both CD73 and CD304 expression reported here 
for the first time. Of note, the above mentioned associations were proven with the use of 
two statistical approaches. Coustan-Smith et al. 12 reported a marginal association (p=0.09) 
between CD86 expression and hyperdiploidy in BCP-ALL patients, which could not be 
confirmed in our series (Table 2). 
It should be noted that relatively high expression levels of CD86 and CD304 were 
detected in our three BCR-ABL1-positive cases, but differences vs. BCR-ABL1-negative 
patients did not reach statistical significance, probably due to the low number of BCR-ABL1-
positive cases. Solly et al. 26 found a higher frequency of BCR-ABL1-positive cases among the 
CD304+ vs. the CD304– patient groups (32% and 5% of patients, respectively); Meyerson 
et al. 25 revealed a higher frequency of CD304-positivity among BCR-ABL1-positive than 
among negative patients (90% vs. 68%, respectively). However, these differences did not 
reach statistical significance in neither study (p-values of 0.08 and 0.09, respectively). 
In order to further confirm the potential utility of the three markers evaluated here for 
MRD monitoring, we assessed the stability of their expression during the early phases of 
therapy, along with other frequently used MRD markers such as CD34, CD10 and CD20. 
MRD results at day +15 of induction therapy was chosen to assess the stability of marker 
expression, as on one hand MRD measurements at day +15 directly provide clinically 
useful information about response to therapy of BCP-ALL patients in most ALL treatment 
protocols 16–20, and on the other hand, MRD-positivity levels higher than 0.1% are observed 
at this time point in the majority of patients, which ensures more reliable comparative 
analyses than at later time points with lower rates and lower levels of MRD-positivity. Of 
the three new markers evaluated, CD73 turned out to be the most stable, being expressed 
at the same or higher levels at day +15 in around 80% of cases, with virtually no complete 
loss of expression observed. The expression levels of CD86 remained stable in around 
half of the cases, while only two patients showed complete loss of CD86 expression at 
day +15. In turn, CD304 expression was the least stable at follow-up – its expression level 
decreased in the majority of cases, however in more than half of them, the leukemic blasts 
still remained CD304-positive (Table 3). 
To date, there is only a limited number of studies in which the stability of CD73, CD86 
and CD304 has been investigated in detail during follow-up. Stability of CD304 expression 
on leukemic blasts after therapy has been previously reported by Solly et al., however 
in this study levels of CD304 in diagnosis samples were compared with that in relapsed 
samples and only on a relatively small patient cohort 26. Meyerson et al. 25 and Coustan-
Smith et al. 12 concluded that CD304 might potentially represent a useful MRD marker, 
based mainly on its relatively high overexpression rate at diagnosis, although stability of 
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CD304 during therapy was not investigated. In this regard, our results showed that CD304 
overexpression at diagnosis does not always predict stability of this aberrant marker, 
even at early time points (day +15 of induction therapy). Despite the fact that decreased 
expression of CD304 was observed in some cases, it does not rule out this antigen as a good 
marker for MRD monitoring, particularly because expression of CD304, as well as of CD86, 
was also found to increase in cases in which leukemic blasts at diagnosis were negative 
for these markers. This is also true for CD73, for which we found the highest stability and 
the highest median MRD15/Diagnosis MFI ratio, confirming what has also been previously 
reported for CD73 by Wang et al. 27 Increased expression during follow-up is of particular 
importance, as it may considerably facilitate MRD identification. Phenotypic modulation 
(switch) is a relatively common finding during treatment, and might occur in up to 70% of 
all BCP-ALL patients 8,10,21, mainly due to down- or upregulation of well-established MRD 
markers by steroid-induced blast cell maturation. As a consequence, decreased expression 
of “immaturity” markers like CD34 and CD10, together with upregulation of differentiation-
associated antigens such as CD20, have been recurrently reported during the early phases 
of treatment (day +15 and day +33) 6,7,9,11,19,29–31. In order to overcome this problem, it is 
recommended that multiple aberrant markers, representing LAIP at diagnosis, should be 
followed, so that at least one LAIP will remain stable.
Finally, a recent study of Theunissen et al. (Blood 2016 – under review) evaluated the 
applicability of CD73 and CD304 antigens based on testing of 319 MRD bone marrow 
samples from BCP-ALL patients, in parallel with molecular IG/TR gene PCR-based MRD 
monitoring. In order not to increase the number of fluorochromes required for the most 
reliable follow-up approach for BCP-ALL patients, this study combined both markers in the 
same tube with the same fluorochrome, which did not affect background staining. The use 
of the antibody combination containing CD73 and CD304, together with the use of a bulk 
lysis protocol enabling the collection of more than 3 million cells, resulted in comparable 
results as obtained by IG gene rearrangement-based MRD approach.
In summary, here we confirm and extend on previous findings about the potential 
utility of three candidate markers for MRD monitoring in BCP-ALL and prove the usefulness 
of a standardized approach to generate convergent and comparable flow cytometric data 
at multiple centers for fast and reproducible evaluation of relatively large numbers of 
samples. Our results provide useful, quantitative information on the expression of CD73, 
CD86 and CD304 antigens on different cell types, including normal BCP. Our study also 
proves that aberrant expression/overexpression of CD73, CD86 and CD304 occurs in a 
significant percentage of BCP-ALL patients; increased expression of CD73 and CD304 being 
particularly associated with specific immunological subtypes of BCP-ALL (common- and 
pre-B-ALL), whereas CD304 expression is particularly frequent among ETV6-RUNX1-positive 
cases. In addition, our results suggest that CD73 expression exhibits more frequently stable 
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or increased levels than CD86 and CD304 during the early phases of therapy, which proves 
the former one to be a promising marker for MRD monitoring in BCP-ALL patients.
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Supplementary Table 1. Patterns of expression of CD73, CD86 and CD304 on different subsets of normal 
bone marrow cells.
CD73 CD86 CD304
MFI range
(MFI step: 
161)
median 
nMFI 
(range)
MFI range
(MFI step: 
52)
median 
nMFI 
(range)
MFI range
(MFI step: 
90)
median 
nMFI 
(range)
mature 
B-cells
N/A N/A 118–159 1 (0–1) 20–94 0 (0–1)
T/NK cells N/A N/A 107–151 0 (0–1) 19–49 0 (0–1)
CD73-
negative 
T/NK-cells
20–44 0 N/A N/A N/A N/A
CD73-
negative 
mature 
B-cells
44–128 1 (0–1) N/A N/A N/A N/A
CD73-
positive 
T/NK-cells
366–699 3 (3–5) N/A N/A N/A N/A
CD73-
positive 
mature 
B-cells
656–3047 10 (4–19) N/A N/A N/A N/A
plasma cells 
(PC)
N/A N/A 553–1063 10 (6–25) 38–256 2 (1–3)
plasmacytoid 
dendritic 
cells (pDC)
N/A N/A 157–264 2 (1–3) 364–1968 10 (4–22)
pre-B-I cells 16–50 0 (0–1) 112–225 1 (0–2) 44–161 1 (1–2)
pre-B-II cells 36–143 1 (0–1) 99–210 0 (0–2) 17–83 0.5 (0–1)
immature 
B-cells
34.8–178.9 1 (0–1) 102.5–158.0 0 (0–1) 21.6–73.8 0.5 (0–1)
MFI – median fluorescence intensity. Negative and positive reference cell populations for each of the three 
markers investigated were marked in bold.
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Supplementary Table 2. Expression of CD73, CD86 and CD304 in different immunological subgroups of 
BCP-ALL as defined by the EGIL classification.
pro-B-ALL common-ALL pre-B-ALL
CD73
negative 4/6 (67%) 25/76 (33%) 8/26 (31%)
positive (nMFI≥2) 2/6 (33%) 51/76 (67%) 18/26 (69%)
overexpression (nMFI≥11) 0/6 (0%) 12/76 (16%) 4/26 (15%)
median nMFI (range) 1 (0–4) 3 (0–60) 3 (0–33)
median nMFI of positive (range) 2.5 (2–3) 6 (2–49) 4.5 (2–18)
median nMFI of overexpressed 
(range)
– 15.5 (11–49) 12.5 (12–18)
CD86
negative 3/8 (38%) 29/69 (42%) 9/22 (41%)
positive (nMFI≥2) 5/8 (63%) 40/69 (58%) 13/22 (59%)
overexpression (nMFI≥11) 1/8 (13%) 7/69 (10%) 0/22 (0%)
median nMFI (range) 5 (1–44) 2 (0–24) 2 (0–7)
median nMFI of positive (range) 7 (5–44) 3 (2–24) 4 (2–7)
median nMFI of overexpressed 
(range)
44 (44) 13 (11–24) –
CD304
negative 10/13 (77%) 49/130 (38%) 23/57 (40%)
positive (nMFI≥2) 3/13 (23%) 81/130 (62%) 34/57 (60%)
overexpression (nMFI≥11) 0/13 (0%) 21/130 (16%) 13/57 (23%)
median nMFI (range) 1 (0–4) 2 (0–60) 3 (0–33)
median nMFI of positive (range) 2 (2–4) 5 (2–60) 7 (2–33)
median nMFI of overexpressed 
(range)
– 14 (11–60) 17 (11–33)
Results expressed as number of cases/total cases evaluated (percentage) unless otherwise specified.
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Supplementary Table 3. Statistical significance of CD73, CD86 and CD304 expression in different 
immunological subgroups of BCP-ALL as defined by the EGIL classification.
A. common-ALL pre-B-ALL
CD73 pro-B-ALL 0.052 0.087
common-ALL – 2.537
CD86 pro-B-ALL 0.617 0.320
common-ALL – 2.252
CD304 pro-B-ALL 0.0007 * 0.0017 *
common-ALL – 2.150
B. common-ALL pre-B-ALL
CD73 pro-B-ALL 0.168 0.198
common-ALL – 0.749
CD86 pro-B-ALL 0.446 0.053
common-ALL – 0.208
CD304 pro-B-ALL 0.014 * 0.027 *
common-ALL – 0.794
A. Bonferroni-corrected p-values calculated for expression levels given in nMFI-based scale. The statistical 
significance (p<0.05) between specific pairs of immunological subgroups was marked with * (Mann-Whitney U 
test).
B. p-values calculated for expression levels based on the classical, 3-step notation (negative / dim / bright). The 
statistical significance (p<0.05) between specific pairs of immunological subgroups was marked with * (Pearson 
chi-square test). 
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Supplementary Table 4. Statistical significance of CD73, CD86 and CD304 expression in different genetic 
subgroups of BCP-ALL.
A. MLL-
rearranged
ETV6-
RUNX1
BCR-ABL1 TCF3-PBX1 hyperdiploidy hypodiploidy
CD73 0.097 5.508 N/A N/A 4.067 N/A
CD86 0.618 2.325 1.673 N/A 0.614 N/A
CD304 0.012 * 0.009 * 0.520 N/A 0.974 1.489
B. MLL-
rearranged
ETV6-
RUNX1
BCR-ABL1 TCF3-PBX1 hyperdiploidy hypodiploidy
CD73 0.159 0.808 N/A N/A 0.516 N/A
CD86 0.196 0.848 0.358 N/A 0.099 N/A
CD304 0.046 * 0.002 * 0.269 N/A 0.080 0.226
A. Bonferroni-corrected p-values calculated for expression levels given in nMFI-based scale. The statistical 
significance (p<0.05) between positive vs. negative cases for an individual genetic aberration was marked with * 
(Mann-Whitney U test).
B. p-values calculated for expression levels based on the classical, 3-step notation (negative / dim / bright).The 
statistical significance (p<0.05) between positive vs. negative cases for an individual genetic aberration was 
marked with * (Pearson chi-square test). 
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Supplementary Figure 1.
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Supplementary Figure 1 (continued).
Expression of CD73, CD86, CD304 and other markers during follow-up. Adjacent bars of the same color represent 
the antigen expression level of the same BCP-ALL patient at diagnosis (left) and at day +15 of induction treatment 
(right).
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aBsTracT
A fully-standardized EuroFlow 8-color antibody panel and laboratory 
procedure was stepwise designed to measure minimal residual disease 
(MRD) in B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) 
patients with a sensitivity of ≤10-5, comparable to real-time quantitative 
(RQ)-PCR-based MRD detection via antigen-receptor rearrangements. 
Leukocyte markers and corresponding antibodies were selected 
based on their contribution in separating BCP-ALL cells from normal/
regenerating BCP cells in multidimensional principal component analyses. 
After five multicenter design-test-evaluate-redesign phases with a total 
of 319 BCP-ALL patients at diagnosis, two 8-color antibody tubes were 
selected, which allowed separation between normal and malignant BCP 
cells in 99% of studied patients. These two tubes were tested with a new 
erythrocyte bulk-lysis protocol allowing acquisition of high cell numbers in 
377 bone marrow follow-up samples of 178 BCP-ALL patients. Comparison 
with RQ-PCR-based MRD data showed a clear positive relation between the 
percentage concordant cases and the number of cells acquired. For those 
samples with >4 million cells acquired, concordant results were obtained in 
93% of samples. Most discordances were clarified upon high-throughput 
sequencing of antigen-receptor rearrangements and re-analysis of 
flowcytometric data, resulting in an unprecedented concordance of 98% 
(97% for samples with MRD <0.01%).
In conclusion, the fully-standardized EuroFlow BCP-ALL MRD strategy is 
applicable to >98% of patients with sensitivities at least similar to RQ-PCR 
(≤10-5), if sufficient cells (>4x106) are evaluated.
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INTroducTIoN 
Most current treatment protocols for B-cell precursor (BCP) acute lymphoblastic 
leukemia (ALL) include minimal residual disease (MRD) measurements, generally based on 
PCR analysis of rearranged antigen receptor genes 1-3. Although flow cytometry (FCM) can 
be used for MRD detection as well 4-9, studies so far indicate that the specificity and sensitivity 
of FCM MRD diagnostics is inferior to PCR-based MRD diagnostics 10-13. Nevertheless, we and 
others have recently shown that the use of 6- or 7-color immunostainings combined with 
the introduction of new markers and new marker combinations significantly improved 
FCM MRD analysis in BCP-ALL patients 10,12. These improvements were particularly related 
to specificity, whereas the sensitivity still appeared to be lower than for the PCR-based 
methods. To further improve FCM-based MRD diagnostics, more objective and efficient 
discrimination of BCP-ALL cells from normal BCP cells and improved sample preparation 
procedures for acquisition of larger numbers of cells are a prerequisite.
Eight-color immunostainings may contribute to improve flowcytometric MRD detection 
in BCP-ALL patients. Recently, an 8-color antibody tube was developed in the ALL-REZ-BFM 
2002 trial 14. This tube contained seven antibodies (CD10, CD19, CD20, CD22, CD34, CD45, 
CD38) and the nucleic acid dye Syto41 and gave concordant MRD results with PCR-MRD 
data in 86.5% of samples. A Chinese study reported an 8-color antibody tube (CD10, CD19, 
CD20, CD34, CD38, CD45, CD58, plus CD66c or CD13/CD33 or NG2/CD15) with a sensitivity 
of 0.001% in 81.6% of patients 8. Shaver et al. elegantly analyzed the relative contribution 
that each marker and/or pair of markers made to detect MRD 15, and concluded that a 
single 8-color tube consisting of CD9, CD10, CD19, CD20, CD34, CD38, CD45, and CD58, 
could provide as much diagnostic utility as their existing three-tube panel with 12 markers.
Within the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708), we aimed to design 
standardized 8-color immunophenotyping protocols for multicenter MRD measurement 
in BCP-ALL and to improve the sensitivity of the assay to ≤10-5 (at least comparable to 
PCR). First, in order to select the most informative markers in distinguishing BCP-ALL 
from normal BCP cells, we applied novel software tools and principal component-based 
analyses (PCA) 16, 17. In each cycle of design-test-evaluate-redesign, the antibody tubes were 
tested on BCP-ALL samples and normal and/or regenerating bone marrow (BM), followed 
by assessment of the contribution of each antibody, until satisfactory results were obtained 
after five testing rounds. Second, a flowcytometric protocol for staining and acquisition 
of large numbers of cells (>4 million) was developed, allowing theoretical sensitivities of 
at least 0.001% (≤10-5). Finally, the selected antibody tubes and standardized laboratory 
procedures were prospectively validated on follow-up samples from BCP-ALL patients, 
using the EuroMRD PCR-MRD method in parallel as gold standard 2.
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BCP-ALL patients and normal controls
Data were collected in seven EuroFlow centers. BM samples obtained from healthy 
donors or patients in whom no hematological malignancy could be detected (e.g. BM 
samples submitted for lymphoma staging, neuroblastoma staging) were used as control 
BM for normal/reactive BCP cells. BM samples obtained from pediatric ALL patients after 
induction therapy (day 78 of therapy) or one year after stop of therapy, proven to be MRD-
negative by RQ-PCR analysis, were used as source of regenerating BCP. In the first part of 
the study (panel design and optimization), 319 BCP-ALL patients which were consecutively 
received during five design-test-evaluate-redesign phases (initial phase: n=69; phase 1: 
n=61; phase 2: n=28; phase 3: n=78; phase 4: n=83) were included. In the second part 
of the study (MRD analysis), 377 follow-up samples obtained from 178 BCP-ALL patients 
(day 15: n= 111; day 33: n= 139; day 78: n= 107; other time points: n=20) were included. 
Patient characteristics are summarized in Table 1. The institutional review board of each 
participating center approved this study and informed consent for study participation was 
obtained from each patient and/or his/her legal guardian.
Immunophenotyping MRD panel design
First, BM samples obtained from 69 BCP-ALL patients at diagnosis were stained with 
the EuroFlow BCP-ALL antibody panel (23 different antibodies in four 8-color tubes) 18. 
The subsequently designed and optimized MRD tubes were tested during phase 1 to 4 on 
diagnostic BM samples from BCP-ALL patients using the standardized EuroFlow sample 
preparation and instrument set-up protocols 18,19. Data were analyzed using Infinicyt 
software by comparing BCP-ALL cells with the nearest normal/reactive BCP subsets using 
APS plots (see Supplemental Methods) as illustrated in Figure 1 and Supplemental Figure 
1 and 2. Regenerating BCP cells from 6 T-ALL patients were used as an additional negative 
control (Supplemental Figure 3).
Immunophenotyping MRD analyses 
The finally selected BCP-ALL MRD tubes were evaluated on BM samples obtained 
during follow-up of BCP-ALL patients, using an optimized bulk-lysis protocol 
(see Results) 20. BM samples were processed according to this new EuroFlow bulk-lysis 
protocol and subsequently stained using the regular EuroFlow protocol 19. MRD analyses 
and interpretation were performed locally and data was subsequently sent to the BCP-ALL-
MRD coordinator for central evaluation. Initial FCM-MRD data analysis was performed using 
two-dimensional dot plots for sequential gating of BCP-ALL cells, comparable to previous 
studies using 4-6 color stainings10, 12. For this study, we provisionally defined a minimum of 
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10 clustered events to consider a sample as MRD positive (lower limit of detection, LOD) 
and a minimum of 40 clustered events for accurate quantitation of the MRD level (lower 
limit of quantitation, LLOQ) 2. Inter-laboratory variability in data analysis was evaluated as 
described in the Supplemental Methods and Supplemental Figure 4). 
Table 1. Patient characteristics. 
Initial 
Phase Phase 1 Phase 2 Phase 3 Phase 4
MRD 
phase
Number 69 61 28 78 83 178
Age (years)
median 6 5 5 5 3 5
min 0 1 1 0 0 0
max 76 75 17 17 55 77
Gender
M 35 56% 40 66% 14 50% 46 59% 43 52% 94 53%
F 27 44% 21 34% 14 50% 32 41% 40 48% 84 47%
WBC (x10e9/L)
median 13.4 8.2 13.7 10.9 15.9 8.5
min 0.4 0.8 1.2 0.7 0.5 0.5
max 818 87.6 312 595 1250 900
No data 10 1 0 2 19 11
Immunophenotype
pro-B-ALL 8 13% 2 3% 4 14% 5 6% 6 7% 5 3%
common-ALL 44 73% 48 79% 20 71% 59 76% 56 67% 137 77%
pre-B-ALL 8 13% 11 18% 4 14% 13 17% 21 25% 35 20%
No data 7 0 0 1 0 1
Genetic dataa
TEL-AML1 6 11% 15 27% 6 27% 11 16% 11 18% 45 26%
BCR-ABL 4 6% 1 2% 0 0% 3 4% 1 2% 4 2%
E2A-PBX1 0 0% 3 6% 0 0% 0 0% 0 0% 4 2%
MLL-AF4 4 6% 1 2% 2 7% 3 4% 4 6% 3 2%
MLL other 2 3% 1 2% 1 4% 1 1% 1 2% 2 1%
hyperdiplod 14 25% 27 48% 6 26% 26 37% 22 37% 67 43%
hypodiploid 0 0% 1 2% 1 4% 1 1% 1 2% 2 1%
a Genetic data were not available for all patients; percentages refer to positive patients per all analyzed patients.
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Figure 1. Data analysis strategy used to optimize the antibody panel for distinguishing between BCP-ALL 
cells and their nearest normal/reactive BCP counterpart. 
First multiple normal/reactive BM samples and/or regenerating BM samples were merged (phase 1: n=7; phase 
2: n=11; phase 3: n=14; phase 4: n=10) and CD19-positive B-cells were selected. These were subdivided in four 
B-cell subsets, based on the backbone markers (CD19/CD10/CD20/CD34/CD45): CD34+ pre-B-I cells (light green), 
CD34-/CD10+/CD20- to dim pre-B-II/immature cells (dark blue), CD34-/CD10+/CD20+ immature/transitional 
B-cells (light blue), and CD34-/CD10-/CD20+ mature B-cells (dark green). Dot plots of CD34 versus CD10 (A.) 
and CD10 versus CD20 (B.) are shown. The 1SD (dashed line) and 2SD lines (solid line) of the two most immature 
BCP subsets (pre-B-I (light green) and pre-B-II/immature (dark blue)) were displayed in an APS view, which was 
subsequently fixed (supervised; C.). Each individual BCP-ALL case was added to the fixed APS plot and the normal 
BCP population nearest to each of the BCP-ALL populations was defined (D.). The BCP-ALL cells and nearest 
normal BCP subset were then visualized in a separate (non-fixed and balanced) APS plot, one using the backbone 
markers only (E.) and one using all eight markers (F.), by plotting the 1SD curve and 2SD curves of the two 
populations. To prevent an influence of the number of cells on the PCA, we opted to use a balanced PCA, implying 
a fixed ratio between normal and pathological events. Finally, the separation between the two populations was 
scored, based on: no overlap between 2SD curves: 3 points; overlap of the 2SD curves: 2 points; overlap of the 
2SD and the 1SD curve: 1 point; overlap of both 1SD curves: 0 points. An example of this scoring is shown in 
Supplemental Figure 1. It should be noted that the above described strategy was only used for optimizing the 
antibody panel for the BCP-ALL MRD tubes, and not for actual MRD analyses.
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RQ-PCR-based MRD analyses
MRD levels were routinely determined by real-time quantitative PCR (RQ-PCR) analysis 
of rearranged immunoglobulin (IG) and/or T-cell receptor (TR) gene rearrangements 
in laboratories participating in the quality control rounds of the EuroMRD network (see 
www.EuroMRD.org) 3,22-26. RQ-PCR data, performed in triplicate, were analyzed according 
to the EuroMRD guidelines, using the criteria to prevent false-negative MRD results 2. 
Since application of these criteria might result in some false-positive RQ-PCR results 2, we 
performed next-generation sequencing (NGS) to confirm or to exclude the presence of 
MRD in discordant samples considered positive by RQ-PCR but negative by FCM.
NGS-based MRD analyses
NGS was generally performed as described previously 27. Briefly, depending on the 
IGH, TRG, and/or TRD rearrangements applied as MRD targets in the RQ-PCR analysis, we 
performed a targeted approach: the follow-up samples were amplified using the multiplex 
primer set(s) of the relevant IG/TR locus only and data analysis was focussed on the specific 
junctional region sequence (i.e. the one used for RQ-PCR analysis). The primers for TRG 
were newly designed (Supplemental Table 1) and individual primer combinations from 
multiplex PCR were tested for sensitivity using NGS on diluted diagnostic ALL samples 
from patients with respective V  and Jgamma segment combinations, all reaching the 
sensitivity of 10-5. All data were finally scored as either MRD-positive or MRD-negative. 
resulTs
Design and optimization of 8-color MRD labeling for BCP-ALL
In the initial phase, five antibodies (CD19, CD45, CD34, CD10 and CD20) were upfront 
selected as backbone markers since they allow appropriate BCP gating as well as 
characterization of several BCP subpopulations, and are known to allow discrimination 
between normal BCP and BCP-ALL cells 10,28,29,30. To evaluate which other markers could 
contribute to optimal separation of BCP-ALL cells from normal/reactive BCP cells, the 
EuroFlow BCP-ALL diagnosis panel 18 was applied to 69 BCP-ALL patients as well as to 
normal/reactive BM samples. Based on principal component analysis (visualized through 
APS plots) 16, 17, 19 of the BCP-ALL cells versus normal/reactive BCP cells (analyzed per 
tube), CD9, CD123, CD66c, CD81, CD24 and CD10 appeared to be markers that were 
most frequently differentially expressed (see Supplemental Figure 5). These markers were 
combined with the five backbone markers listed above and complemented with TdT and 
CD58, both previously reported to be of relevance for BCP-ALL MRD analyses 10,28,29,31. The 
remaining open position was filled in with surface membrane (Sm) IgKappa/IgLambda, as 
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a potential exclusion maker for more mature BCPs. Fluorochrome positions were primarily 
determined based on the position of the involved markers in the EuroFlow BCP-ALL panel 18. 
The resulting three Phase-1 MRD tubes (Table 2) were subsequently tested on 61 
consecutive BCP-ALL patients at diagnosis and the discriminatory power was evaluated 
by comparing the leukemic BCP with the nearest normal BCP subset in APS plots. Whereas 
both tube 1 and tube 3 gave good/fair separation in approximately 60% of cases, tube 2 
was clearly less informative (fair/good separation in <35% of cases)(Figure 2). When the 
tube providing the best separation for each patient was selected, good/fair separation was 
observed in 77% of cases. Considering only tube 1 and 3, good/fair separation was still 
observed in 71% of cases. These data indicate that tube 1 and 3 had complementary value 
and confirm the limited value of tube 2.
To evaluate the relevance of each individual marker in discriminating BCP-ALL cells 
from normal/reactive BCP cells, those markers that received a weight over 10% in the 
first or second prinicipal component in an APS view of the nearest normal BCP cells and 
Table 2. Development and design of the EuroFlow BCP-ALL MRD panela.
Phase Violet laser Blue laser Red laser
Initialb PB PO FITC PE PerCP Cy5.5 PECy7 APC APC H7
CD20 CD45 CD58 CD66c CD34 CD19 CD10 CD38
CD9 CD45 TdT CD13 CD34 CD19 CD22 CD24
CD21 CD45 CD15/CD65 NG2 CD34 CD19 CD123 CD81
1 PB PO FITC PE PerCP Cy5.5 PECy7 APC APC H7
CD20 CD45 CD58 CD66c CD34 CD19 CD10 CD38
CD20 CD45 TdT SmIgK/L CD34 CD19 CD10 CD24
CD20 CD45 CD9 CD123 CD34 CD19 CD10 CD81
2 PB PO FITC PE PerCP Cy5.5 PE Cy7 APC APC H7
CD20 CD45 CD9 CD22 CD34 CD19 CD10 CD38
CD20 CD45 CD123 CD66c CD34 CD19 CD10 CD24
3 PB PO FITC PE PerCP Cy5.5 PE Cy7 APC APC C750
CD20 CD45 CD9 (ML13) CD66c/CD123 CD34 CD19 CD10 CD38
CD20 CD45 CD58 CD22 CD34 CD19 CD10 CD81
4 PB PO FITC PE PerCP Cy5.5 PE Cy7 APC APC C750
CD20 CD45 CD81 CD66c/CD123 CD34 CD19 CD10 CD38
CD20 CD45 CD81 CD73/CD304 CD34 CD19 CD10 CD38
a Markers that were changed as compared to the previous panel are marked grey.
b Only tube 1, 3 and 4 of the EuroFlow BCP-ALL diagnosis panel were evaluated, since most markers in tube 2 
(Cyµ, SmIgK, SmIgL, SmIgM) were not expected to contribute to separation of normal and malignant BCP cells.
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the BCP-ALL cells were selected. CD66c (80% of cases), CD9 (63%), and CD123 (55%) 
contributed most frequently.
Based on these Phase-1 BCP-ALL results, the panel was redesigned: CD58, TdT, SmIgK/L, 
and CD81 were (at least provisionally) excluded, whereas CD22, which might be important 
for gating of B-cells in case of CD19-targeting therapies, was included (Table 2). 
The Phase-2 BCP-ALL MRD tubes were evaluated on diagnostic samples from 28 
consecutive BCP-ALL patients. Good/fair separation between BCP-ALL cells and their 
nearest normal/reactive BCP counterpart was possible in approximately 75% of cases in 
both tubes (Figure 2), showing significant improvement over the Phase 1 tubes. If the best 
score of both tubes was used for each case, over 85% of BCP-ALL cases showed good/fair 
separation from the corresponding normal BCP subset and in only 3 cases (12%) separation 
was poor.
During Phase-2, additional studies were performed: 1) Because of non-optimal 
(relatively weak) CD9 (MEM61) staining, another CD9 clone (ML13) was evaluated with much 
stronger results; 2) Two newly available fluorochromes (APC-C750 and APC-A750) showed 
Figure 2. Power to distinguish BCP-ALL cells from their nearest normal BCP counterpart using the EuroFlow 
BCP-ALL MRD tubes. 
Data reflect the percentage of patients that reached the specified score, obtained as described in Supplemental 
Figure 1. Briefly, for each patient BCP-ALL cells and their nearest normal BCP subset were visualized in a (non-
fixed and balanced) APS plot showing the median, 1SD curves and 2SD curves for both populations. Each patient 
was subseqently scored as follows: no overlap between 2SD curves: 3 points; overlap of the 2SD curves: 2 points; 
overlap of the 2SD and the 1SD curve: 1 point; overlap of both 1SD curves: 0 points. Max refers to the maximal 
score of the individual tubes. Phase 1: seven normal/reactive BM samples and 61 BCP-ALL patients; Phase 2: seven 
normal BM samples, four regenerating BM samples, and 28 BCP-ALL patients; Phase 3: five normal/reactive BM 
samples, nine regenerating BM samples, and 78 BCP-ALL patients; Phase 4: ten normal/reactive BM samples and 
83 BCP-ALL patients). 
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lower background than APC-H7 (less binding to apoptotic cells; no binding to monocytes); 
3) More detailed evaluation of the usefulness of CD81 versus CD24 (re-evaluation of Phase 
1 data) showed that CD81 was more frequently differentially expressed between normal/
reactive BCP cells and BCP-ALL cells and showed that CD81 in combination with only the 
backbone markers resulted in a higher percentage of cases with good separation than 
CD24 did (31% versus 20%); 4) Because CD66c and CD123 are both virtually negative on 
normal/reactive BCP cells, we tested whether these markers could be combined in the PE 
channel and concluded that background levels were not affected by combining these two 
markers (data not shown). Based on these data, the new CD9 clone was included in the 
MRD panel, APC-H7 was replaced by APC-C750/A750, CD24 was replaced by CD81, and 
CD66c and CD123 were combined into one fluorescence channel. The open FITC position 
was used for further evaluation of CD58. The combined data provided the Phase-3 BCP-
ALL MRD tubes (Table 2).
The two Phase-3 BCP-ALL MRD tubes were evaluated on 78 BCP-ALL patients. Overall, 
tube 1 resulted in good/fair separation in 90% of cases, whereas this was achieved in 82% 
of cases for tube 2 (Figure 2). In the three cases for which tube 1 did not result in good 
separation, normal/reactive BCP and BCP-ALL cells could be separated in tube 2, mainly 
due to differential expression of CD81. Further evaluation showed that CD38 (~35% of 
cases), CD66c/CD123 (~30%), and CD81 (~19%) improved the separation between normal/
reactive and malignant BCP cells as compared to the five backbone markers only, whereas 
CD9, CD58 and CD22 had no or limited additional value. CD9 in tube 1 was therefore 
replaced by CD81-FITC (which demonstrated equally good staining patterns as CD81-
APC-C750) and tube 2 was discarded. 
Since in a few cases the evaluated MRD tubes did still not yet result in sufficient 
separation between normal/reactive and malignant BCP cells, we evaluated several other 
markers reported to be of potential interest for MRD analysis (e.g.: CD44-FITC, CD27-PE, 
CD164-FITC, CD73-PE, CD49f-FITC, CD200-PE, CD86-FITC, and Drebrin-PE) 32-36. Based on 
initial testing on diagnostic BCP-ALL samples, CD73 and CD304 appeared to be most 
promising based on the level and frequency of overexpression (~20% for CD73 and ~40% 
for CD304) and their stability during follow-up (data not shown). Since it appeared not to 
be possible to combine these two markers with CD66c and CD123 in a single fluorescence 
channel (due to too high background levels), a second tube was designed; this tube was 
identical to tube 1 but with CD73/CD304 instead of CD66c/CD123 in the PE channel 
(Table 2).
The two Phase-4 BCP-ALL MRD tubes were run on 83 consecutive diagnostic BCP-ALL 
samples. Overexpression of CD66c/CD123 or CD73/CD304 was observed in 45% and 46% 
of cases, respectively; 31% of cases did not show overexpression of either CD66c/CD123 
or CD73/CD304. Tube 1 resulted in good/fair separation in 89% of cases, whereas this was 
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attained in 82% of cases for tube 2 (Figure 2). If the best score of both tubes was used, 99% 
of cases showed good/fair separation between the BCP-ALL cells and the nearest normal/
reactive BCP subset. Therefore, tube 1 and tube 2 were complementary to each other 
and one might either decide at diagnosis which tube is best for monitoring the particular 
patient or use both tubes to have an extra internal control and more precise measurements. 
These two optimized tubes were considered to be final and ready for further evaluation in 
follow-up samples of BCP-ALL patients.
Optimization of the flowcytometric MRD sample preparation protocol
We aimed for a sensitivity of ≤10-5, at least comparable to the sensitivity reached 
in RQ-PCR-based MRD analysis. If a cluster of 10-40 BCP-ALL cells should be present to 
consider a sample as positive, one should acquire at least 4 million cells in order to reach 
the required sensitivity. Since the cellularity of BM samples obtained during the early 
phases of treatment is frequently low 37, staining whole BM samples using the regular 
EuroFlow protocols would not allow acquisition of millions of cells. We therefore designed 
and tested a new EuroFlow erythrocyte bulk-lysis procedure: sufficiently large volumes 
of BM, i.e. containing >10 million cells, are lysed and the leukocytes are subsequently 
resuspended in a small volume of washing buffer. This new protocol allowed staining of 
10 million cells in 100 µl cell suspension per tube (Supplemental Table 2). Evaluation of this 
new protocol showed that the percentage of doublets did not increase, that the number 
of evaluable leukocytes increased significantly, and that there were no major differences 
in cellular composition as compared to the regular EuroFlow staining protocol (Figure 3). 
Given the large increase in the number of cells stained with this new approach, all antibody 
titers were re-evaluated; modifications appeared not to be necessary.
Evaluation of the EuroFlow BCP-ALL MRD tube
To evaluate whether the newly designed high-throughput EuroFlow BCP-ALL MRD 
strategy performed well, we tested the final MRD tubes on follow-up samples of BCP-ALL 
patients. Based on the immunophenotype of the BCP-ALL cells at diagnosis, one MRD 
tube was selected and subsequently used for MRD evaluation. First, flowcytometric MRD 
data obtained in 178 BCP-ALL patients were compared with routinely obtained PCR-MRD 
data. As shown in Figure 4A, the concordance between the FCM-MRD data and PCR-based 
MRD data was highly dependent on the number of cells acquired by flow cytometry. In 
addition, the sensitivity of FCM-MRD (percentage samples positive by both FCM and PCR 
relative to samples positive by PCR) significantly increased when higher cell numbers were 
acquired (Figure 4B). Therefore, only samples in which MRD could clearly be detected by 
FCM-MRD or samples which had sufficient cells acquired for reaching a sensitivity of ≤10-5 
were included in the subsequent analyses. Based on a LLOQ of 40 events, at least 4x106 
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Figure 3. Evaluation of the EuroFlow bulk-lysis protocol. 
BM samples (day 15: n=15; day 33: n=15; day 78: n=12) were stained with the standard EuroFlow protocol 
(FL) and with the EuroFlow bulk-lysis protocol (BL). A. Number of leukocytes, debris and doublets, calculated 
as percentage of acquired events. Using BL, significantly less debris (p=0.032 by paired t-test) and significantly 
more leukocytes (p=0.03 by paired t-test) were measured. There were no significant differences between the two 
methods for the percentage of doublets. B. Absolute number of leukocytes acquired. Using BL, on average 12-
fold more leukocytes could be acquired (p<0.0001). Please note that we included relatively many day 15 samples 
in order to be able to evaluate the impact of the two methods on the MRD levels as well. However, these day 15 
samples generally have a very low WBC; consequently, the number of leukocytes acquired after BL is still relatively 
low in a subset of samples. C. Distribution of leukocyte subpopulations, defined as percentage of leukocytes. By 
paired t-test (two-sided), small but statistically significant differences were observed for T/NK cells (mean: 24% 
versus 26%, p=0.0047), granulocytes (mean: 33% versus 38%, p<0.001) and monocytes (mean: 3.2% versus 4.5%, 
p<0,001) between FL and BL respectively, whereas no significant differences were observed for the remaining 
populations. Of note, in two samples MRD was only detected using BL (0.013% and 0.018%) but not using FL. 
In the 11 samples MRD positive by both methods, MRD levels were not significantly different from each other 
(paired t-test: p=0.30), with mean values of 6.3% and 6.7% by FL and BL method, respectively. Correlation analysis 
showed a Spearman r of 0.964 (95% CI: 00.857-0.991; p<0.0001).    
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cells should be acquired, which was possible in 227 out of 377 samples (60%). FCM-MRD 
data obtained in these patients was comparable to PCR-based MRD results in 93% of 
samples (Table 3 and Figure 5). All but one of the 17 discordant samples (seven FCM+/PCR- 
and ten FCM-/PCR+) had MRD levels <10-4 (Supplemental Table 3). Bland–Altman analysis 
showed higher PCR-based MRD values with a mean difference of 0.34 log or factor 2.2 
(Supplemental Figure 6).
Detailed evaluation of discordant cases
To evaluate the discordant cases, several additional analyses were performed. First, 
flow cytometry FCS data files were blindly distributed to four laboratories for re-analysis 
of the FCM-MRD data. Out of the seven cases initially scored positive by FCM-MRD and 
negative by PCR-MRD, six were interpreted as negative by all four centers upon FCM-MRD 
re-analysis, while one sample (day 15) was consistently scored positive by all four centers. 
Second, RQ-PCR-MRD data were checked for cases negative by FCM-MRD and positive 
by PCR-MRD. In eight of ten cases (all confirmed to be FCM-MRD negative by re-analysis 
Figure 4. Performance of FCM-MRD versus PCR-based MRD is dependent on the number of acquired cells.
A. The percentage of discordant cases by FCM-MRD and PCR-MRD is shown for individual time-points (day 15, 
day 33, and day 78) as well as for all samples together. Data are presented for variable numbers of acquired 
cells: all samples (independent of cell number) and samples with at least 1, 2, 3, 4, or 5 million cells acquired. 
B. The sensitivity of FCM-MRD relative to PCR-MRD is shown for individual time-points (day 15, day 33, and day 
78) as well as for all samples together. Data are presented for variable numbers of acquired cells: all samples 
(independent of cell number; n=377) and samples with at least 1 (n=330), 2 (n=287), 3 (n=255), 4 (n=227), or 5 
million cells (n=191) acquired. Sensitivity is calculated as the number of samples positive by both FCM and PCR 
divided by the total number of samples positive by PCR (i.e. the reference method).
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in different centers), PCR-MRD data were considered positive based on a single well in a 
single target. To further evaluate whether this low-level positivity was potentially caused 
by nonspecific amplification, NGS was used to confirm the possible presence of the 
leukemia-specific antigen-receptor rearrangement. In seven out of nine available samples, 
NGS-MRD was negative, whereas MRD-positivity could be confirmed in the remaining two 
patients. Thus, 6/17 (35%) discordant cases were due to initial misinterpretation of the 
FCM-MRD data and at least 7/17 (41%) was due to over-interpretation of PCR-MRD data; 
the remaining 4 cases appeared to be truly discordant cases (Supplemental Table 3). After 
these additional evaluations the actual concordance increased to 98%. If only samples 
with MRD levels <0.01% were included, 97% gave concordant results.
dIscussIoN
After five phases of optimization, we finally selected two 8-color antibody tubes which 
only differed for the markers present in the PE channel (CD66c/CD123 versus CD73/
CD304). These tubes are comparable with 8-color BCP-ALL MRD tubes recently used in 
other studies, since all proposed panels include CD19, CD10, CD20, CD34, and CD45. In our 
study, these markers were considered as backbone markers from start onwards, based on 
our previous experience 10, 12, 18, 28-30. Also CD38 is present in all proposed panels and was 
proven to be relevant in our present study, as well as in the studies of Karawajew et al. 14 
and Shaver et al 15. The remaining two positions were completed with different markers: 
CD9, CD13/CD33, CD15/NG2, CD58 (two studies), CD66c (two studies), CD73, CD81, 
CD123, CD304, and a nucleic acid dye. In our analysis, CD9, CD58, and CD22 appeared 
be of limited value and were therefore discarded, while Shaver and colleagues, who also 
applied mathematical modelling systems, identified these as important MRD markers 15. 
Table 3. Concordance between flowcytometric and molecular MRD data.a
Day 15 Day 33 Day 78 Other TP Total % %
Concordant
FCM+/PCR+ 102 47 11 9 169 74
93
FCM-/PCR- 1 5 31 4 41 18
Discordant
FCM-/PCR+ 0 5 5 0 10 4
7
FCM+/PCR- 1 4 2 0 7 3
Total 104 61 49 13 227 100
a Only samples in which MRD could clearly be detected by FCM-MRD or samples which had at least 4x106 cells 
acquired were included in the analyses. Based on a LLOQ of 40 events, this allowed a sensitivity of at least 10-5.
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However, they did not test CD66c, CD73, CD123, or CD304 and the difference between the 
contribution of CD9 and CD81 in their study was limited 15. CD15/NG2 might be relevant 
in ALL with MLL gene rearrangements, mainly occurring in infants 38. These cases, however, 
are rare and frequently present with a pro-B-ALL immunophenotype which can relatively 
easily be distinguished from normal BCP cells and plasma cells 39. In our study, we tested 
Figure 5. Comparison of MRD data obtained by 8-color EuroFlow flow cytometry and routinely obtained 
molecular MRD data. 
Flowcytometric MRD data were compared with molecular MRD data and are shown for samples obtained at day 
15 (A), day 33 (B), or day 78 (C). In the lower right part of each panel the number of FCM-/PCR+, FCM+/PCR+, 
FCM+/PCR-, and FCM-/PCR- is indicated. Only samples in which MRD could clearly be detected by FCM-MRD 
or samples which had sufficient cells acquired for reaching a sensitivity of ≤10-5 (i.e. ≥4x106 cells acquired) were 
included in the analyses. Based on a LOD of 10 events, the sensitivity of FCM-MRD was 2.5x10-6; the quantitative 
range (based on a LLOQ of 40 events) was 10-5. Consequently, FCM-MRD data between 2.5x10-6 and 10-5 should 
be considered as positive, but are below the limit of quantitation.
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and finally selected four markers that are frequently abnormally expressed on BCP-ALL 
cells: CD66c (associated with BCR-ABL and hyperdiploidy)  40, 41, CD123 (associated with 
hyperdiploidy 42), CD73 36, and CD304 (possibly associated with TEL-AML1) 33. By combining 
two of these markers in a single fluorescence channel, abnormal expression could be 
identified in approximately 70% of BCP-ALL patients. Furthermore, in combination with 
the backbone markers and CD81, BCP-ALL cells could clearly be distinguished from normal 
BCP cells in virtually all patients. Thus, after multiple phases of multicenter testing of a 
wide range of leukocyte markers, antibody clones and fluorochrome-conjugated reagents 
using objective novel software tools, we were able to select two highly effective BCP-ALL 
MRD tubes.
It remains to be evaluated whether the designed BCP-ALL MRD tubes can also be used 
during antibody-based therapies. Especially Blinatumomab and CAR-T-cells (targeting 
CD19) may hamper the gating of BCP based on CD19. Although alternative gating strategies 
can be applied (e.g. based on CD10, CD34 and/or CD45), one could also decide to add CD24 
and/or CD22 to the current tubes (transforming it into a 10-color tube) in MRD-based trials 
involving Blinatumomab 43. Addition of CD24 and CD22 will also have the advantage that 
the earliest BCP cells, expressing CD24 and/or CD22 but not yet CD19 44, can be identified; 
this may be of relevance for the identification of all BCP cells in regenerating BM samples. 
In order to obtain MRD data with good sensitivity, acquisition of large numbers of cells 
appears to be a prerequisite. There is no consensus yet about the number of cells needed 
for a population. Most studies in BCP-ALL indicate a minimum number between 10 and 50 
events, while a recent consensus report on MRD detection in multiple myeloma patients 
defined 20 and 50 cells as the LOD and LLOQ, respectively 21,14,45. Consequently, a sensitivity 
of 10-5 (generally reached in PCR-MRD and NGS-MRD analysis) requires acquisition of ≥106 
cells, preferably ≥5x106 cells. We therefore developed the new Euroflow bulk lysis protocol, 
allowing acquisition of such high cell numbers. Although the bulk lysis protocol contains 
several washing steps, which will likely result in some cell loss, there is no evidence for 
selective loss of BCP-ALL cells, given the high concordance between the final FCM-MRD 
results and the molecular MRD results. To our best knowledge, other FCM-MRD studies 
so far have not acquired ≥4x106 events and therefore could not have reached the same 
sensitivity as shown here, although the study by the ALL-REZ-BFM 2002 trial group comes 
close 14. Our data clearly shows that acquisition of large numbers of cells (≥4x106) is a 
prerequisite for obtaining good sensitivities and data which are truly comparable to PCR-
MRD data. 
We finally tested the newly designed and optimized BCP-ALL MRD tubes in combination 
with the bulk-lysis protocol on follow-up samples from BCP-ALL patients and compared 
the FCM-MRD data with PCR-MRD data. The concordance between both methods (in the 
absence of any cut-off) was extremely high (93%), and was significantly better than in 
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previous studies (82.3% 10 and 86.5% 14). As mentioned above, this increased concordance is 
likely due to the higher sensitivity of the current study, resulting from the higher number of 
cells analyzed. Detailed evaluation of the discordant samples using NGS-based approaches 
showed that several discrepant cases were due to over-interpretation of the PCR-MRD 
data, as the involved leukemia-specific IG/TR rearrangements could not be detected by 
(qualitative) NGS analysis. Consequently, it is most likely that in these discordant cases the 
positive RQ-PCR MRD data, interpreted according to the EuroMRD criteria for prevention 
of false-negative MRD results, are due to non-specific amplification 2,10,47,47 and that these 
samples actually were MRD-negative. 
Next to these “false-positive PCR-MRD” samples, part of the initially discordant cases 
could be explained by “false-positive FCM-MRD” results: samples were initially scored 
MRD-positive (generally at very low levels of <0.01%), but these samples were consistently 
scored MRD-negative upon blind re-analysis at four different centers. Interpretation of 
FCM-MRD data, especially at MRD levels <0.01%, is still expert-based and depends on 
the number of events in the suspected population, their distance from normal, and the 
homogeneity of the suspected population (clustering of suspected cells). Whereas the 
number of events may easily be defined, distance from normal, and homogeneity of the 
population are more complex to be objectively defined. Novel software tools, including 
automated gating approaches and maturation pathway analysis (Supplemental Figure 7), 
are currently being developed within the EuroFlow consortium and will facilitate FCM-MRD 
in BCP-ALL in the near future 37. Preliminary maturation-based FCM-MRD data showed very 
good concordance with PCR-MRD data, although further improvements are needed for 
detection of low levels of MRD (<0.01%). 
The NGS-MRD analyses and re-analyses of FCM-MRD data increased the concordance to 
an unprecedented rate of 98%; the remaining discordant cases are likely due to statistical 
variation around the detection limits of both assays 14. Therefore, the here presented 
EuroFlow FCM-MRD strategy proved to be highly sensitive (at least comparable to PCR-
MRD) and fast, and allows standardized quantification of MRD in virtually all BCP-ALL 
patients. By increasing the number of acquired cells to 107 (e.g. by running both tubes with 
5x106 cells), the sensitivity and robustness likely can even be further increased.
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suPPleMeNTal MeThods & fIGures
suPPleMeNTal MeThods
Flowcytometric analysis
Flowcytometric (FCM) data were acquired using BD Biosciences FACS Diva software 
(BD Biosciences, Erembodegem, BE) and further analyzed using Infinicyt software 
(Cytognos, Salamanca, ES). In addition to the classical 2-dimensional dot plots, the Infinicyt 
sofware allows visualization of the data using the Automatic Population Separator (APS) 
graphical representation. Such APS is based on principal component analysis (PCA) with 
bi-dimensional graphical representations of Principal Component (PC) X versus PC Y. On 
the basis of such APS representation, information about the separation between two 
populations is obtained through definition of median and/or mean ± standard deviations 
(SD) borders together with information about the most informative (versus redundant) 
parameters 1-4. To prevent the number of normal cells influencing the PCA, we opted to 
use a previously reported balanced PCA 2, implying a fixed ratio between normal and 
pathological events. Briefly, data on normal or regenerating B-cell precursor (BCP) cells were 
obtained from a merge of 7 to 14 different data-files, each corresponding to a normal or 
regenerating bone marrow (BM) sample. From this merged file, a pool of 28.000 to 1.124.900 
normal/regenerating BCP events was obtained. Next, each BCP-ALL case (generally 5000 
events/case) was merged with this normal/regenerating BCP cells pool in a balanced ratio 
of 1/1 of normal/leukemic events. Finally, a PCA transformation was calculated to achieve 
the maximum variance (‘distance’) between the normal/regenerating BCP cells and the 
leukemic cells for each individual BCP-ALL patient. Therefore, by using the balanced APS 
the composition of the sample (number of events) will not have an impact on the final 
results 1-4. Of note, the above described strategy was only used for optimizing the antibody 
panel for the BCP-ALL MRD tubes, and not for actual MRD analyses.
Bulk lysis evaluations
To allow acquisition of sufficient numbers of cells (up to 5 million per tube), a bulk-lysis 
protocol 5 was optimized. Initial testing (washing buffer (PBS) with 0.5% BSA or 4% BSA;  with 
or without a FACSLysing step after the final staining) showed that washing buffer with 0.5% 
BSA in combination with a FACSLysing step resulted in best results (lowest percentage of 
debris). To evaluate whether the optimized bulk-lysis procedure does not result in selective 
loss of certain populations (especially normal or malignant B-cells), 42 follow-up samples 
of BCP-ALL patients (day 15, n=15; day 33, n=15; and day 79, n=15) were stained using the 
EuroFlow BCP-ALL MRD tube (either tube 1 or 2, dependent on the immunophenotype 
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at diagnosis). For each sample, staining was performed in two ways: (1) using 50 ul whole 
BM, stain, FACSLysing, wash (i.e. the regular EuroFlow protocol); and (2) using 100 ul of 
bulk-lysed BM, stain, FACSLysing, wash (i.e. the EuroFlow bulk-lysis protocol). Data were 
analyzed with respect to the total number of events acquired, the percentage debris 
and doublets (% of all events), the number of leukocytes, and percentages of leukocyte 
subpopulations (% of leukocytes). Statistical evaluation (using GraphPad Prism 5, La Jolla, 
CA) of potential differences between the two methods was performed using the paired 
t-test; the correlation of MRD levels as determined by both methods was evaluated using 
the Spearman’s r test 
Re-analysis of FCM-MRD data
To evaluate the inter-laboratory (inter-observer) variability in FCM-MRD, 27 electronic 
data files (FCS) of 27 BCP-ALL patients during follow-up were selected based on variable 
levels of MRD (as determined by PCR-MRD). These data were distributed, together with 
the corresponding diagnostics file, amongst six EuroFlow laboratories participating in this 
study and analyzed blinded. Data were reported to the principal investigator (VHJvdV) 
who further analyzed the data using GraphPad Prism 5. Correlations between the FCM-
MRD data of the individual laboratories and the median FCM-MRD value of the seven 
laboratories were analyzed using the Speaman’s r test.
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suPPleMeNTal fIGures aNd TaBles
Supplemental Figure 1. Scoring system for discrimination of normal and leukemic B-cell BCP cells.
First, data from multiple normal/reactive BM samples and regenerating BM samples were used to define 
four particular B-cell subsets. The two most immature BCP subsets were displayed in an APS view, which was 
subsequently fixed (supervised). Each individual BCP-ALL case was added to the fixed APS plot and the normal 
BCP population nearest to the BCP-ALL cells was defined. The BCP-ALL cells and nearest normal BCP subset 
were then visualized in a separate (non-fixed and balanced) APS plot. Data are presented as 1SD curves (dashed 
lines) and 2SD curves (solid lines) for the normal/reactive BCP cells (green lines) and the BCP-ALL cells (red lines). 
Scoring was performed as follows: overlap of both 1SD curves: 0 points (A.); overlap of the 2SD and the 1SD curve: 
1 point (B.); overlap of the 2SD curves only: 2 points (C.); no overlap between 2SD curves: 3 points (D.).
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Supplemental Figure 2. Representative examples of different scores for discrimination of normal and leukemic BCP cells.
Scoring was performed as described in Supplemental Figure 1 for four BCP-ALL patients. The green dots, 1 SD contour (dashed 
line), and 2 SD contour (solid lines) represent normal/regenerating BCP cells, whereas the red dots, 1 SD contour (dashed line), 
and 2 SD contour (solid lines) represent BCP-ALL cells. A. BCP-ALL case receiving 3 points based on the APS view. In the classical 
dot plot showing CD66c/123 versus CD81, indeed complete separation between the BCP-ALL cells and normal/regenerating BCP 
cells can be observed. B. BCP-ALL case receiving 2 points based on the APS view, with some overlap between the two 2SD curves. 
In the classical dot plots showing CD34 versus CD38 or CD10 versus CD20, indeed good separation between the BCP-ALL cells 
and normal/regenerating BCP cells can be observed, but there is some overlap. 
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Supplemental Figure 2 (continued). Representative examples of different scores for discrimination of normal and 
leukemic BCP cells.
C. BCP-ALL case receiving 1 point based on the APS view. In the classical dot plot showing CD38 versus CD34, part of the BCP-
ALL cells separates well from the normal/regenerating BCP cells, but a part of the BCP-ALL cells clearly overlaps with normal/
regenerating BCP cells. Also in the CD10 versus CD20 dot plot there is some separation, but also overlap. D. BCP-ALL case 
receiving 0 points based on the APS view. The BCP-ALL population appeared to be heterogeneous, with part of the BCP-ALL cells 
clearly different from normal/regenerating BCP cells, but also part of the BCP-ALL cells clearly overlapping with the normal BCP 
cells. In agreement with this, in none of the classical dot plots good separation between the various BCP-ALL cells and normal/
regenerating BCP cells was observed.
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Supplemental Figure 3. BCP cells present in follow-up samples of T-ALL patients overlap with normal/
regenerating BCP cells – proof of validity of scoring system.
BM samples from six T-ALL patients were obtained at day 78 and stained with the EuroFlow BCP-ALL MRD tube 1 
(final) according to the EuroFlow BCP-ALL MRD protocol. CD19+ BCP cells (red) were gated and compared with 
two early normal/regenerating BCP subsets (green: pre-B-I-cells; blue: pre-B-II and immature B-cells). Since BCP 
cells in the T-ALL patients are heterogeneous (the total BCP population, including pre-B-I, pre-B-II, and immature 
cells, is shown), part of the BCP cells present in the T-ALL patients show overlap with the most immature normal 
BCP subset (green), whereas the other BCP cells in the T-ALL sample show overlap with the more mature normal 
BCP subset (blue). Consequently, in all cases this would result in a scoring of zero points.
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Supplemental Figure 4. Inter-laboratory variability in FCM-MRD data analysis. 
Correlation between median FCM-MRD data and FCM-MRD data obtained in the six participating laboratories. 
Resulting Spearman r values (median FCM-MRD data versus FCM-MRD data from individual laboratory) were 
0.9376, 0.9503, 0.9558, 0.9546, 0.9334, and 0.9583, respectively (p<0.001 for all six comparisons) (mean±SD 
of six laboratories: 0.95±0.01). The qualitative concordance was 100%, 100%, 96.3%, 92.6%, 96.3%, and 100%, 
respectively (mean±SD of six laboratories: 98.7%±1.7%). The different symbols represent different laboratories. 
The dashed lines represent the borders between negative FCM-MRD data and positive FCM-MRD data. 
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Supplemental Figure 5. Contribution of individual markers to discriminating between BCP-ALL cells and 
normal/reactive BCP cells.
The EuroFlow BCP-ALL diagnosis panel (tube 1, 3, and 4) was applied to 69 patients with BCP-ALL as well as to 
normal/reactive bone marrow samples. Data from each individual tube was analyzed by principal component 
analysis (APS plots), showing BCP-ALL cells and normal BCP-cells. Markers were scored based on their relative 
contribution to the separation in the APS plot: the top ranked marker received 3 points, the second ranked 
marker 2 points, the third 1 point; other markers did not get any points. For each evaluated marker, the mean 
score is shown. CD9, CD123, CD66c, CD81 and CD24 (marked by the red arrows) appeared to be markers that 
were most frequently differentially expressed between leukemic and normal/reactive BCP cells. The green arrows 
refer to the backbone markers (CD45, CD19, CD34) of the EuroFlow BCP-ALL diagnosis panel.
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Supplemental Figure 6. Bland-Altman analysis of all samples with quantitative MRD data obtained by 
both FCM and PCR.
MRD data were first log10-transformed. The Bland–Altman difference plot showed a mean difference of 0.34 log 
(or factor 2.2; solid green line). The dashed green lines indicate the upper and lower 95% limits of agreement 
(-0.87-1.15). These data are comparable to previous studies comparing FCM and PCR (mean difference of 0.20 log; 
95% limits of agreement from -0.72 to 1.13) 6 and may in part be explained by the use of mononuclear cells for the 
PCR-MRD data and whole BM for the FCM-MRD data in the present study. 
Chapter 6
174
Supplemental Figure 7. Example of maturation-based FCM-MRD analysis. 
FCM-MRD data were obtained from a BCP-ALL patient at day 33 of treatment as described in the Materials 
and Methods section. After gating on CD19+ cells and exclusion of debris and doublets (based on scatter 
characteristics), the resulting B-cells were compared with the maturation profile of normal/regenerating B-cells, 
obtained from six normal and five regenerating (day 78, MRD-PCR negative) BM samples (A.). The resulting 
maturation plot (B.) shows the normalized expression data, where the x-axis shows the various stages of B-cell 
development and the y-axis shows the level of abnormality (Grey zone: 2SD range of normal/reactive and 
regenerating BM). Since CD45 expression appeared to be abnormal, a maturation plot was made for CD45 only 
(C.). The orange curve shows the maturation pathway (2SD range) of the normal/reactive and regenerating BCP 
cells. The dots represent the data from the patient. Cells displaying aberrant phenotypes fall outside the normal 
maturation pathway and are gated and subsequently shown in classical dotplots (D.). The gated cells (indicated 
in red; green is other (normal) B-cells) clearly show an abnormal immunophenotype, as is demonstrated by their 
position outside the normal reference images (in green and yellow). The BCP-ALL cells represented 0.13% of all 
leukocytes. 
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Supplemental Table 1. Primers used for next-generation sequencing of TCRG rearrangements.
System Oligo Name Oligo Sequence (5' to 3')
TR
G
forward primer Vg1 GTAAAACGACGGCCAGAAATCTAATTAAAAATGATTCTGGG
forward primer Vg2 GTAAAACGACGGCCAGAAATCTAATTGAAAATGACTCTGGG
forward primer Vg3-5 GTAAAACGACGGCCAGAAATCTAATTGAAAATGATTCTGGG
forward primer Vg4 GTAAAACGACGGCCAGGAAATCTTATTGAAAATGACTCTGGA
forward primer Vg8 GTAAAACGACGGCCAGAAAATCTAATTGAACGTGACTCTGG
forward primer Vg9 GTAAAACGACGGCCAGCAATGTAGAGAAACAGGACATAGCTA
forward primer Vg10 GTAAAACGACGGCCAGCGTAGAGAAAGAAGACATGGCC
forward primer Vg11 GTAAAACGACGGCCAGAAGTTCTTAGAGAAAGAAGATGAGGTG
reverse primer Jg1Jg2 CAGGAAACAGCTATGACTGTTGTTCCACTGCCAAAGAG
reverse primer JgP1 CAGGAAACAGCTATGACAGGTGAAGTTACTATGAGCTTAGT
reverse primer JgP2 CAGGAAACAGCTATGACAGGCGAAGTTACTATGAGCCTAGT
reverse primer JgP CAGGAAACAGCTATGACCGGGACCAAATACCTTGATTTT
Target-specific sequences are depicted in black colour, universal adaptors for second round of PCR are 
in red.
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Supplemental Table 2. EuroFlow Standard Operating Protocol (SOP) for Bulk Lysis for MRD panelsa
1. Transfer the sample containing at least 10 x 106 nucleated cells for each MRD tube to be stained to a 50 mL 
Falcon tube. Do not use more than 2 mL of sample per 50 mL of lysing solution. If more sample need to be 
processed (i.e. starting cells concentration is low), use several 50 mL tubes.
2. Fill the tube up to reach 50 mL volume with Pharm Lyse solution (diluted to 1X in dH2O and at room 
temperature ‐ RT) or in‐house made NH4CL working solution.
3. Mix well and incubate for 15 min in a roller or sample‐shaker device.
4. Centrifuge at 800 g for 10 min and remove the supernatant using a Pasteur pipette or a vacuum system 
without disturbing the cell pellet. Alternatively, the supernatant can be decanted and drops attached to 
the rim of the tube can be sucked away using a paper towel. Typically, 300 μL of cell suspension should 
remain in the tube.
5. Add 2 mL of PBS + 0.09% of NaN3 + 0.5 % of BSA and resuspend the cell pellet vigorously.
6. Complete the volume of the tube containing the cell suspension up to 50 mL final volume with PBS + 
0.09% of NaN3 + 0.5 % of BSA.
7. Mix well.
8. Centrifuge at 800 g for 5 min and remove the supernatant using a Pasteur pipette or a vacuum system, 
without disturbing the cell pellet. Alternatively, the supernatant can be decanted and drops attached to 
the rim of the tube can be sucked away using a paper towel.
9. Resuspend the cell pellet in 2 mL of PBS + 0.09% of NaN3 + 0.5 % of BSA. Mix well and transfer this volume 
to a 5 mL polystyrene round‐bottom Falcon tube (“FACS tube”).
10. Wash the 50 mL Falcon tube with 2 mL of PBS + 0.09% of NaN3 + 0.5 % of BSA more to recover cells that 
might have been left in the original tube. Add this volume to the 5 mL Falcon tube containing the rest of 
the sample transferred in step 9.
11. Centrifuge at 540 g for 5 min and remove the supernatant by decanting or using a Pasteur pipette. If the 
remaining cell volume is lower than 300 μL, PBS + 0.09% of NaN3 + 0.5 % of BSA will be added to reach a 
volume of at least 300 μL.
12. In case multiple 50 mL tubes were used (because it was needed to lyse large sample volumes) the 
cell suspensions from the same sample should be combined at this moment, before adjusting cell 
concentration. Try to keep the final volume low, so that, in case that cell concentration needs to be 
adjusted as indicated in the next step, it can be easily done by diluting with the recommended buffer.
13. Adjust the final cells concentration to 1 x 105 cells / µL, by resuspending the pellet with PBS + 0.09% of 
NaN3 + 0.5 % of BSA.
14. Use 100 µL (i.e. 10 million cells) of the cell suspension per each tube to be stained.
a For up-to-date EuroFlow protocols please see www.EuroFlow.org.
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Supplemental Table 3. Original MRD data and data of additional evaluations of those 17 cases that initially 
showed discordant results between flowcytometric MRD analysis and RQ-PCR-based MRD analysis.
Sample
Initial 
FCM 
analysis 
(%)
Final 
FCM 
analysis 
(%)
RQ-PCR 
data
NGS 
target(s)
NGS 
MRD Conclusion
Day 15
PRA 0597 0.14 0,09 negative no material Remains discordant 
a
Day 33
PRA 0993 0.016 negative negative TRD neg Concordant after flow consensus
MON042 negative negative pos, <10e-4 IGH negative Concordant, RQPCR false positive
TH16466 negative negative pos, <10e-4 IGH negative Concordant, RQPCR false positive
TH16836 0.0036 negative negative TRD negative Concordant after flow consensus
TH17174 0.006 negative negative TRD negative Concordant after flow consensus
ROT16666 negative negative pos, <5x10e-4
no 
material Remains discordant
ROT 16643 negative negative pos, <5x10e-4 IGH negative Concordant, RQPCR false positive
ROT16278 negative negative pos, <5x10e-4 IGH positive Remains discordant
ROT16434 0,008 negative negative IGH negative Concordant after flow consensus
Day 78
TH16297 0.0002 negative negative IGH negative Concordant after flow consensus
TH16415 negative negative pos, <5x10e-4 IGH negative Concordant, RQPCR false positive
TH16539 negative negative pos, <10e-4 TRD negative Concordant, RQPCR falsely positive
TH16651 negative negative pos, <10e-4 TRD negative Concordant, RQPCR false positive
TH17068 0.00013 negative negative IGH negative Concordant after flow consensus
PRA 0530 negative negative 1.8e-4 IGH/IGH positive Remains discordant
ROT 16506 negative negative pos, <5x10e-4 IGH/TRG negative Concordant, RQPCR false positive
a Sample was positive by RQ-PCR analysis of BCR-ABL
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GeNeral dIscussIoN
In this thesis, we studied the role of both leukemic and newly generated normal B-cells 
in children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). We therefore 
focused on the leukemic B-cell population at BCP-ALL diagnosis, the recovery of the 
B-cell system during and after BCP-ALL therapy and the improvement of flow cytometric 
minimal residual disease (MRD) detection by the development of a new protocol for flow 
cytometric MRD detection.
BcP-all cloNes aNd TheIr dIsTrIBuTIoN 
Although the exact pathogenesis of BCP-ALL is unclear, the development of BCP-ALL is 
characterized by an initiating genetic lesion, often a chromosomal translocation, which is 
followed by the acquisition of structural variations and sequence mutations 1. The order of 
genetic events resulting in the development of overt BCP-ALL is best described for patients 
with an ETV6-RUNX1 translocation. 
ETV6-RUNX1 translocations can already develop in utero, since they could be traced back 
in neonatal blood spots in at least 50% of the ETV6-RUNX1-positive BCP-ALL patients 2-4. The 
ETV6-RUNX1 translocation causes an arrest in B-cell development and permanent activity of 
the recombination-activating gene (RAG) enzymes 5. This continuous RAG-enzyme activity 
mediates ongoing immunoglobulin (IG) or T-cell receptor (TR) gene rearrangements, but 
also deletions (or other types of structural variations) in genes that do not encode immune 
receptors. This could be deduced from the presence of recombination signal sequence (RSS) 
motifs and nontemplated sequences at the sites of the deletion break points 5. Finally, on 
top of the ETV6-RUNX1 translocation and the genomic deletions, single nucleotide variants 
(SNVs) are acquired 6. Presumably, this is not, as previously thought, a linear process in 
which a leukemic stem cell population is successively replaced by new clones without self-
renewing capacity, but rather a process of clonal branching within the leukemic stem cell 
population itself (Figure 1). In the latter model, acquisition of advantageous genetic lesions 
in the ancestral clone leads to new clones with self-renewing capacity, as well as ‘non-stem 
cell’ clones that form dead ends in the evolutionary tree 7,8. Selective pressure, for example 
caused by different phases of therapy or changes in microenvironment, determines which 
clones will disappear, which will grow out as dominant clones, and which will survive as 
subclones. Consequently, the clonal diversity and the relative dominance of clones can 
vary during development and progression of BCP-ALL 7. This is in accordance with studies 
on paired diagnosis-relapse samples (using IG/TR gene rearrangements or copy number 
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alterations (CNAs) as read-out), which showed that small subclones at diagnosis can 
develop into major clones at relapse (Figure 2) 9-13. 
The genetic heterogeneity in a BCP-ALL population does however not directly 
translate into immunophenotypic subpopulations 8. Immunophenotypic heterogeneity 
is common, but mostly comprises only a few subpopulations, often characterized by 
bimodal expression of TdT, CD34 and/or cyIgµ. The immunophenotypic subpopulations 
within a BCP-ALL patient do not differ from each other with regard to their IG/TR gene 
rearrangement profile or genetic aberrancies 7,14. 
The maximum number of genetically distinct clones that can be found within one 
BCP-ALL patient differs between studies, depending on the technique that was used. 
Studies which tracked BCP-ALL subclones based on their CNAs, used a limited number 
of pre-selected CNAs. Therefore, any other CNA or mutation was not registered, and the 
total number of subclones underestimated 5,7. Studies which used PCR-based methods 
to analyze IGH gene rearrangements in BCP-ALL found, when excluding infants with an 
MLL-rearrangement (which are known to be highly oligoclonal), a maximum of 9 clonal 
rearrangements per patient 15. A study which used next generation sequencing (NGS) to 
analyze IGH gene rearrangements detected up to thousands of clonal rearrangements in 
Figure 1.
Schematic view of clonal evolution. Different colors represent different clones.
A. Linear model in which new, advantageous genetic lesions occur successively, resulting in the replacement of 
the ancestral clone by the new clone.
B. Branch-like model in which genetically divergent clones co-exist and can change in size over time, dependent 
on the positive selection pressure (Marusyk et al., Biochim. Biophys. Acta, 2011) 8.
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a single patient 16. In this thesis, we found, by using NGS-based IG/TR gene rearrangement 
analysis, up to 171 clonal IGH gene rearrangements per patient (Chapter 2). Also for 
the other IG/TR gene rearrangements, we detected relatively high numbers of clonal 
rearrangements per patient. Although the number of clonal rearrangements is not directly 
representative for the number of clones (one leukemic cell can harbor multiple IG and/or TR 
gene rearrangements and can be mono-allelic or bi-allelic for a specific type of IG/TR gene 
rearrangement), NGS-based IG/TR gene rearrangement analysis shows that the number of 
subclones that can be present in a single BCP-ALL patient is higher than previously found 
with PCR-based IG/TR gene rearrangement analysis. 
NGS-based IG/TR gene rearrangement analysis might be able to replace PCR-based 
methods in MRD detection. In this case, all leukemic clones, even the very minor subclones, 
can be identified in bone marrow (BM) or peripheral blood (PB) at diagnosis and subsequently 
retraced in follow up samples. Since all IG/TR gene rearrangements in a follow up sample are 
sequenced, patient-specific assays are not needed anymore 16,17. However, certain technical 
issues are still hindering adequate NGS-based IG/TR gene rearrangement analysis. First, it is 
Figure 2.
Clonal relationship of diagnosis and relapse samples in ALL. The majority of relapse cases have a clear relationship 
to the diagnosis leukemic clone, either arising through the acquisition of additional genetic lesions or, more 
commonly, arising from an ancestral (prediagnosis) clone. In the latter scenario, the relapse clone acquires new 
lesions while retaining some but not all of the lesions found in the diagnostic sample. In only a minority of 
ALL cases does the relapse clone represent the emergence of a genetically distinct and thus unrelated second 
leukemia (Mullighan et al., Science, 2008) 11.
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difficult to discriminate between IG/TR gene rearrangements derived from small subclones 
and IG/TR gene rearrangements derived from normal B-cell and T-cell clones in a diagnosis 
sample (Chapter 2). Therefore, thresholds above which IG/TR gene rearrangements can 
reliably be regarded as leukemic should be carefully determined, thereby taking into 
account the cell input, the specific clinical setting (e.g. normal lymphocyte clones might 
be larger in regenerating BM or in case of infection), and age (in adult PB, non-leukemic 
B-cell and T-cell clones are frequently observed). Second, disproportionate amplification 
in super-multiplex PCR reactions prior to NGS can cause problems with the quantification 
of clonal IG/TR gene rearrangements. DNA barcoding techniques (in which barcodes are 
appended to each DNA template molecule before PCR amplification) or single cell NGS could 
circumvent this disproportional amplification 18. Finally, before NGS-based MRD detection 
can be implemented in routine practice, full standardization and subsequent validation 
by scientifically independent laboratories is required 19. The EuroClonality and EuroMRD 
consortia are currently optimizing NGS-based IG/TR gene rearrangement analysis (e.g. by 
developing new primers and bioinformatics strategies), after which the standardized NGS 
protocol will be validated via multi-laboratory testing rounds 19. However, even if these 
technical problems can be overcome, it still needs to be elucidated whether NGS will be 
of additional value in BCP-ALL MRD monitoring, i.e. whether the monitoring of all clonal 
IG/TR gene rearrangements rather than a few major clonal IG/TR gene rearrangements 
will lead to improved assessment of treatment effectiveness and better relapse prediction. 
So far, PCR-based monitoring of a few major clonal IG/TR gene rearrangements present 
at diagnosis (index clones with a frequency >5%), has resulted in a 5-year cumulative 
relapse incidence of the Standard Risk and Medium Risk patients of only 6% respectively 
8% and a loss of all MRD targets in only 10% within the relapsed patients 12,20. In the future, 
retrospective studies in which samples of relapsed patients are re-analyzed by NGS-based 
MRD detection could determine whether these patients would have been stratified in a 
higher risk group (with a potentially decreased risk of relapse) if NGS-based MRD detection 
had been applied. Alternatively, NGS-based IG/TR gene rearrangement analysis could be 
used to acquire a complete overview of all leukemic IG/TR gene rearrangements present at 
diagnosis, after which the rearrangements with the lowest degree of oligoclonality could 
be selected as MRD targets for fully standardized PCR-based MRD detection during follow 
up.
An important aim of this thesis was to study the tissue distribution of clones and subclones 
in BCP-ALL patients (Chapter 2). Different BCP-ALL clones can have different functional 
properties, for example with regard to quiescence, drug sensitivity and angiogenic, 
proliferative or immunogenic potential 7,8. Therefore, the degree of dissemination could 
also vary between clones. Previous studies, using mice models, found that CXCL12/CXCR4 
interactions play a major role in the retention of ALL cells in the BM microenvironment 
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and that administration of CXCR4 antagonists mobilized ALL cells into PB 21-23. However, 
only limited research was performed on the distribution of different ALL clones in BM and 
PB in humans. A previous study using Southern blot to study IG/TR gene rearrangements 
in paired BM-PB samples reported that subclonal IGH gene rearrangements found in BM 
were not always found in the corresponding PB sample in oligoclonal BCP-ALL patients 24. 
However, this absence of clonal IG/TR gene rearrangements in PB could at least partly be 
explained by the limited sensitivity of the Southern blot technique (5-10%). Using NGS-
based IG/TR gene rearrangement analysis, we found that almost all clones disseminate 
homogeneously via PB throughout the BM compartment (Chapter 2). This finding implies 
that any sample, i.e. taken from PB or any location in BM, could be used for NGS-based 
selection of MRD targets. 
recovery of The NorMal B-cell sysTeM 
Traditionally, immunophenotypic B-cell precursor (BCP) differentiation can be 
divided into a pro-B (CD22+CD19-CD34+), pre-B-I (CD19+CD10highCD34+), pre-B-II-
Large (CD19+CD10+CD34-CD20high), pre-B-II-Small (CD19+CD10+CD34-CD20low) and 
immature (CD19+CD10+Igĸ/λ+) stage 25-27. By using EuroFlow-based multiparametric 
analysis, we were capable of visualizing the BCP differentiation as one continuum 
(Chapter 4). This way, transition phases that formed the missing links between the pre-B-I 
and pre-B-II-Large stage as well as the pre-B-II-Large and pre-B-II-Small l B-cell stage were 
identified. 
After differentiation in BM, BCPs are released in PB as transitional B-cells, which mature 
in the lymphoid tissues and spleen to become naive mature, natural effector and memory 
B-cells 28. In healthy infants, the BCP population in BM consists of all BCP subsets, but the 
mature B-cell population in PB consists mainly of transitional B-cells and naive mature 
B-cells (Figure 3) 29. Around the age of four years old, the mature B-cell subsets, including 
the natural effector B-cell subset and memory B-cell subset, are present in a ratio that is 
more comparable to that in healthy adults 29. In healthy individuals, the absolute number 
of naive B cells is regulated by BM output, apoptosis, antigen-independent homeostatic 
proliferation and further maturation after antigen encounter (Figure 4). Homeostatic 
proliferation of naive mature B-cells consists of 1 to 2 cell cycles, expanding the naive B-cell 
compartment maximally two to four fold 30,31. The balance between the output of B-cells 
from BM and peripheral expansion of naive mature B-cells is tightly controlled in order to 
maintain a diverse naive B-cell receptor (BCR) repertoire.
By comparing BCPs and mature B-cells of healthy children with those of children treated 
for BCP-ALL, we gained new insights into the recovery of the B-cell system during and 
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Figure 4.
The absolute number of naive mature B-cells in PB is the result of four processes: output of newly generated 
mature B-cells from BM (1), homeostatic proliferation of naive mature B-cells (2), apoptosis (3) and further 
maturation upon antigen encounter(4) (Van Zelm, Cell Cycle, 2007) 30.
Figure 3.
B-cell subset distribution within the mature B-cell population during childhood. RBE: recent BM emigrants 
(transitional B-cells) (Van Gent et al., Clin. Immunol., 2009) 29. 
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after BCP-ALL therapy. First, we found that previously unknown CD34-/dim pre-B-I cells, 
which were rare in BM of healthy children, are abundantly present in regenerating BM of 
children treated for BCP-ALL (Chapter 4). We speculated that these CD34-/dim pre-B-I cells 
might represent pre-B-I cells that are negatively selected based on two unproductive IGH 
gene rearrangements and are consequently pre-apoptotic. By sampling at the time the 
regenerating BCPs simultaneously reach the stage of negative pre-B-I cell selection (like a 
‘wave’), the amount of CD34-/dim pre-B-I cells is relatively large. Alternatively, the CD34-/
dim pre-B-I cells are not pre-apoptotic, negatively selected cells, but part of a parallel 
maturation pathway. According to this theory, a part of the pre-B-I cells follows a parallel 
maturation pathway in which CD34 expression is downregulated before a functional IGH 
gene rearrangement, and consequently cyIgμ, has been formed (Figure 5). This parallel 
maturation pathway might, for yet unknown reasons, be preferred under regeneration 
conditions, resulting in a relatively large number of CD34-/dim pre-B-I cells. One year 
after end of therapy, the frequency of the CD34-/dim pre-B-I cells had normalized to that 
in BM from healthy children (Chapter 4). Second, we found that the B-cell maturation 
pattern during the first year posttreatment was strikingly similar to that during initial B-cell 
development in healthy infants, i.e. we found a delayed formation of classical CD38dim 
naive mature B-cells, natural effector B-cells and memory B-cells shortly after treatment 
(Chapter 3). In contrast, a relatively high percentage of CD38high naive B-cells was 
observed in the first six months posttreatment. These cells represent pre-naive B-cells, an 
intermediate stage between the CD38bright transitional B-cells and the classical CD38dim 
naive mature B-cells 32,33. High percentages of pre-naive B-cells were previously found in 
neonates and in patients after stem cell transplantation 32-34. We can therefore conclude that, 
during constitution or reconstitution of the B-cell system, including reconstitution after 
BCP-ALL therapy, B-cell maturation does initially not pass the pre-naive B-cell stage. Third, 
we showed that B-cell reconstitution after BCP-ALL treatment was a result of increased de 
novo early BCP generation, rather than the result of enhanced proliferation within a BCP 
subset or within the naive mature B-cell subset (Chapter 3). Moreover, also when therapy 
was still ongoing, profound B-lymphopenia did not lead to enhanced proliferation of 
residual naive B-cells. In contrast, lymphopenia as a result of certain immune deficiency 
disorders (such as specific variants of ataxia telangiectasia or common variable immune 
deficiency disorder) does lead to compensatory proliferation of naive mature B-cells 35,36. 
However, since B-cell reconstitution cannot take place in these immunodeficient patients 
(due to an arrest in B-cell differentiation), compensatory proliferation might only under 
these circumstances be used as a last resort to increase the number of B-cells. 
Our findings on the recovery of the B-cell system in children during and after BCP-ALL 
therapy can have clinical implications. First, the immunophenotype of newly identified 
CD34-/dim pre-B-I cells, found in regenerating BM during BCP-ALL therapy, overlapped 
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with leukemic cells in a significant part of the patients (Chapter 4). These CD34-/dim pre-
B-I cells should be carefully discriminated from residual BCP-ALL cells in order to prevent 
false-positive MRD results. It is therefore recommended to use regenerating BM (with 
abundant CD34-/dim pre-B-I cells) as reference in flow cytometric MRD measurements. 
Second, the infant-like B-cell maturation after end of therapy implies a temporary absence 
of the memory B-cell compartment and thus a temporary decreased humoral immunity 
(Chapter 3). Moreover, although part of the tissue plasma cells might survive BCP-ALL 
treatment, previous studies showed that plasma cells do not produce protective levels 
of immunoglobulins anymore in a significant part of the posttreatment patients 37,38. 
The temporary lack of serum immunoglobulins and the partial loss of vaccine-induced 
memory indicate that administration of intravenous immunoglobulins (IVIGs) during 
and shortly after therapy and revaccination after end of therapy might be beneficial. The 
effect of IVIG administration during BCP-ALL treatment is still unclear and might even 
have an adverse effect, since IVIGs could potentially suppress the generation of new 
B-cells by a negative feedback mechanism. To determine the protective effect of IVIGs in 
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Figure 5.
Hypothetical model of two parallel routes of immunophenotypic BCP differentiation. In the classical route (1), a 
functional complete IGH gene rearrangement (and consequently cyIgμ) is formed before CD34 is downregulated. 
In the alternative route (2), which could be the route of preference during BCP regeneration, CD34 is already 
downregulated before a functional complete IGH gene rearrangement has been formed.
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children treated for BCP-ALL, patients currently included in the DCOG ALL11 protocol are 
randomized into a group with and a group without IVIG administration during treatment. 
The need for revaccination after BCP-ALL treatment is also still under debate, since data on 
immunoglobulin levels against vaccine-preventable diseases during BCP-ALL treatment 
are conflicting 38-42. 
IMProveMeNT of floW cyToMeTrIc Mrd deTecTIoN
To optimize antibody panels for flow cytometric MRD measurement, many studies have 
focused on the identification of new MRD markers. Based on cell surface proteome analysis 
and genome-wide gene expression profiles of leukemic cells, several new candidate 
markers were found 43, 44. Markers are only suited for flow cytometric MRD detection 
if they are aberrantly expressed in a significant part of the BCP-ALL patients, if their 
expression level clearly deviates from that on normal BCPs and if their expression pattern 
remains stable during follow up. Early during follow up, particularly the glucocorticoids 
in the induction therapy can cause modulation of marker expression levels 45,46. This 
phenomenon, also called glucocorticoid-induced immunophenotypic shift, was amongst 
others observed for B-cell markers CD34, CD10, CD20 and CD45 45. In this thesis, we studied 
whether CD73, CD86 and CD304 could be useful in flow cytometric MRD detection in BCP-
ALL patients. Since we found that these markers are clearly overexpressed on leukemic 
cells in a substantial number of BCP-ALL patients and that they are relatively stable during 
treatment (Chapter 5), these markers could be suitable for inclusion in a BCP-ALL MRD 
antibody panel.
As discussed in Chapter 1, different techniques can be used for MRD detection in BCP-
ALL (i.e. NGS, PCR and flow cytometry), each with its own advantages and disadvantages. 
For adequate MRD detection, a sensitivity of at least 10-4 and preferably down to 10-5 is 
required. This requirement is met by PCR-based IG/TR gene rearrangement analysis, which 
is currently the gold standard in Europe for MRD detection in BCP-ALL patients 47,48. The 
sensitivity of 4 to 6-color flow cytometric MRD detection generally reaches 10-4 19, but the 
concordance between 4 to 6-color flow cytometry and PCR can be rather poor below a 
level of 10-3 (Figure 6) 49-51. In this thesis we selected, based on our results on CD73, CD86 
and CD304 and our previous studies, a number of potentially useful MRD markers. These 
markers were evaluated in multiple testing rounds, resulting in the design of a novel 
8-color MRD antibody panel (Chapter 6). This antibody panel allowed for improved 
discrimination between leukemic cells and normal BCPs. Also, we optimized the sample 
processing procedure, so that a much higher number of cells (≥4x106) could be acquired 
(Chapter 6). Together, the newly developed MRD antibody panel in combination with the 
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acquisition of sufficient cells resulted in a sensitivity of ≤10-5, in turn leading to a very high 
concordance (98%) with PCR-based MRD detection (Chapter 6). 
To implement a technique into clinical practice, also other requirements, such as 
broad availability, easy implementation, applicability in the vast majority of patients, a 
short turnaround time and the possibility to standardize, should be fulfilled 19. To meet 
these requirements, some aspects of flow cytometric MRD detection still need to be 
improved. First, the interpretation of flow cytometric data should become easier and more 
objective. This could be achieved by using automatic analysis tools, which are currently 
in development within the EuroFlow Consortium. These tools can take into account all 
markers at the same time and determine the ‘distance’ between the potential leukemic 
cells and normal BCPs. Second, antibody panels with a slightly adapted composition 
should be available for patients who are treated with antibody therapy. For example, in 
patients treated with Blinatumomab (which targets CD19), CD19 cannot be used as a 
gating marker. Replacement of CD19 with CD22 or CD24 could resolve this problem.
dIaGNosTIc recoMMeNdaTIoNs 
So far, the sensitivity of flow cytometric MRD detection has always been poorer than 
that of PCR-based MRD detection. Still, flow cytometry has been used as a complementary 
method to PCR-based IG/TR gene rearrangement analysis, since its rapid turnaround time 
allows for early assessment of the therapy response and consequently early identification 
of HR patients (MRD levels >10-3), i.e. before the results of PCR-based IG/TR gene 
Figure 6.
Example of comparison of MRD levels measured by the PCR-based method and 4-color flow cytometry at day 78 
after start of treatment (Gaipa et al., Haematologica, 2012) 49. FCR = flow cytometry. 
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rearrangement analysis become available 52. In this thesis, we showed that flow cytometric 
MRD detection can reach a sensitivity of ≤10-5 and can be highly standardized. Therefore, 
concerning sensitivity and standardization, flow cytometric MRD detection performed 
according to the newly designed protocol can now meet and further improve the criteria 
as set by PCR-based MRD detection. Since flow cytometric MRD detection has specific 
advantages compared to PCR-based MRD detection, i.e. a rapid turnaround time, additional 
information on the normal B-cell compartment, and small effects of clonal evolution, we 
believe that PCR-based MRD detection can and should be replaced by EuroFlow-based, 
8-color flow cytometry in the near future. 
In the meanwhile, the role of NGS in BCP-ALL MRD detection should be further 
investigated. It can be expected that the current technical problems of NGS-based MRD 
detection concerning quantification as well as discrimination between leukemic and 
background IG/TR gene rearrangements will eventually be resolved by NGS methods 
that do not require ‘pre-PCRs’ and by databases with ‘background-thresholds’ for each 
clinical situation and cell input, respectively. In that case, NGS-based MRD detection may 
potentially be preferred above flow cytometric MRD detection, since NGS requires a lower 
cell number (which is especially advantageous in the context of low-cellular follow up 
samples) and circumvents the problem of immunophentypic shifts, while it still enables 
monitoring of almost all subclones (in contrast to PCR-based MRD detection). The next step 
would then be to compare NGS-based MRD monitoring of a large number of clonal IG/TR 
gene rearrangements versus PCR-based MRD monitoring of a selected number of clonal 
IG/TR gene rearrangements. Importantly, standardization of NGS-based MRD detection is 
currently ongoing. However, the use of NGS-based MRD detection in BCP-ALL patients is at 
the current stage of development not yet recommended. 
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aBBrevIaTIoNs
AL Acute leukemia
ALL Acute lymphoblastic leukemia 
ASO Allele-specific oligonucleotide
ADCC Antibody dependent cellular cytotoxicity 
ATM Ataxia-telangiectasia-mutated protein 
BCP-ALL B-cell precursor acute lymphoblastic leukemia 
BCP B-cell precursors 
BCR B-cell receptor 
BM Bone marrow 
CSR Class switch-recombination 
CDC Complement dependent cytotoxicity 
CNA Copy number alteration
Cy Cytoplasmic 
D Diversity 
Dx Diagnosis 
DNA-PKcs DNA-dependent protein kinase catalytic subunit
FC / FCM Flow cytometry 
GC Germinal center 
HR High Risk 
IG Immunoglobulin 
IVIG Intravenous immunoglobulin
J Joining 
LAIP Leukemia-associated immunophenotype
LSC Leukemic stem cell
MR Medium Risk 
MRD Minimal residual disease 
MNC Mononuclear cell
NGS Next generation sequencing 
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nMFI Normalized median fluorescence intensity 
PB Peripheral blood 
PC Plasma cell
pDC Plasmacytoid dendritic cell
RCT Read count threshold
RQ-PCR Real-time quantitative PCR 
RAG Recombinase activating gene 
RSS Recombination signal sequence
SNV Single nucleotide variant
SHM Somatic hypermutation
SB Southern blot 
SR Standard Risk
SCT Stem cell transplantation
Sm Surface membrane 
TR T-cell receptor 
TdT Terminal deoxynucleotidyl transferase 
V Variable 
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B-cell precursors (BCPs) in the bone marrow (BM) differentiate through the pro-B, 
pre-B-I, pre-B-II-Large, pre-B-II-Small, and Immature stages to become mature B-cells, 
which express a functional B-cell receptor (BCR) and circulate through the peripheral 
blood (PB) and lymphoid tissues. The mature B-cell population in PB can be subdivided 
into a translational B-cell, naive mature B-cell, natural effector B-cell, memory B-cell and 
plasmablast subset. Plasmablasts mature into plasma cells, which are able to secrete 
immunoglobulins that are similar to their BCR. During BCP differentiation, the BCR is 
generated through a process called V(D)J-recombination, which allows for the creation of 
a wide variety of BCRs and consequently the recognition of a large number of antigens.
In patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), a BCP 
is arrested in a particular BCP differentiation stage and transformed into a malignant 
cell. Subsequently, clonal expansion takes place, resulting in suppression of the normal 
hematopoiesis in BM. Each year, approximately 100 new cases of pediatric BCP-ALL are 
diagnosed in the Netherlands. The general prognosis for children with BCP-ALL is good, 
with a cure rate of approximately 90%. However, depending on clinical features, specific 
genetic aberrancies and treatment response, the prognosis differs between individual 
patients. The strongest prognostic factor is the level of residual leukemic cells, i.e. minimal 
residual disease (MRD), during the first 3 months of treatment. To detect MRD, different 
methods can be used, i.e. flow cytometry, PCR-based immunoglobulin/T-cell receptor 
(IG/TR) gene rearrangement analysis, and next generation sequencing (NGS)-based IG/
TR gene rearrangement analysis. Depending on the MRD level, patients are stratified in 
a Standard Risk, Medium Risk or High Risk treatment arm. Patients with a standard risk 
receive less intense therapy, resulting in a significant reduction of drug-induced morbidity, 
whereas patients with a medium and high risk receive more intense therapy to increase 
the cure rate.
The aim of this thesis was to study the role of both leukemic and newly generated 
normal B-cells in children with BCP-ALL. 
First, we focused on the leukemic B-cell population at BCP-ALL diagnosis. As a 
result of clonal evolution during disease development and progression, a BCP-ALL 
population can consist of multiple clones. Different clones may have different properties 
and might be differently distributed within the body. In Chapter 2, we aimed to study 
the distribution of all leukemic clones, including the small subclones, throughout the 
BM and PB compartments. For this purpose we used NGS-based analysis of IG/TR gene 
rearrangements in paired BM samples and paired BM-PB samples from BCP-ALL patients 
at diagnosis. We found a high number of clonal IG/TR gene rearrangements per patient, 
indicating that a BCP-ALL population can contain more subclones than previously 
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thought. Importantly, we showed that the relative quantity of IG/TR gene rearrangements 
within the total (rearranged) BCP-ALL population was generally equal between different 
locations within the BM compartment and between the BM and the PB compartments. 
Therefore, we conclude that almost all BCP-ALL clones, even the small subclones, are fairly 
homogeneously distributed throughout the BM and PB compartments at diagnosis (albeit 
that the frequencies in total mononuclear cells may be lower in PB because of the presence 
of remaining normal leukocytes).
BCP-ALL treatment destroys, besides the targeted leukemic cells, also the normal B-cell 
compartment. In Chapter 3, we studied the reconstitution of the B-cell compartment in 
both BM and PB in patients treated for BCP-ALL. We showed that, during treatment intervals, 
regenerating BCPs maximally reached the pre-B-II-Large stage and were therefore not 
capable of supplying the PB with new mature B-cells. Also, we found that the maturation 
pattern during B-cell reconstitution in patients after end of therapy, was strikingly similar 
to that during initial B-cell development in healthy infants. Finally, we showed that B-cell 
reconstitution was the result of increased de novo generation of the earliest BCPs, rather 
than the result of enhanced proliferation within a BCP subset or the naive mature B-cell 
subset. Consequently, a naive B-cell population with broad BCR repertoire will be rebuild. 
Together, these data indicate that, after an infant-like memory B-cell deficit in the first 6 to 
12 months after treatment, a B-cell compartment similar to that in healthy children will be 
reestablished in posttreatment BCP-ALL patients.
Flow cytometric MRD detection at time points of BCP regeneration (during treatment 
intervals) can be difficult, due to potential immunophenotypic overlap between residual 
leukemic cells and regenerating BCPs. In Chapter 4, we obtained detailed data on the 
immunophenotypic maturation of regenerating BCPs in BM from treated BCP-ALL patients 
by using 8-color immunostainings and novel EuroFlow-based multiparameter software 
tools and compared these with the immunophenotypic maturation of BCPs in BM from 
healthy children. We found a previously unknown (expanded) immunophenotypic BCP 
subset in the regenerating BCP population, which consisted of pre-B-I cells with a negative 
to dim CD34 expression. Due to their ‘aberrant’ immunophenotype, these BCPs could 
potentially be mistaken for residual leukemic cells, which could further complicate flow 
cytometric MRD detection at time points of BCP regeneration. Additionally, by studying 
the immunophenotypic maturation of normal BCPs in healthy children, we identified two 
additional maturation stages which could be regarded as transition stages in between the 
conventional BCP differentiation stages.
To implement flow cytometry as first choice for MRD detection in BCP-ALL, a sensitivity 
of ≤10-4 should be achieved. Therefore, an improved immunophenotypic identification of 
leukemic cells and an increased acquisition of cells per follow up time point is required. To 
improve the identification of leukemic cells in a background of normal BCPs, new markers 
A205
Summary 
that are differentially expressed on normal BCP and leukemic cells are needed. In Chapter 5, 
we studied the expression of CD73, CD86 and CD304 in a large cohort of pediatric BCP-
ALL patients, included in multiple laboratories of the international EuroFlow Consortium. 
We showed that these markers were overexpressed in a substantial part of the BCP-ALL 
patients and that expecially CD73 was relatively stable during the first phase of treatment. 
Inclusion of these markers in BCP-ALL MRD antibody panels may therefore contribute to 
improved flow cytometric MRD analysis. In Chapter 6, we designed, via four testing- and 
evaluation rounds, an optimized 8-color antibody panel (in which CD73 and CD304 were 
included), and developed a sample processing procedure for the acquisition of large cell 
numbers (≥4x106 per tube). The final flow cytometric BCP-ALL MRD detection protocol 
was fully standardized and tested in parallel to PCR-based MRD detection in multiple 
laboratories participating in the EuroFlow Consortium. The data from this study showed 
that the new protocol was applicable to >98% of the patients and reached a sensitivity of 
≤10-5, which is comparable to (or even better than) real-time quantitative (RQ)-PCR-based 
MRD detection. Importantly, concordant results between flow cytometric and PCR-based 
MRD measurements were obtained in an unprecedented >98% of the samples.
Since the sensitivity of flow cytometric MRD detection now at least equals that of 
PCR-based MRD detection and since flow cytometry has additional advantages, we finally 
conclude, in Chapter 7, that implementation of EuroFlow-based 8-color flow cytometry as 
primary MRD detection method in children with BCP-ALL can be recommended.
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saMeNvaTTING
Voorloper B-cellen in het beenmerg (BM) differentiëren via de pro-B, pre-B-I, pre-B-II-
Large, pre-B-II-Small en Immature stadia tot rijpe B-cellen, die een functionele B-cel receptor 
(BCR) tot expressie brengen en door het perifere bloed (PB) en de lymfoide weefsels 
circuleren. De rijpe B-cel populatie in PB kan onderverdeeld worden in een transitional, 
naive mature, natural effector, memory B-cel en plasmablast subset. Plasmablasten rijpen 
verder uit tot plasma cellen, welke immunonglobulines secreteren die gelijk zijn aan hun 
BCR. De BCR wordt gedurende de B-cel differentiatie gevormd door middel van een proces 
genaamd V(D)J recombinatie, hetgeen zorgt voor de vorming van een grote diversiteit aan 
BCRs en daarmee de herkenning van een groot aantal antigenen.
In patiënten met B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is een BCP 
geblokkeerd in een specifiek differentiatie stadium en getransformeerd tot een maligne cel. 
Vervolgens treedt klonale expansie op, met onderdrukking van de normale hematopoiese 
in het BM tot gevolg. In Nederland worden er elk jaar ongeveer 100 nieuwe gevallen van 
BCP-ALL bij kinderen gerapporteerd. De prognose van kinderen met BCP-ALL is over het 
algemeen goed met een overlevingspercentage van ongeveer 90%. De prognose verschilt 
echter per patiënt, afhankelijk van klinische karakteristieken, specifieke genetische 
afwijkingen en de respons op behandeling. De sterkste prognostische factor is het aantal 
leukemische cellen dat nog aanwezig is gedurende de eerste drie maanden na het starten 
van de therapie, hetgeen minimale restziekte (MRD) wordt genoemd. Voor de detectie van 
MRD kunnen verschillende methoden worden gebruikt, namelijk flowcytometrie, PCR-
gebaseerde immunoglobuline/T-cel receptor (IG/TR) gen herschikking analyse en next 
generation sequencing (NGS)-gebaseerde IG/TR gen herschikking analyse. Aan de hand 
van het MRD niveau worden patiënten ingedeeld in een standaard risico, middelhoog 
risico of hoog risico groep. Patiënten met een laag risico krijgen minder intense therapie, 
resulterend in significant minder bijwerkingen, terwijl patiënten met een middelhoog of 
hoog risico zwaardere therapie krijgen om de kans op genezing te vergroten.
Het doel van dit proefschrift was om in kinderen met BCP-ALL de rol van zowel de 
leukemische als nieuw gegenereerde normale B-cellen te bestuderen.
We richtten ons hierbij eerst op de leukemische B-cel populatie op het moment van 
diagnose. Ten gevolge van klonale evolutie gedurende de ontwikkeling en progressie van 
BCP-ALL, kan de BCP-ALL populatie uit meerdere klonen bestaan. Deze klonen kunnen 
verschillende eigenschappen hebben en zich potentieel in verschillende mate door het 
lichaam verspreiden. In Hoofdstuk 2 hadden we als doel om de verspreiding van alle 
leukemische klonen, inclusief de kleine subklonen, over het BM en PB compartiment 
te onderzoeken. Hiervoor gebruikten we NGS-gebaseerde analyse van IG/TR gen 
herschikkingen in gepaarde BM monsters en gepaarde BM-PB monsters, afgenomen op 
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het moment van diagnose. We vonden een groot aantal IG/TR gen herschikkingen per 
patiënt, hetgeen erop duidt dat een BCP-ALL populatie uit meer subklonen kan bestaan 
dan voorheen werd gedacht. Ook toonden we aan dat de relatieve hoeveelheid IG/TR 
gen herschikkingen binnen de totale (herschikte) BCP-ALL populatie gelijk was tussen 
verschillende BM locaties en tussen BM en PB. Daarom kunnen we concluderen dat bijna 
alle BCP-ALL klonen, inclusief de kleine subklonen, behoorlijk homogeen verspreid zijn 
over het BM en PB compartiment op het moment van diagnose (hoewel de frequenties 
binnen de totale mononucleaire cellen lager kunnen zijn in PB vanwege de aanwezigheid 
van resterende normale leukocyten).
De behandeling van BCP-ALL vernietigt, naast de beoogde leukemische cellen, ook 
het normale B-cel compartiment. In Hoofdstuk 3 onderzochten we de heropbouw van 
het B-cel compartiment in zowel BM als PB van patiënten die behandeld worden voor 
BCP-ALL. We lieten zien dat, tijdens therapie intervallen, regenererende BCPs maximaal 
het pre-B-II-Large stadium bereikten en daarom het PB tijdens therapie niet van nieuwe 
mature B-cellen konden voorzien. Daarnaast vonden we dat het maturatie patroon tijdens 
B-cel reconstitutie in patiënten na beëindiging van therapie gelijk was aan dat tijdens de 
initiële opbouw van het B-cel systeem in gezonde pasgeborenen. Tenslotte toonden we 
aan dat het herstel van het B-cel compartiment na BCP-ALL therapie het resultaat was van 
de novo regeneratie van de meest vroege voorloper B-cellen, en niet van compensatoire 
proliferatie in een BCP subset of de naive mature B-cel subset. Hierdoor zal opnieuw een 
naïeve B-cel populatie met een breed BCR repertoire ontstaan. Deze data wijzen erop 
dat, na het tijdelijk gebrek aan geheugen B-cellen in de eerste 6 tot 12 maanden na de 
therapie, een B-cel compartiment gelijk aan dat in gezonde kinderen gevormd zal worden 
in patiënten die BCP-ALL therapie hebben ondergaan. 
Flowcytometrische MRD detectie op tijdstippen waarop BCP regeneratie 
plaatsvindt (gedurende therapie intervallen) wordt bemoeilijkt door mogelijke 
immunofenotypische overlap tussen resterende leukemische cellen en regenererende 
BCPs. In Hoofdstuk 4 verzamelden we gedetailleerde data over de immunofenotypische 
maturatie van regenererende BCPs in BM van behandelde BCP-ALL patiënten, door gebruik 
te maken van 8-kleuren flowcytometrie en nieuwe EuroFlow-gebaseerde multiparameter 
software tools, en vergeleken deze met de immunofenotypische maturatie van BCPs 
in BM van gezonde kinderen. We vonden een tot nu toe onbekende (geëxpandeerde) 
immunofenotypische BCP subset in de regenererende BCP populatie, welke bestond 
uit pre-B-I cellen met negatieve tot zwakke expressie van CD34. Door dit ‘afwijkende’ 
immunofenotype kunnen deze regenererende BCPs potentieel foutief aangezien worden 
voor resterende leukemische cellen, hetgeen flowcytometrische MRD detectie op 
tijdstippen van BCP regeneratie nog complexer kan maken. Daarnaast identificeerden we, 
door tevens de immunofenotypische maturatie van normale BCPs in gezonde kinderen 
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te onderzoeken, twee extra normale BCP differentiatie stadia, welke beschouwd kunnen 
worden als overgangsfasen tussen de conventionele BCP differentiatie stadia.
Om flowcytometrie als eerste keus voor MRD detectie bij kinderen met BCP-ALL te 
implementeren, zal een sensitiviteit van ≤10-4 behaald moeten worden. Daarvoor is een 
verbeterde immunofenotypische identificatie van leukemische cellen en een toegenomen 
acquisitie van cellen per follow up tijdstip vereist. Om de identificatie van leukemische 
cellen in een achtergrond van normale BCPs te verbeteren zijn nieuwe markers nodig, die 
verschillend tot expressie komen op normale BCPs en leukemische cellen. In Hoofdstuk 5 
onderzochten we de expressie van CD73, CD86 en CD304 in een groot cohort kinderen 
met BCP-ALL, geïncludeerd in verschillende laboratoria behorend tot het EuroFlow 
Consortium. We vonden dat deze markers overexpressie toonden op leukemische cellen 
in een substantieel deel van de BCP-ALL patiënten en dat vooral CD73 relatief stabiel bleef 
gedurende de eerste fase van therapie. Inclusie van deze markers in een BCP-ALL MRD 
antistof panel kan daarom mogelijk bijdragen aan verbeterde flowcytometrische MRD 
detectie. In Hoofdstuk 6 ontwierpen we, via vier test-en-evaluatie rondes, een optimaal 
8-kleuren antistof panel (waarin CD73 en CD304 werden geïncludeerd), en ontwikkelden 
we een monster verwerkingsprocedure waarmee grote cel aantallen verkregen konden 
worden (≥4x106 cellen). Het uiteindelijke flowcytometrische BCP-ALL MRD detectie 
protocol werd volledig gestandaardiseerd en, in parallel met PCR-gebaseerde MRD 
detectie, getest in meerdere laboratoria participerend in het EuroFlow Consortium. De 
resultaten van deze studie lieten zien dat het nieuwe protocol toepasbaar was bij >98% 
van de patiënten en een sensitiviteit behaalde van ≤10-5, hetgeen vergelijkbaar is met (of 
zelfs beter is dan) de sensitiviteit van real-time quantitative (RQ)-PCR gebaseerde detectie 
van IG/TR gen herschikkingen. Concordante MRD resultaten werden, voor het eerst, 
verkregen in >98% van de monsters.
Omdat de sensitiviteit van flowcytometrie die van PCR op zijn minst evenaart en 
flowcytometrie extra voordelen heeft, concludeerden we ten slotte in Hoofdstuk 7 dat 
implementatie van EuroFlow-gebaseerde 8-kleuren flowcytometrie als primaire methode 
voor MRD detectie bij kinderen met BCP-ALL kan worden aanbevolen.
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